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Quantitative MRI in the diagnosis and monitoring of human prion diseases 
 
Abstract 
This thesis examines the application of cerebral diffusion weighted imaging (DWI) and 
short echo time (TE) proton magnetic resonance spectroscopy (1H-MRS) for the 
evaluation of patients with different forms of human prion disease.  Human prion 
diseases are progressive, uniformly fatal neurodegenerative diseases and as treatments 
are developed, early diagnosis is essential.  Particularly important is the diagnosis of 
presymptomatic cases and prediction of disease onset in these individuals. 
 
In this thesis I demonstrate that MRI measures of Apparent Diffusion Coefficient 
(ADC) at low and high b-value and short TE 1H-MRS are potential neuroimaging 
biomarkers of prion disease activity.   I show that ex-vivo MRI at high field provides 
important insights into the microstructural changes underlying the sensitivity of some of 
these quantitative MRI methods to prion disease pathology.  The findings presented 
here exemplify the potential of quantitative MRI in both increasing our understanding 
of the pathophysiology of prion diseases and in providing neuroimaging biomarkers 
which will be of great importance for the future evaluation of treatment efficacy.  
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Overview 
 
This thesis evaluates the potential of quantitative MRI measurements in the 
understanding of the pathophysiological changes underlying human prion diseases and 
their potential in providing neuroimaging markers of disease activity.  As the first 
therapeutic trials are underway for these disorders, including the recently completed 
MRC Prion-1 Trial, quantitative MRI techniques offer considerable potential for 
evaluating treatment efficacy. 
 
The thesis is divided into two parts describing our findings.  Part A (chapters 2-4) 
examines whether in vivo ADC and 1H-MRS measurements are able to detect regional 
and global changes in patients with prion disease as a diagnostic tool and, by correlation 
with cognitive scales, to monitor disease activity.  Part B (chapter 5) describes our ex 
vivo work, where quantitative MRI measurements at high magnetic field strength (9.4T) 
were performed in order to determine and quantify the microstructural changes that 
affect the MRI signal in post-mortem brain tissue of patients with prion disease. 
 
The subject of prion diseases and the potential of quantitative MRI as a tool to monitor 
disease activity are introduced firstly in chapter 1.  Chapters 2-4 describe the in vivo 
application of cerebral DWI and 1H-MRS in patients in the MRC Prion-1 trial.  Chapter 
2 examines the value of basal ganglia regional ADC measurements and the use of whole 
brain and grey matter ADC histograms in monitoring disease activity in inherited prion 
diseases (inhPrD).  Chapter 3 describes the value of basal ganglia ADC measurements 
at low and high b-values in the diagnosis and differentiation of sporadic CJD (sCJD) 
and variant CJD (vCJD).  Chapter 4 describes a pilot study in a small group of patients 
with inhPrD, investigating the use of single voxel short echo time (TE) 1H-MRS in two 
regions of the brain.  Longitiudinal data and correlation with clinical scores enabled us 
to evaluate this technique as a tool to monitor disease activity.  Chapter 5 describes ex 
vivo high resolution MRI and quantitative MRI measurements in fixed post-mortem 
brain tissue at 9.4T in patients with vCJD.  Through comparison with histopathology, I 
discuss how this technique can be used to detect and quantify the microstructural 
changes that affect the MRI signal in vCJD thus improving our understanding of the 
pathophysiology of this disease.  Finally, in Chapter 6, the findings are summarised, the 
relative strengths and weaknesses of these techniques are discussed and suggestions for 
future research directions are given. 
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Aim 
 
Specifically, this thesis examines whether: 
 
1.  Regional differences in cerebral ADC can be detected in variant, sporadic and 
inherited forms of prion disease when compared to controls. 
 
2.  Regional and global cerebral ADC measures in inherited prion disease correlate with 
clinical disease severity. 
 
3. Regional differences in single voxel short TE 1H-MRS measurements can be detected 
in inherited prion disease when compared to controls, can be correlated with disease 
severity and can be demonstrated to evolve in serial MRS examinations. 
 
4.  Quantitative MRI measurements of T1- and T2 relaxation times, FA and MD in 
fixed post-mortem brain tissue at 9.4T can be correlated with histopathological 
measures to better understand the pathophysiological changes underlying the early 
disease course. 
 
5.  High resolution MRI images of fixed post-mortem tissue at 9.4T can detect the 
histopathological changes characteristic of human prion diseases. 
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Hypothesis 
 
Regional and global ADC measures and short TE 1H-MRS measures are potential 
markers of disease activity in prion diseases. 
 
High field MRI at 9.4T can detect and quantify the histopathological changes 
characteristic of this disease. 
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1 Introduction 
 
1.1 Human Prion Diseases 
Human prion diseases are a group of progressive, invariably fatal neurodegenerative 
disorders characterised by accumulated aggregates of an abnormally folded, relatively 
protease-resistant, beta-sheet rich isoform (PrPSc) of a normal cellular protein (PrPc).  
Deposition of PrPSc in the form of diffuse deposits or plaques of various morphologies is 
accompanied by a classic histological triad of spongiosis, gliosis and neuronal loss 1.  
Most cases occur sporadically but hereditary, iatrogenic and dietary transmission can 
occur.  There has been considerable recent interest in human prion disease following the 
identification of vCJD and the demonstration through transmission studies in mice and 
other research that vCJD is caused by the same prion strain as that causing Bovine 
Spongiform Encephalopathy (BSE)2.  With recent reports of blood-borne transmission 3, 
prion diseases remain an important public health issue and attention has focussed on the 
development of therapeutic agents.  
 
 
 
1.1.1 Molecular neurology of prion diseases 
The biology of prion diseases is unique because of the transmissible agent or prion 
(proteinaceous infectious particle).  Prions are defined as “small proteinaceous 
infectious particles which resist inactivation by procedures which modify nucleic acid”4.  
Prions consist principally or entirely of abnormal isoforms of host encoded prion 
protein.  In human prion diseases, the abnormal isoform is designated PrPSc (denoting 
the scrapie isoform of the protein) and the normal prion protein is protease sensitive and 
is termed PrPc (denoting the normal Cellular isoform of the protein).  PrPSc is derived 
from PrP by a post-translational mechanism with no amino acid or covalent differences 
between PrPSc and PrPc 4-6.   
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PrPc is a glycoprotein consisting of an N-terminal region and a C-terminal domain.  The 
N-terminal region contains five repeats of 8 amino-acid sequence (the octapeptide 
region) and mutations in this region can lead to forms of inherited prion disease7.  In 
this region, there are two tight binding sites for Cu ions, suggesting a role for PrP in 
copper metabolism or transport 8.  Disturbance of this function could be involved in 
prion related neurotoxicity.  
 
 
                              
(Courtesy of Ray Young, MRC Prion Unit) 
 
Figure 1.1.1:  Model of the C-terminal domain of human prion protein indicating 
positions of single disulphide bond linking the α-helices, position of the 
carbohydrate and the GPI anchor which attaches the protein to the outer surface of 
the cell membrane.  
 
PrPSc is a highly aggregated, detergent insoluble material that has a high β-sheet 
content.  It is thought that the protein PrP can exist in a dominant native state (PrPC) and 
several minor conformations, one or a set of which can associate to form a 
supramolecular structure PrPSc, composed of misfolded PrP monomers.  When a stable 
“seed” structure of a critical size has been formed, further recruitment of unfolded PrP 
occurs as an irreversible process driven thermodynamically by intermolecular 
interactions 7 (Figure 1.1.2). 
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(Courtesy of Ray Young, MRC Prion Unit) 
 
Figure 1.1.2:  Scheme demonstrating the hypothesis for prion propagation.  Largely 
α-helical PrPC proceeds via unfolded state (i) to re-fold into a largely β-sheet form, 
β-PrP (ii). β-PrP is prone to aggregation in physiological salt concentrations.  Prion 
replication may require a critical “seed” size.  Further recruitment of β-PrP 
monomers (iii) or unfolded PrP (iv) then occurs as an essentially irreversible 
process driven thermodynamically by intermolecular interactions (red arrows). 
 
 
 
1.1.2 Prion strains 
Distinct naturally occurring isolates or strains of human PrPSc are observed which are 
associated with different phenotypes of CJD 9;10.  The different strains are identified on 
the basis of their different incubation periods and neuropathology, as well as 
physicochemical properties including differences in fragment size and glycoform ratio 
(of diglycosylated, monoglycosylated and unglycosylated forms) seen on Western blots 
following treatment with proteinase K (Figure 1.1.3).  Four types of human prion 
disease have been described using molecular strain typing:  sCJD and iatrogenic CJD 
are associated with strain types 1-3 whilst vCJD is uniquely associated with type 4 PrPSc 
and has a distinct glycoform ratio (Figure 1.3).  Normally occurring polymorphisms 
coding for either methionine (M) or valine (V) at codon 129 of the prion gene also 
influence strain type propagation. Strain types 1 and 4 have only been detected in MM 
individuals whilst type 3 is seen in MV or VV individuals and type 2 with any codon 
129 mutation.   
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(Courtesy of Ray Young, MRC Prion Unit) 
 
Figure 1.1.3:  Molecular strain typing of human prions.  Western blot of brain 
homogenate after treatment with proteinase K shows different apparent molecular 
mass and glycoform ratios in patients with forms of sporadic or iatrogenic (T1-3) or 
vCJD (T4). 
 
 
 
1.1.3 Pathogenesis 
In some animal models, infectivity detected in the spleen precedes neuroinvasion 11.  
CNS prion replication then rises to high levels and the clinical phase follows.  The route 
of entry of prions after oral exposure may be through invasion of Peyer’s patches and 
other gut lymphoid tissue.  Neuroinvasion may then involve the autonomic nervous 
system innervating lymphoid tissue, with retrograde invasion via the spinal cord12.  In 
human sCJD prion infectivity is largely confined to the CNS, whereas in vCJD, there is 
involvement of the lymphoreticular tissues and evidence of transmission via blood 
transfusion 3;13;14.    
 
It has been proposed that prion disease pathogenesis can be explained in terms of the 
kinetics of prion propagation, as determined by an interplay between prion strain type 
(the dominant PrPSc polymer and its ensemble) and the tissue-host environment 
(including PrP sequence and expression level, modifier genes, and clearance 
mechanisms).  Neurotoxicity is then mediated by a PrP species designated PrPL (lethal), 
distinct from PrPSc but catalyzed by it, when PrPL concentrations of this species pass a 
local toxic threshold.  Rapid propagation (with a host-adapted strain and normal or high 
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levels of host PrPC expression) results in severe neurotoxicity and death whereas slow 
propagation (infection across a transmission barrier or with low host PrPc expression) 
results in low neurotoxicity, prolonged more variable incubation periods, or a persistent 
carrier state 15. 
 
1.1.4 Molecular classification of prion diseases 
Human prion diseases have been traditionally classified on clinical grounds into 
Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker disease (GSS) and 
Kuru but can also be classified as occurring in inherited, sporadic and acquired forms 
with sub-classification according to molecular criteria. 
 
Inherited prion diseases (inhPrD) comprise 15% of recognised prion disease and are 
associated with one of the more than 30 recognised coding mutations in the PRNP gene 
(Collinge, Dementia, London).  Kindreds with inhPrD have been described with the 
phenotypes of classical CJD, GSS and with other clinico-pathological syndromes 
including familial fatal insomnia (FFI).   
 
sCJD makes up 85% of all recognised human prion disease and occurs in all countries 
with an apparently random distribution and annual incidence of 1-2 per million.  
Possible causes are spontaneous production of PrPSc via rare stochastic events, somatic 
mutation of PRNP or unidentified environmental exposure.  There is a marked genetic 
susceptibility with most cases occurring in homozygotes of methionine (M) or valine 
(V) at codon 129 of the PRNP gene.  MV heterozygotes appear to be relatively 
protected from developing sCJD 16. 
 
Acquired prion diseases include iatrogenic CJD, Kuru and vCJD.  Iatrogenic exposure 
occurs through accidental exposure to human prions through medical or surgical 
procedures, most frequently through implantation of dural grafts or through 
administration of growth hormone derived from the pituitary glands of human cadavers 
17.  Kuru arose from exposure to prions during cannibalistic mortuary feasts.  vCJD has 
been shown through strain-typing studies and transmission studies in transgenic mice to 
be caused by the same prion strain as that causing BSE 9;18.   
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1.1.5 Clinical features of each type of prion disease 
 
Table 1.1:  Diagnosis of different forms of human prion disease.  
Diagnosis of prion disease 
 
 
Sporadic (classical) CJD 
Rapidly progressive dementia with two or more of myoclonus, cortical blindness, pyramidal 
signs, akinetic mutism 
Most cases aged 45-75  
Serial EEG shows pseudoperiodic complexes in most cases 
CSF 14-3-3 protein usually positive 
MRI: T2W hyperintensity in basal ganglia and cortex  
PRNP analysis: no pathogenic mutations 
Brain biopsy in highly selected cases (to exclude treatable alternative diagnoses):  PrP 
immunocytochemistry or western blot for PrPSc types 1-3 
 
vCJD (Human BSE) 
Early features:  depression, anxiety, social withdrawal, peripheral sensory symptoms 
Cerebellar ataxia, chorea, or athetosis often precedes dementia, advanced disease as sCJD 
Most in young adults:  however age at onset 12-74 years seen 
EEG non-specific slow waves, CSF 14-3-3 may be elevated or normal 
MRI: most show high T2W signal in the posterior thalamus bilaterally 
PRNP analysis: characteristic PrP immunostaining and PrPSc on western blot (type 4) 
 
Inherited prion disease 
Varied clinical syndromes between and within kindreds: should consider in all pre-senile 
dementias and ataxias irrespective of family history 
MRI: normal, atrophy or basal ganglia T2W hyperintensity 
PRNP analysis: diagnostic codon 129 genotype may predict age at onset in pre-symptomatic 
testing 
 
 
Adapted from Collinge et al 2005 7. 
 
1.1.5.1 Sporadic CJD 
sCJD typically presents with a rapidly progressive dementia and additional neurological 
features including cerebellar ataxia (10%), neuropsychiatric symptoms and myoclonus.  
Onset usually occurs from 45-75 years of age with a peak age of onset between 60-65 
years.  Rapid clinical progression usually leads to akinetic mutism and death within 
weeks or months.  The median duration of illness in sCJD is four months with 14% of 
cases having an illness duration of a year or more and only 5% of cases surviving 2 or 
more years 19.   
 
There is clinical heterogeneity within sCJD, especially at symptom onset where 
particular focal deficits may be present:  an isolated progressive cerebellar syndrome 
(10%) 20 or an isolated progressive visual disturbance culminating with cortical 
blindness may be seen, known as the Heidenhain’s variant.   
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Table 1.2: World Health Organisation Updated Diagnostic criteria for sCJD.  
Diagnostic criteria 
 
I. Clinical signs 
1. Dementia 
2. Cerebellar or visual 
3. Pyramidal or extrapyramidal 
4. Akinetic mutism, 
 
II. Tests 
1. PSWCs in EEG 
2. 14-3-3 detection in CSF (in patients with disease 
duration of less than 2 year) 
3. High signal abnormalities in caudate nucleus or 
putamen or at least two cortical regions (temporal-
parietal-occipital) either in DWI or FLAIR 
 
 
Probable sCJD 
           Two out I and at least one of II 
 
Possible sCJD 
           Two out of I and duration less than 2 years 
 
  
As published in Zerr et al 2009 21 
 
The diagnosis should be considered in any individual with a rapidly progressive 
dementia where other more common causes have been excluded.  Routine 
haematological and biochemical investigations are normal and no immunological 
markers or acute phase proteins are elevated.  In the CSF, 14-3-3, which is a normal 
neuronal protein that has no specific connection to CJD and is released following 
neuronal damage can be a useful adjunct to diagnosis with a  reported sensitivity of 94% 
in the appropriate clinical context 22;23.  CSF 14-3-3 protein is also elevated in cerebral 
infarction, cerebral haemorrhage or viral encephalitis although these conditions can 
usually be differentiated from sCJD on clinical grounds.  
 
EEG shows a progressive deterioration in the normal background rhythms with the 
appearance of periodic sharp wave complexes (PSWCs) with a specificity of 74% 24;25.  
Cerebral imaging is important in the exclusion of other diagnoses but more recently 
imaging features that are characteristic of sCJD have been demonstrated and a 
combination of cortical and basal ganglia signal change on MRI is reported to have a 
diagnostic sensitivity of >91% 26 (see chapter 1.1.7). 
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The different molecular subtypes of sCJD have been associated with particular clinical 
phenotypes (table 1.3).   Clinically the most difficult differential diagnosis for sCJD is 
rapidly progressive Alzheimer’s disease (AD), with cases misdiagnosed as sCJD in 
several large series 25;27.  The differential diagnosis also includes Dementia with Lewy 
Bodies, lymphoma and multiple cerebral infarctions 28;29.    
 
Table 1.3:  Clinical features, EEG, CSF 14-3-3 and MRI findings in sCJD subtypes. 
Subtype of 
sCJD 
Frequency 
(% of 
sCJD 
cases) 
Clinical presentation EEG 
positive  
14-3-3 
positive 
MRI 
positive 
MM1/MV1 60-70% “Classical” form:  rapidly 
progressive dementia and 
neurological signs including 
Heidenhain form 
75-80% >96% Striatum 
79% 
(15/19) 
MM2-
cortical 
1-2% Slowly progressive dementia, 
late myoclonus, 
pyramidal/extrapyramidal signs 
50% 
(2/4 
100% 
(4/4) 
Striatum 
0% (0/4) 
Cortex 
100% (2/2) 
MM2-
thalamic 
1-2% Psychiatric symptoms, 
autonomic failure, ataxia, 
dementia (“sporadic fatal 
insomnia”) 
0% 
(0/1)-
20% 
(1/5) 
20%(1/5)-
100% 
(1/1) 
Normal (5/5 
MRI) 
MV2 10% Slow cognitive decline, 
extrapyramidal akinetic-rigid 
sign, myoclonus 
0% 
(0/10) 
30% 
(3/10)  – 
57% (4/7) 
Striatum 
50% (5/10) 
– 100% 
(7/7) 
VV1 1-2% Young patients, prolonged 
duration, personality changes, 
dementia 
0% (0/9) 100% 
(9/9) 
Striatum 
28% (2/7) 
Cortex 
100% (7/7) 
VV2 10-15% Dementia, ataxia, myoclonus 0% 
(0/15) 
84% Striatum 
70% (7/10) 
 
 
Adapted from Tschampa et al 2007 30. 
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1.1.5.2 Variant CJD 
In 1995 reports of suspected sCJD occurring in teenagers 31;32 were considered to be 
extremely rare and unusual findings.  When further cases in young adults were 
discovered a review of the histology showed a consistent and unique neuropathological 
appearance and this previously unrecognised disease was termed vCJD.  Direct 
experimental evidence from molecular analysis of prion strain type and transmission 
studies in transgenic and wild type mice revealed that the disease was caused by the 
same prion strain as that causing BSE in cattle18.   
 
In June 2010, a total of 195 vCJD cases had been reported, including 173 cases in the 
UK, 25 in France, 5 in Spain, 4 in Ireland, 3 in the USA and Netherlands, 2 in Italy and 
1 each in Canada, Saudi-Arabia and Japan (for up-to-date numbers please refer to 
www.eurocjd.ed.ac.uk/vCJD.htm).   
 
Patients typically present with subtle behavioural or psychiatric disturbance and in some 
cases dysaesthetic or sensory limb symptoms are a prominent early feature 33.  
Depression is common but other psychiatric features also occur including anxiety, 
withdrawal, emotional lability, aggression, insomnia or auditory and visual 
hallucinations.  Will et al reported that 17 of 33 early vCJD patients were first seen by a 
psychiatrist and all but one demonstrated psychiatric symptoms in the early stages of the 
disease 33.   
 
A prominent feature is dyasthesia or pain in the limbs.  Henry et al reported sensory 
symptoms in 42 of the first 50 vCJD cases which included predominantly lower limb 
pain (63%), paraesthesia (31%), dysaesthesia (28%), numbness (25%) and cold feelings 
(25%) 34.  In most cases overt neurological signs are not apparent until later in the 
course of the disease.  In most cases cognitive impairment is accompanied by a 
progressive cerebellar syndrome with gait and limb ataxia.  As deterioration continues, 
limb rigidity and primitive reflexes become evident, eventually with progression to 
akinetic mutism 33.   
 
The mean age of onset is 29 years and the clinical course is usually prolonged (median 
14 months).  The EEG is abnormal with generalised slow wave activity but without the 
pseudoperiodic pattern seen in most sCJD cases.  The CSF 14-3-3 may also be elevated, 
detected with a sensitivity 50-60% and specificity of 94% in vCJD cases.   
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Table 1.4:  World Health Organisation criteria for the diagnosis of vCJD. 
Diagnostic criteria 
 
I 
 A  Progressive neuropsychiatric disorder 
 B  Duration of illness >6 months 
 C  Routine investigations do not suggest an alternative diagnosis 
 D  No history of potential iatrogenic exposure 
 E  No evidence of a familial form of TSE 
II 
 A  Early psychiatric symptoms 
 B  Persistent painful sensory symptoms 
 C  Ataxia 
 D  Myoclonus or chorea or dystonia 
 E  Dementia 
III 
 A  EEG does not show the typical appearance of sCJD (or no EEG 
performed) 
 B  MRI brain scan shows bilateral symmetrical pulvinar high signal 
IV 
 A  Positive tonsil biopsy 
DEFINITE:  IA and neuropathological confirmation of vCJD 
PROBABLE:  I and 4/5 of II and IIIA and IIIB 
 OR 
 I and IVA 
POSSIBLE: I and 4/5 of II and IIIA 
 
 As published in Heath et al 2010 35 
 
In the appropriate clinical setting, the pulvinar sign on MRI is extremely helpful, 36with 
a reported sensitivity of 100% on FLAIR imaging 37 and is now included as part of the 
WHO criteria for the identification of vCJD (Table 1.4).  
 
Polymorphisms at codon 129 appear to be the main genetic risk factor for vCJD 38 with 
every case genotyped being homozygous for methionine at codon 129 apart from one 
recent case report of vCJD in an individual heterozygous for PRNP codon 12939.  This 
case highlights the potential of further clinically silent cases of vCJD in the UK 
population. 
 
1.1.5.3 Inherited prion disease 
10-15% of prion diseases are inherited and occur due to pathogenic mutations in the 
prion protein gene.  Over 30 different mutations have been recognised, due to 3 types of 
pathogenic PRNP mutation:  point mutations leading to either an amino acid 
substitution or a premature stop codon, or insertion of additional octapeptide repeats 
(Figure 1.1.4).   
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(Courtesy of Ray Young, MRC Prion Unit) 
 
Figure 1.1.4:  Scheme demonstrating pathogenic mutations in the PRNP gene.  
Definite or suspected pathogenic mutations are shown above the scheme and 
neutral or disease susceptibility/modifying polymorphisms are shown below. 
 
Some of the mutations are associated with a particular category of prion disease and 
others with a spectrum of clinical phenotypes.  The clinical phenotypes have historically 
been divided into Gerstmann-Straussler-Scheinker syndrome (GSS), fatal familial 
insomnia (FFI) and familial CJD (fCJD).  These descriptions preceded the advent of 
molecular genetic diagnosis.  As clinical experience has been gained in the different 
mutations, the heterogeneity of clinical phenotypes even between individuals with the 
same family has been striking.   
 
The most common worldwide PRNP mutations are P102L, E200K, D178N and OPRI 
40.  Several European studies have reviewed the incidence of inherited CJD: in Germany 
40 out of 578 suspected prion disease cases had a PRNP mutation 41; in Italy, the most 
common mutation was the E200K (30 of 38 inherited cases) 42and in Finland, D178N 
was the most common mutation (12 of 44 cases) 43.  In the UK, the 6-OPRI mutation is 
the most frequently detected40. 
 
The clinical phenotype of inhPrD often overlaps with common causes of dementia such 
as AD and also with sCJD.  However, confirmation of the diagnosis of inhPrDs is easily 
achieved since a blood test is definitive.  Diagnosis may be difficult as often there is no 
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family history (47% of cases report no family history) 43. Non-paternity, the absence of 
a family history and individuals where death occurs prior to disease onset may all make 
diagnosis difficult and some mutations occur de novo 44 or are not fully penetrant 45. 
 
E200K 
The typical presentation is a rapidly progressive dementia with myoclonus and 
pyramidal, cerebellar or extrapyramidal signs.  The presentation of E200K may be 
highly variable, with disease onset occurring over a wide age range  The age of onset is 
slightly younger than that for sCJD with a median age of onset at 58 and a mean disease 
duration of 7 months 46;47.  Atypical clinical presentations include peripheral 
neuropathy, supranuclear gaze palsy and sleep disturbance 40. 
 
Octapeptide repeat insertions 
The clinical phenotype is again highly variable with a median age of onset of 35 years 
(range 21-82) and a disease duration of 7 years (range 3 months – 21 years) 48.  Cortical 
dementia, often with apraxia, is the main clinical feature but cerebellar ataxia, 
pyramidal and extrapyramidal signs, myoclonus, chorea and seizures also occur 49.   
 
P102L 
The typical clinical phenotype of the P102L mutation is the GSS syndrome, which was 
later also described with the less common F198S, A117V, P105L and some D178N 
mutations.  Phenotypic variability is a major feature with a median age of onset at 50 
years (range 25-70) and median duration of disease of 4 years 50 with earliest clinical 
onset for MM homozygotes 51.  The traditional GSS phenotype is of a slowly 
progressive ataxia with later dementia but amyotrophy 52 and a rapid course are also 
sometimes seen.   
 
D178N 
Patients with the D178N mutation may present with the clinicopathological syndrome 
of FFI, characterised by prominent autonomic dysfunction, untreatable insomnia, and 
often myoclonus in addition to other features of prion disease.  The median age of onset 
is 50 years (range 20-71) and median duration of disease 11 months (range 5 months – 4 
years). 
 
 27 
1.1.6 Histopathological findings in prion diseases 
A triad of spongiform change, neuronal loss and gliosis involving astrocytes and 
microglia is the neuropathological hallmark of CJD 53.  Spongiform change is relatively 
specific to CJD and characterised by diffuse or focally clustered, small, round or oval 
vacuoles in the neuropil of the cerebral cortex (whole thickness or deep layers), the 
subcortical grey matter (especially the head of the caudate nucleus), the cerebellar 
molecular layer, and more rarely the brainstem and spinal cord 54.  The extent of 
spongiform change varies greatly between patients, disease subtype and from region to 
region in the brain but the absence of spongiosis is rare.  The presence of vacuoles in the 
nerve cell bodies is uncommon and if ballooning of nerve cells occurs this is usually 
due to ballooning of neurofilament proteins.  The white matter may also be involved, 
with spongiform change and astrocytosis being prominent pathological features of the 
pan-encephalopathic form of prion disease described most frequently in Japan 55. 
 
Neuronal loss occurs in the cortical and subcortical regions and seems to correlate with 
microglial activation and neuronal damage rather than prion protein deposition. This 
frequently affects the granular layer of the cerebellum and variably affects the basal 
nucleus of Meynert 56..     
 
1.1.6.1 Sporadic CJD 
In 1996, Parchi et al. established a molecular basis for pathologically distinct 
phenotypes of sCJD 10.  A classification of sCJD according to prion codon 129 genotype 
and prion strain type (1 or 2) identified six subtypes designated as MM1, MM2, MV1, 
MV2, VV1 and VV2.  The different subtypes of sCJD not only have specific molecular 
and clinical characteristics but also have specific histological characteristics.  The most 
common subtypes accounting for 70% of all sCJD and associated with PrPSc strain type 
1 (MM1 and MV1) are characterised by a variable degree of spongiform change, gliosis 
and neuronal loss affecting mainly the cerebral cortex, striatum, medial thalamus and 
cerebellum, whereas the hippocampus, hypothalamus and brainstem are relatively 
spared.  In the cerebral cortex vacuolization is seen in all layers and is often more 
prominent in the occipital lobe.  Immunohistochemistry demonstrates a synaptic pattern 
of PrP staining involving most grey matter structures of the cerebrum with relative 
sparing of the hippocampal formation. 
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The second most common phenotype, comprising 15% of case, includes patients with 
strain type 2 (VV2) and is characterised by moderate to severe spongiform change and 
gliosis with variable neuronal loss in the limbic structures, striatum, thalamus, 
hypothalamus, cerebellum and brainstem nuclei.  Neocortical involvement occurs as the 
disease progresses, particularly in the occipital lobe which may be spared with a 
relatively rapid course.  The spongiform change is often laminar and mainly involves 
the deep cortical layers.  Immunostaining is characterised by the presence of plaque-
like, focal PrP deposits which are present in relatively large amounts throughout the 
brain other than the neocortex where these are barely detectable 53. 
 
The third most common phenotype described in approximately 8% of cases is the MV2 
subtype, characterized by kuru type amyloid plaques in the upper regions of the granular 
layer of the cerebellum but also in the cerebral cortex, striatum and thalamus.  The 
MM2-cortical subtype shows similar pathology to that of the MM1 subtype except that 
the cerebellum lacks significant spongiform change, typically consisting of large and 
coarse vacuoles.  The MM2-thalamic variant is indistinguishable from fatal familial 
insomnia (FFI).  Finally, in the rare phenotype VV1, the corticostriatal regions are 
predominantly affected while other subcortical structures including the cerebellum are 
relatively spared.  There is relative sparing of the occipital lobe in comparison to the 
frontal and temporal lobes with numerous ballooned neurons in the cerebral cortex 53. 
 
1.1.6.2 Variant CJD 
Post-mortem findings in vCJD show the histopathological hallmarks of prion disease:  
degeneration, astrocytic proliferation and neuronal loss 57.  However in vCJD, this is 
accompanied by deposition of PrPSc in the form of multiple rounded amyloid plaques 
often with a dense eosinophilic core and a pale radiating fibrillary periphery surrounded 
by a rim or halo of spongiform change (Figure 1.1.5) 53.   
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Figure 1.1.5:  Histology sections demonstrating large plaques in the frontal cortex 
and tonsil in vCJD. H&E staining reveals rounded amyloid plaques with a dense 
eosinophilic core and a halo of spongiform change (A), PrP immunostaining with 
ICSM35 shows that the plaques are composed of PrP (B), PrP immunostaining also 
reveals large plaques in the tonsil (C). 
 
These plaques are present in large numbers in the cerebral and cerebellar cortex, 
particularly in the occipital cortex.  Rounded amyloid plaques without spongiform 
change can be identified in subcortical grey matter structures including the basal 
ganglia, thalamus and hypothalamus.  However, they are not found in the brainstem and 
spinal cord.  Spongiform change is most severe in the basal ganglia, particularly in the 
caudate nucleus and putamen which contain relatively few amyloid plaques.  The 
thalamus, hypothalamus, brainstem and spinal cord exhibit little spongiform change or 
amyloid plaque formation.  Severe neuronal loss occurs in the posterior thalamic nuclei, 
periaqueductal grey matter and colliculi with a marked accompanying astrocytosis.   
 
1.1.6.3 Inherited prion diseases 
E200K 
The histological changes are similar to those of the sCJD MM1 subtype and 
characterised by the presence of spongiform degeneration, astrogliosis and neuronal loss 
without amyloid plaques.  The cerebral cortex, striatum, medial thalamus and 
cerebellum are mainly involved and immunostaining consistently shows a synaptic 
pattern 58.   
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D178N 
The most frequent findings are of spongiform degeneration, associated with a prominent 
astrogliosis, often in the form of gemistocytic astrocytes and variable degrees of 
neuronal loss 59.  Frontal and temporal cortices are generally more severely affected 
than the occipital cortex.  The caudate and putamen usually show severe spongiform 
degeneration. The thalamus is minimally affected and the cerebellum is spared 58. 
When associated with the FFI phenotype, there is severe atrophy of the anterior ventral, 
medial dorsal and thalamic nuclei with 80-90% neuronal loss and a 2-3 fold increase in 
astrogliosis whilst spongiform change is relatively absent.   
 
P102L 
This genotype is characterized by PrP-amyloid plaques and diffuse deposits that are 
associated with moderate to severe neuronal loss and glial proliferation in the cerebral 
cortex, deep grey nuclei and cerebellar cortex.  The PrP amyloid deposits are 
birefringent after Congo red staining and strongly fluorescent after thioflavin S 
treatment.  The amyloid is composed of bundles of fibrils radiating out from a central 
core, each fibril measuring 8-10 nm in diameter. 
 
 
 31 
1.1.7 MRI findings in prion disease 
Although initially performed to exclude treatable brain diseases, recent advances in 
MRI technology, including more sensitive and faster sequences, have lead to MRI 
becoming an extremely important diagnostic tool in human prion diseases.  MRI studies 
are now included in the WHO diagnostic criteria for vCJD and the routine use of DWI 
has enabled earlier and more accurate diagnosis of sCJD, often with avoidance of brain 
biopsy.  MRI is a very powerful non-invasive technique for imaging soft tissue in vivo 
with detailed anatomical resolution and has a high sensitivity for the detection of 
neuropathology which alters T1 and T2 relaxation or the water diffusion properties of 
affected tissue.   
 
1.1.7.1 Sporadic CJD 
Increased signal in the striatum, cortex and to a lesser extent in the thalamus are the 
classical findings in sCJD (Figure 1.1.6).  The extent of involvement and the 
distribution of signal changes varies amongst patients with Young et al reporting in 40 
patients with sCJD that the combination of signal changes in the cortex and deep grey 
matter occurred in 68% of subjects whilst involvement of the cortex alone was less 
common (24%) and high signal in the deep grey matter without cortical signal change 
was extremely rare (5%) 26.  The cortical signal changes involve all lobes, mainly 
frontal (89%), limbic (79%), parietal (72%) and temporal (65%), while the precentral 
and central gyri are usually spared 60.  However, in another study of 55 patients with 
sCJD, isolated cortical involvement was seen in as many as one third of patients61.   
 
 
Figure 1.1.6:  Axial FLAIR (A) and DWI (b=1000s/mm2) (B) demonstrating 
increased signal in the caudate and putamen bilaterally and diffuse cortical 
hyperintensity 
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There is now evidence that a characteristic lesion profile may occur with each molecular 
subtype of sCJD.  In a study of 211 patients with histopathologically confirmed sCJD, 
basal ganglia hyperintensities occurred more frequently with MV2, VV2 and MM1 
subtypes and widespread cortical signal most common in VV1, MM2 and MV1 
subtypes with thalamic hyperintensities in VV2 and MV2 subtypes 62. 
 
In the majority of cases, the signal changes in the basal ganglia and cortex are 
symmetrical, although a unilateral predominance does occur 63.  Striate and thalamic 
high signal is best detected on T2- and PD sequences 64-72. Recent studies have shown 
that DWI is the best sequence for detecting signal change in the cortex 26;73-75.  The 
combined use of DWI and FLAIR sequences to identify abnormal high signal in the 
cortex and striatum is reported to increase diagnostic sensitivity and specificity for 
sCJD to greater than 91% 26.  In previous studies without the routine use of DWI to 
identify cortical signal change the sensitivity of the striate changes alone was reported 
as 58-78% 65;72.   
 
In many cases, the T2W MRI acquired at an early stage of the disease is normal 76.  
Cortical signal changes often precede the basal ganglia signal changes 76.  Murata et al 
reported a defined temporal sequence of events where high signal starts in the 
anteroinferior putamen and spreads to the posterior part, leading to complete 
involvement of the putamen.  They reported that all putaminal lesions were 
accompanied by increased signal in the ipsilateral putaminal head.  There is one report 
of expansion of the signal changes and general progression to cerebral atrophy 77 and 
there are two reports of disappearance of diffusion signal changes 76;78.  In the end 
stages of disease, there is severe cerebral and cerebellar atrophy, ventricular 
enlargement, atrophy of the brain stem and midbrain 79. 
 
The panencephalic type of sCJD is defined by the prominent involvement of white 
matter and has been reported in a series of 8 cases from Asia, and especially in Japan.  
In this study, prion protein subtypes and codon 129 data were not available and it is not 
yet clear whether this subtype represents a distinct entity or a non-specific end-stage of 
sCJD 80.  T1-weighted (T1W) images are usually normal but one publication reported 
high signal in the globus pallidus 81.  Contrast enhancement does not occur and CT only 
shows atrophy in advanced cases 82.      
 
 33 
The radiological differential diagnosis for the signal change seen in sCJD includes 
carbon monoxide poisoning, cerebral hypoxia, and Leigh’s disease where signal change 
may be seen in the basal ganglia. Cortical signal changes may also be present in cerebral 
hypoxia.  However, the clinical presentation in these cases is entirely different to that of 
sCJD.   
 
1.1.7.2 Variant CJD 
Symmetrical hyperintensity in the pulvinar thalami (relative to the cortex and especially 
the anterior putamen) is characteristic of vCJD and is known as the pulvinar sign 
(Figure 1.1.7).  The pulvinar sign was initially reported to have a sensitivity of 78-90% 
and a specificity of 100% for vCJD and was originally described on T2W, PD and 
FLAIR images 36;37.  The mediodorsal thalamic nucleus is additionally affected in 56% 
of cases and the combination of this with pulvinar signal change on axial MRI produces 
an appearance named the “hockey stick” sign.  In 86 neuropathologically confirmed 
cases, the caudate nucleus was involved in 40% of cases, the putamen in 23.3%, and the 
periaqueductal grey matter in 83.3% 37.  The radiological differential diagnosis for the 
pulvinar sign includes post-infectious encephalitis, cat-scratch disease, and Alpers 
syndrome but again, these diseases have a very different clinical presentation to vCJD. 
 
 
Figure 1.1.7:  Axial T2W (A) and FLAIR (B) demonstrating hyperintensity within the 
pulvinar nuclei and dorsomedial thalamus bilaterally. 
 
 
Variant CJD has the most consistent changes on MRI of any human prion disease type, 
perhaps because only one molecular strain is present.  As yet, there is no evidence to 
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support the use of the pulvinar sign in pre-symptomatic testing for vCJD as all reports 
refer to symptomatic patients.  In one report of a blood transfusion acquired case of 
vCJD, imaging at the time of initial clinical presentation was negative for the pulvinar 
sign and was only positive when the patient was severely affected, suggesting that the 
pulvinar sign is a late feature of vCJD 3.   
 
1.1.7.3 Inherited prion diseases 
Unlike other forms of prion disease MRI is less important in the diagnosis of inhPrD 
since a definitive diagnosis can be made with PRNP genotyping performed on a blood 
sample. MRI is still useful to exclude treatable diseases such as subdural collections or 
vasculitis and can point towards the diagnosis in the early stages, perhaps before an 
inhPrD has been considered.  In a European study of 445 patients with inhPrD, MRI 
scan data was available in 43% of cases and was positive in 50% of patients with the 
E200K mutation, 33% of cases with the GSS clinical phenotype and 18% of cases with 
the FFI clinical phenotype 43.  However, the study did not specify which MRI sequences 
were available.  There are few reports of MRI findings in specific genotypes but a 
recent reports of a family with the E200K mutation have described increased signal in 
the caudate, putamen and thalamus bilaterally 83.  On DWI, abnormalities in the 
cingulate, frontal and occipital cortex were also identified in a pattern similar to that 
seen in sCJD 84.   
 
1.1.8 Histopathology and MRI 
It is not yet known which histopathological changes are responsible for the pathological 
signal change seen on MRI, with many conflicting reports in the literature.  A few 
studies have reported increased spongiosis in anatomical areas corresponding to DWI 
signal change 85-88.  However, another study claims that DWI signal change correlates 
with accumulation of PrPSc, whereas another study found no correlation between ADC 
measurements and any histopathological findings 89.   
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1.1.9 Early diagnosis of human prion disease 
Although the current prognosis for human prion disease is poor, it is important to 
establish an early diagnosis and to exclude potentially treatable alternative diagnoses 
such as cerebral vasculitis.  Early confirmation also excludes uncertainty, allowing a 
care plan to be established including infection control measures and appropriate 
counselling.  With the advent of the first therapeutic trials in prion disease, there is the 
need for early diagnosis in order to allow the possibility of therapeutic intervention 
before significant irreversible neuronal damage has occurred.  Currently, diagnosis of 
human prion disease occurs at a late, clinically-advanced stage on the basis of clinical 
criteria with the support of diagnostic test such EEG, CSF and neuroimaging.   
 
The identification of the pulvinar sign as highly sensitive for vCJD 37;90 has brought 
neuroimaging to the forefront in the diagnosis of prion diseases.  There is a need for a 
non-invasive diagnostic test, ideally of blood, which would allow screening of affected 
or asymptomatically infected individuals.  Until this is developed, neuroimaging has the 
advantage of being non-invasive and potentially a reliable and quantifiable marker of 
disease activity.  
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1.2 Quantitative MRI 
Over the last few years a number of advanced MRI techniques have been developed 
with the aim of detecting subtle pathological changes in brain tissue and indirectly 
reflecting microscopic aspects of tissue damage such as demyelination, microtubule 
breakdown and axonal loss.  The techniques of 1H-MRS, DWI and magnetization 
transfer imaging have been applied to a variety of diseases with clinical applications 
particularly for DWI in stroke imaging.  In dementia imaging, these techniques have not 
been shown to be useful in clinical diagnosis but have shown promising results when 
applied to studies involving groups of patients 91.   In addition, magnetic resonance 
microscopy (MRM) of post-mortem tissue allows the direct investigation of the 
relationship between these quantitative MRI measures and tissue microstructure. 
 
1.2.1 DWI and diffusion tensor imaging (DTI) 
MRI is naturally sensitive to water self-diffusion, as spins undergoing a random 
diffusional motion in the presence of a magnetic field gradient accumulate different 
randomly distributed phase shifts.  This results in a loss of phase coherence and 
therefore in a decrease in signal intensity (SI) which is proportional to the diffusion 
coefficient.  This provides a unique form of MRI contrast that enables the diffusional 
motion of water molecules to be measured and as a consequence of interactions between 
tissue water and cellular structures, provides information about the size , shape, 
orientation and geometry of brain structures 92 
 
1.2.1.1 MRI sequences 
The most commonly applied sequence for producing diffusion-weighted contrast is the 
pulsed gradient spin echo (PGSE) method.  It consists of a 90-180 spin echo pair of 
radiofrequency pulses with large and equal gradients placed on either side of the 180 
pulse (Figure 1.2.1).     
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Figure 1.2.1:  Pulse sequence for DWI 
 
  
 
(As published in Patterson et al 2008 93). 
 
Manipulating the strength of the gradient amplitude (G) and the timing elements of δ 
(little delta), the pulse width, and Δ (big delta), the leading edge of separation or centre-
to-centre spacing, we can control the degree of weighting or b-factor.  In the PGSE 
sequence the value of b is given by 
 
b = γ2 G2δ2 (Δ- δ/3) 
 
Large gradient amplitudes of up to 30mT m-1 are highly advantageous because their use 
means that the timing parameters can be minimized, thus avoiding very long TE values 
but even so, DW acquisitions will have some T2 weighting 94. 
 
The signal strength is described by the equation 
 
S(b) = S(0)exp(-bD) 
 
Where S(b) is the signal for a particular b value and D is the self-diffusion constant for 
the tissue.  However, in practice, the actual diffusion coefficient may contain 
contributions from other movement sources such as micro-circulation in pseudo-random 
capillary systems, bulk flow and movement artefact and also the imaging gradients can 
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also contribute to diffusion weighting.  We therefore usually refer to the ADC which 
can be calculated from two images using the Stejskal Tanner equation 95 
 
ADC=-{In(S1/S2)/(b1-b2)} 
 
where S1 and S2 are the signal intensities of DWI with b-factors of 0 (b1) and 1000 
s/mm2 (b2), respectively.  Alternatively, a range of b values can be applied and a “least 
squares fit” performed which is usually more accurate. 
 
In practice, the echo planar imaging (EPI) is the sequence of choice for DWI with a 
very rapid acquisition time so that little motion induced artefact is encountered 94.   
 
1.2.1.2 DTI 
Pure water is said to have isotropic diffusion properties, in that the direction of 
movement of the water molecules is equal in all directions.  In biological tissues, 
diffusion is restricted by the presence of cell membranes and there may be a preferential 
diffusion direction.  Such directionally-dependent diffusion behaviour is termed 
anisotropy, which reflects to some extent the underlying fibre structure.  The physical 
orientation of the tissue, together with the applied gradient direction will determine the 
SI 96.  The diffusion properties may be described mathematically by a tensor, which is a 
matrix of nine values corresponding to a gradient orientation and a cell orientation:   
 
 
 
 
 
 
The first subscript (x, y, z) refers to the “natural” orientation of the cells or tissue and 
the second refers to the gradient orientation.  The orthogonal elements Dxx, Dyy and Dzz 
correspond to the simple three direction measurements found in commercial scanners.  
In practice, only seven measurements, six tensor components and an unweighted b=0 
image are required.  Once the tensor terms have been found, the diffusivity can be 
described by three eigenvalues that describe the axes of an ellipsoid with direction of 
the eigenvector associated with the largest eigenvalue coinciding with direction of 
maximum diffusion (Figure 2.2) 96.   
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(As published in Beaulieu C, 2002 96) 
 
Figure 1.2.2:  Diagram demonstrating the eigenvalues that describe the diffusion 
tensor.  The ellipsoid representation of the diffusion tensor (A) with λ1  representing 
the diffusivity along the longest axis of the ellipsoid, λ2  represents the diffusivity 
along the second longest axis and λ3  represents diffusivity along the shortest axis 
of the ellipsoid. (A) represents anisotropic diffusion and (B) represents isotropic 
diffusion. 
 
Diffusion tensor measurements result in a rich data set.  Diffusion anisotropy can be 
measured in different ways by applying mathematical formulae and recalculations using 
the underlying eigenvectors97.  A common way to summarise diffusion measurements in 
DTI is calculation of  parameters for overall diffusivity and anisotropy.  The ADC or 
mean diffusivity (MD) serves for overall diffusivity  and is derived from the from the 
trace tensor, while anisotropy is represented by fractional anisotropy (FA) or relative 
anisotropy (RA).94. 
 
FA is a measure of the diffusion tensor due to anisotropy.  The RA is derived from a 
ratio between the anisotropic water and isotropic portions of the diffusion tensor.  Both 
FA and RA are 0.0 for a purely isotropic medium.  For higher symmetric anisotropic 
media FA tends towards 1 whilst RA tends towards √2.  FA can be respresented as 
grey-scale maps but by choosing the eigenvector associated with the largest eigenvalue, 
the principal diffusion direction of the brain structure to be examined can be colour-
coded to give directionally encoded colour FA maps97 
 
DTI provides some insight into the nature and degree of pathological damage that 
occurs in central nervous system diseases when cellular structures are damaged or 
damaged as part of the pathological process.  In white matter, where bundles of axons 
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give healthy tissue a highly ordered structure, diseases that cause axons to degenerate 
and be replaced by amorphous cells cause a reduction in diffusion anisotropy as a result.  
98. Several studies of diffusion tensor imaging in AD have found a specific pattern of 
regional abnormalities with reduced FA in the fibre tracts of the corpus callosum, and 
the white matter of the frontal, temporal and parietal lobes which showed strong 
correlations with neuropsychological measures 99;100[Bozzali et al. 2002;Rose et al. 
2000].  In addition, whole brain and hippocampal ADCs have shown to be higher in 
patients with AD compared to controls 101;102. This increase in diffusivity is thought to 
be associated with loss of neuron cell bodies, synapses and dendrites which cause an 
expansion of the extracellular space where water diffusivity is fastest103. 
 
1.2.1.3 High b value DWI 
The b values that are applied in clinical diffusion studies are usually of the order of 
b=1000 s/mm2.  The application of higher b values has shown that water diffusion in the 
brain is bi-exponential and can be described by fast and slow diffusion coefficients.  
The fast component has a diffusion coefficient on the order of 1.2µm2/ms with a volume 
fraction of 70% whereas the slow population has a diffusion coefficient of 0.2µm2/s 
with a volume fraction of 30%  104.  The assignment of the slow fraction to a distinct 
water population is difficult.  Although it was previously thought that the fast and slow 
water populations represent water from the extra- and intracellular spaces 
respectively105, there is now evidence that both the fast and slow water diffusion 
components arise from the intracellular space 104.   
 
The slow diffusion coefficient offers potential as an image contrast or clinical parameter 
106.  Recent applications of higher b value DWI has increased sensitivity for the 
detection of signal abnormality in ischaemic stroke 107;108 and the grading of cerebral 
gliomas  as well as being more sensitive to white matter degeneration in AD 109.  
Although at higher b values, there is a decrease in signal-to-noise ratio (SNR), this is 
compensated for by an increase in contrast-to noise ratio (CNR)110;111. 
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1.2.2 1H-MRS 
1H-MRS has become well established as a non-invasive technique for studies of 
biological systems in vivo and in vitro 112.  1H-MRS is unique among diagnostic 
imaging modalities in that the signals from several different metabolites are measured 
within a single examination period and each metabolite is sensitive to a different aspect 
of in vivo pathological processes at the molecular or the cellular level.  
 
1.2.2.1 Principles of MRS 
Over the last 50 years, nuclear magnetic resonance spectroscopy has been the 
preeminent technique for determining the structure of organic compounds.  Proton 
nuclei in different compounds behave differently in the NMR experiment because of the 
electrons which surround the protons in covalent compounds and ions.  Since electrons 
are charged particles, they move in response to the external magnetic field and (B0), 
generating a secondary field that opposes the much stronger external field.  This 
shielding effect means that the applied field must be increased for the nucleus to absorb 
at its transition frequency.  The difference between the applied magnetic field and that 
experienced at the nucleus is known as nuclear shielding or chemical shift (σ).    
 
B=B0 (1-σ)  
The chemical shift is so small compared to the actual field strength that it is referred to 
in units of parts per million (ppm) and is it is dependent on the strength of the applied 
field, is often given in reference to a standard compound tetramethylsilane (CH3)4Si 
which as a single proton resonance because it is a completely symmetrical molecule 113. 
 
1.2.2.1 MRI sequences for in vivo 1H-MRS  
PRESS or Point-RESolved Spectroscopy is based on a spin-echo (SE) sequence where 
the 90º pulse is followed by two 180º pulses so that the primary SE is refocused again 
by the third pulse.  Each pulse has a slice selective gradient in order that protons within 
a voxel are the only ones to experience all three RF pulses (Figure 1.2.3).  The SI is 
intrinsically twice as high as STEAM and therefore spectra with a good SNR can be 
acquired in a relatively short time 113. 
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(Courtesy of Ray Young, MRC Prion Unit) 
 
Figure 1.2.3:  Pulse sequence for PRESS:  90º pulse is followed by two 180º pulses 
so that the primary SE is refocused again by the third pulse. 
 
Voxel positioning in the most appropriate anatomical location for the detection of 
neuropathology is paramount and a good shim over the voxel is essential to produce a 
good spectrum preferably with a line width of less than 0.08ppm.  Voxels in 
inhomogenous regions of the brain are difficult to shim.  In general smaller voxels are 
easier to shim, but the signal acquired also depends on the voxel size and therefore 
voxels with 1cm sides are considered the most practical minimum size to achieve a 
reasonable SNR.  Consistent voxel positioning is extremely important for obtaining 
reliable spectra and short echo times give improved SNR.  
  
1.2.2.4 In vivo 1H-MRS 
The most prominent peak of the 1H spectrum belongs to N-acetylaspartate (NAA), at 
2.0ppm (Figure 1.2.5) which under normal conditions is exclusively synthesized in the 
mitochondria of neurons 114 and is considered to be a marker of neuronal density and 
integrity.  Other peaks in the 1H spectrum belong to creatine/phosphocreatine (Cr) at 
3.0ppm considered to be a marker for energy metabolism as phosphocreatine acts as 
reservoir for the generation of ATP.  As the Cr peak is relatively stable with age and in 
a variety of diseases, it is commonly used as a concentration reference.  However, there 
are recent reports of decreased levels with tumours and stroke 112. 
 
For MRS studies on tissues, the choline (Cho) signal is observed as a prominent signal 
at 3.2ppm that includes contributions from free choline, glycerol-phosphorylcholine 
(GPC) and phosphorylcholine (PC) 115.  These are thought to be markers of membrane 
activity since phosphocholines are released during myelin breakdown and increased 
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signal is observed in cancer, ischaemia, head trauma and AD116.  With shorter echo 
times at 10-35ms, the peaks of myo-inositol (MI) become visible with a peak at 3.6ppm.  
The function of MI is not well understood but as glia are known to express higher levels 
of MI than neurons, it has been proposed as a glial marker112. Increased levels have 
been observed in AD and other neurodegenerative conditions 117;118.  However, there are 
technical challenges in obtaining short TE 1H-MRS such as water suppression, signal 
contribution from subcutaneous fat and gradient eddy current distortions, all of which 
reduce the test-retest reproducibility of metabolite measurements.119   
 
  
Figure 1.2.4:  Example of an in vivo 1H-MRS spectrum of the human brain showing 
positions of the NAA at 2.0ppm, Cr at 3.0ppm, Cho at 3.2 ppm and MI at 3.6ppm.
 
 
ppm 
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1.2.3 Magnetic Resonance Microscopy 
MRI has been used to acquire images of the post-mortem brain for a number of years.  
These images complement the work of the neuropathologist by allowing comparison of 
these MRI images with the equivalent physical sections prepared for neuropathological 
assessment.  Post-mortem MRI acquisition provides the opportunity to directly 
investigate the relationship between MRI measures and histology parameters.  Post-
mortem MRI imaging has been applied to the brains of people with diagnoses of 
AIDS120, AD 121 and multiple sclerosis 122;123 focussing on correlating MRI detectable 
lesions directly with the histological findings. 
 
Magnetic resonance microscopy (MRM) refers to the use of high magnetic field 
strength magnetic resonance imaging (MRI) to characterise tissue structure at a 
resolution of less than 100µm.  The high spatial resolution and high signal-to-noise ratio 
(SNR) allows the use of this technique for the mapping of various physical properties of 
tissue water reflecting different aspects of normal tissue microstructure and pathology 
124.  Their measurement, ex vivo, may both inform the interpretation of in vivo MRI data 
and provide pathological measures complementary to conventional histology.  The high 
spatial resolution is attained through the use of strong magnetic field gradients (200-800 
mT/m) and specialized radiofrequency coils 125;126. 
 
To our knowledge, postmortem MRI of tissue at high magnetic field strengths has not 
previously been performed in prion diseases.  Correlation of post-mortem findings with 
antemortem MRI should be interpreted with caution in the context of such a rapidly 
progressive disease as prion disease but the use of magnetic resonance microscopy 
allows an opportunity to directly investigate the relationship between quantitative MRI 
measures and histopathology.
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1.2.4 Methods of image analysis 
1.2.4.1 Region of interest (ROI) 
ROI analysis is extremely useful when there is a priori hypothesis about the location of 
pathology and a good knowledge of neuroanatomy.  The technique can be very sensitive 
to small changes and is relatively easy to implement.  However, ROI analysis can be 
time consuming and poorly reproducible.  To avoid potential bias, the ROI should be 
defined on an image where the contrast does not depend on the quantity being 
measured.  For ADC measurements, the ROIs are usually defined on the b0 image 
which is often of poor contrast and low spatial resolution.  In addition, the ROI size is 
also of importance:  a larger ROI is associated with a reduction in the standard error of 
each measurement due to averaging over more pixels, but also with increased partial 
volume effect 127.  Finally, when comparing multiple ROIs, a correction for multiple 
comparisons must be performed. 
 
1.2.4.2 Histograms 
Histograms are frequency distributions showing the number of voxels within a 
particular range of values defined as “bins”.  Histograms are generally normalized with 
respect to the total number of voxels considered in order to remove variations due to 
between-subject differences in head size.  Several metrics, the most commonly used 
being peak height, peak location and the sample mean can be extracted from the 
histogram and subject to statistical analysis (Figure 1.2.5).  
 
This technique is ideal for studying conditions that affect large regions of the brain, 
avoids bias in positioning ROIs and therefore observer-dependent bias, and avoiding the 
need for performing multiple statistical testing.  A major issue is the performance of the 
segmentation procedures to select the voxels to be included in the analysis.  Poor 
segmentation of CSF might result in different degrees of partial volume, with cerebral 
atrophy therefore providing an undefined contribution to any observed changes.  Again, 
to avoid potential bias, the image data used for segmentation should have the same 
geometric properties as the quantitative images under investigation but the contrast 
should not be dependent on the quantity being measured.  This technique can also be 
relatively insensitive to small, highly localised changes. 
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Figure 1.2.5:  Histogram demonstrating the metrics that can be obtained. 
  
 
 
 
1.2.4.3 Voxel-based analysis 
In voxel-by-voxel analysis, the map of interest is registered into a standard space and 
then voxel-wise statistics are performed to detect regional differences between 
populations or to find areas that correlate with a covariate of interest.  This technique is 
useful when there is no a priori hypothesis about the location of the neuropathology but 
can have a low sensitivity.  However, there can de difficulties when there is 
misalignment, after standard normalization algorithms are employed, leading to 
misinterpretation.  Spatial smoothing is a pre-requisite for this technique, but the extent 
of spatial smoothing can lead to different interpretations 128, such that the optimal extent 
of spatial smoothing is still a matter of debate.  
 
1.2.4.4 Conclusion 
For the purposes of studying this disease, I had a good a priori knowledge as to the 
location of neuropathology from both histological studies and previous MRI reports, as 
mentioned previously.  Therefore, a combination of ROI analysis for small areas of 
interest such as the basal ganglia and histogram analysis for large parts of the brain such 
as the cortical grey matter were used.  Voxel-based analysis techniques were considered 
inappropriate, as the location of neuropathology excluded the white matter and with 
such small numbers of patients, the technique was expected to have a relatively low 
sensitivity. 
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1.3 Therapeutic trials in prion diseases 
Therapeutic strategies in prion diseases include targeting normal PrPC to rendering it 
less available for conversion to pathological PrPSc. These approaches might include the 
isolation of small molecule PrP ligands which bind to and stabilise PrPC, antibodies that 
bind or sequester PrPC, and methods to down-regulate PrPC transcription or translation.  
The conversion of PrPC to PrPSc is postulated to proceed through a highly unfolded state 
that retains little organised native structure, so that compounds which bind to any 
ordered region of PrPC could inhibit the conversion pathway129.  High throughput 
screening of large compound libraries can be applied to detect such ligands and this 
method has already been used for the proteins p53 and transthyretin where genetic 
mutations and altered protein conformations result in disease. 
 
Antibodies against several PrP epitopes have been identified which might act by 
binding cell surface PrPC and reducing its availability for incorporation into propagating 
prions 130;131.  As antibodies do not cross the blood brain barrier, there was no protective 
effects in intracerebrally infected mice but humanised anti-PrP monoclonal antibodies 
may be used for post-exposure prophylaxis of particular risk groups.  Active 
immunisation is limited by immune tolerance to PrP which is a naturally occurring host 
protein.    
 
Other possible future approaches include the use of small duplex RNA molecules to 
silence gene expression in a sequence specific manner – RNA interference (RNAi) 132.  
Lentiviral mediated RNA silencing of PrPC as a possible therapeutic tool may be 
possible but would require effective CNS penetration.   
 
At the request of the Government’s Chief Medical Officer, a clinical trial protocol to 
rigorously assess the effect of the drug Quinacrine was developed and also to provide a 
framework for assessment of new therapies as they are developed.  The MRC Prion-1 
trial, a partially randomised patient preference trial to evaluate the activity and safety of 
quinacrine in human prion disease is now completed 133.  This trial showed that 
Quinacrine at a dose of 300mg does not significantly affect the clinical course of prion 
diseases.   
 
Therapeutic trials in human prion diseases are beset with a number of issues relating to 
the rarity of the disease, the rapid progression, and being uniformly fatal which make 
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randomisation to placebo unacceptable.  As the first generation of treatments proposed 
for prion disease are likely to have only modest effects on disease progression, survival 
duration as an outcome measure requires studies of a large number of patients in order 
to determine efficacy.  The lack of systematic natural history studies of disease 
progression and an absence of biological markers of disease activity makes assessment 
of the effects of treatment extremely difficult.   
 
In clinical trials of neuroprotective drugs, surrogate outcome markers, which are 
supposed to reflect the number of surviving neurons in a clinically meaningful way, 
have been used in addition to clinical measures of cognitive impairment and disease 
severity in AD.  Clinical outcome markers may not distinguish between disease 
modifying effects and purely symptomatic drug effects.  In addition, clinical symptoms 
are usually manifest when the amount the neuron loss/dysfunction is fairly substantial, 
relatively late in the disease process.  Some clinical outcome measures have poor test-
retest reliability, usually because they are based on subjective semi-quantitative 
measures resulting in considerable between-rater and between-site variability.   
 
There is therefore a need to complement clinical outcome markers with objective and 
quantifiable markers that can detect changes in the preclinical stage of disease, have a 
high re-test reliability, that are non-invasive and well-tolerated and also relatively 
inexpensive 134.  Quantitative MRI measures which fulfil the above requirements are 
increasingly being investigated for replacing clinical measures in outcome trials for 
neuroprotective drugs. 
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A IN VIVO 
 
The next three chapters describe the analysis of in vivo MRI data obtained from patients 
diagnosed with prion diseases.  The majority of the work focuses on the use of 
quantitative neuroimaging techniques as measures of disease activity in inhPrDs.  I 
specifically investigated the use of regional and global ADC measures and in a small 
subgroup of patients and I investigated the use of single voxel 1H-MRS.  In addition, I 
also investigated the use of DWI with higher diffusion factors for improved radiological 
diagnosis of sCJD and vCJD. 
 
 
 
2.  Regional and global cerebral diffusion coefficients and disease severity in 
inherited prion disease 
 
2.1 Introduction 
ADC measurements obtained by MRI provide quantitative estimates of regional and 
whole brain water MD and may provide objective non-invasive markers for early 
diagnosis, disease progression or monitoring the effects of therapeutic intervention.  
Although DWI has emerged as a sensitive diagnostic technique in cases of sCJD 
26;60;72;135, few studies have quantified cerebral ADC in the various forms of human 
prion disease 78;136, with even fewer addressing cerebral ADC in inhPrD 83;137.  
 
In this chapter, I measure regional and whole brain cerebral ADCs in patients with 
inhPrD, and for comparison healthy control subjects.  By correlating ADC measures 
with clinical scores I aimed to find sensitive MRI indices of disease severity as potential 
objective biomarkers of disease progression. 
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2.2 Methods 
2.2.1 Patients 
Twenty five patients with inhPrD (13 female, 12 male, mean age 45.2 years, range 32-
58 years) referred to the National Prion Clinic, National Hospital for Neurology and 
Neurosurgery, London, U.K., were included in this study.  All patients were recruited 
into the MRC Prion-1 trial, a partially randomised patient preference trial to evaluate the 
activity and safety of quinacrine in human prion disease 133. Ethical approval for the 
study was granted by the Eastern Multi-centre Research Ethics Committee (MREC), 
and informed consent for participation in the study was given by either the patient or 
patient’s next of kin.  Seven healthy volunteers were also recruited (4 female, 3 male; 
mean age 54.1 years; range 42 – 61 years) with no personal or family history of 
neurological disorders and gave informed consent.   
 
Patients were subject to a structured neurological examination at the time of the MRI 
scan session by a qualified neurologist blinded to the MRI findings, and the following 
scores calculated:  Mini Mental State Examination (MMSE) 138, Clinician’s Dementia 
Rating Scale (CDR) 139, Rankin scale 140, Alzheimer’s Disease Assessment Scale 
(ADAS-COG) 141, Barthel Activities of Daily Living scale (ADL) 142, A clinician’s 
global impression of disease severity (CGIS) 143, Brief Psychiatric Rating Scale (BPRS) 
144.   Please see Appendices A-G. 
 
Fourteen patients were taking a standard clinical dose of Quinacrine 300mg once daily 
as part of the MRC Prion-1 Trial. 
 
2.2.2 MRI acquisition 
All subjects were examined using a GE Signa LX 1.5T MRI system (GE Healthcare, 
Milwaukee, WI).  After scout images were obtained, axial images with slice thickness 
5mm, parallel to the bicommisural line from the craniovertebral junction to the vertex, 
were acquired with T2-weighting (TE 106ms, TR 6000ms, 2 averages, field of view 
(FOV) 24x18cm, matrix 256x224, slice thickness 5mm), and fluid attenuation inversion 
recovery (FLAIR) contrast (TE 161ms, inversion time (TI) 2473ms, TR 9897ms, one 
average, FOV 24 x 24cm, matrix 256 x 224, slice thickness 5mm).  DWI was performed 
using a single-shot echo-planar technique (TE 101ms, TR 10000ms, one average, 
matrix 96 x 128, FOV 26 x 26cm, slice thickness 5mm) with diffusion-weighting 
factors (‘b values’) of 0 and 1000 s/mm2 applied sequentially along three orthogonal 
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axes.  Three-dimensional T1W image data were acquired from 124 contiguous 1.5mm 
thick coronal slices (inversion-recovery prepared spoiled gradient-echo sequence; TE 
5ms, TR 35ms, flip angle 35º, matrix 256x128, FOV 24x24cm). 
 
2.2.3 MRI analysis 
2.2.3.1 Conventional MRI 
The T2W, FLAIR and DWI were reviewed independently by 2 consultant 
neuroradiologists.   Pathological signal changes were assessed in the following regions:  
caudate, putamen, thalamus, frontal, parietal, temporal and occipital cortex.  Where a 
discrepancy was identified, the images were re-reviewed in a consensus reading.  A 
kappa statistic was calculated to assess the level agreement between the two 
independent observers for pathological signal change. 
 
2.2.3.2 Quantitative MRI 
Post-processing was performed at a dedicated work station (Sun Microsystems, 
Mountain View, CA) by a single neuroradiologist blinded to the clinical and genetic 
data.   Using commercially available software (Jim Version 4.0; Xinapse Systems Ltd, 
Thorpe Waterville, UK.), pixel-by-pixel ADC maps were generated from the 
directionally-averaged b=0 and b=1000 s/mm2 images using the Stejskal Tanner 
equation 95 for ADC calculation:  ADC=-{In(S1/S2)/(b1-b2)}, where S1 and S2 are the 
signal intensities of DWI with b-factors of 0 (b1) and 1000 s/mm2 (b2), respectively.  
Following automatic segmentation of brain from non-brain tissue using the brain 
extraction tool (BET), a part of the FSL 3.2 software, FAST segmentation 145 was 
applied to the b=0 images to classify each pixel as either white matter (WM), grey 
matter (GM), CSF or other tissues.  Four classes were selected for segmentation in order 
that dark non-brain matter was processed correctly.  This method uses a prior 
knowledge of the spatial distribution of tissues in the brain in the form of standard 
tissue-type probability maps (provided by the Montreal Neurological Institute) to 
initialise the segmentation and for final segmentation 146. For each data set a mask was 
generated with each intracranial pixel classified as either GM or CSF and, the masks 
were used to extract the appropriate pixels from the ADC map to create a GM ADC 
map and whole brain (WB) ADC map.  To minimise contamination of the measured 
ADC by values from CSF due to partial volume effects, a single morphological erosion 
operation was applied to the both the whole brain and grey matter ADC masks.  The 
GM segment was too thin to support more than one erosion. 
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In order to explore the potential confounding effects of progressive cerebral and 
cerebellar atrophy upon the ADC measurements, normalized volumes of the entire brain 
parenchyma (NBV) were estimated from the T1W volumetric image data for  each 
subject  using the SIENAX software 147;148, again provided as part of FSL 3.2. 
Following extraction of separate  brain and skull images from the single whole-head 
input data 145 the brain image is affine-registered to MNI152 space 149;150 (using the 
skull image to determine the registration scaling); this is primarily in order to obtain the 
volumetric scaling factor, to be used as a normalisation for head size. Next, tissue-type 
segmentation with partial volume estimation is carried out 151 in order to calculate total 
volume of brain tissue.  
 
2.2.3.2.1 Histogram analysis 
A histogram generation algorithm was implemented with in-house software to calculate 
the ADC frequency distribution for each segmented tissue fraction using 3x10-5 mm2/s 
bin widths.  To adjust for inter-subject variability in specific tissue volumes the ADC 
histograms were normalized by dividing the number of counts in each sample bin by the 
total number of pixels for the respective tissue type.  From each normalised histogram, 
the peak height (PH), peak location (PL), mean ADC and ADC value of the 25th, 50th 
and 75th percentiles were calculated (Figure 2.1A for examples of WB and GM ADC 
normalized histograms). 
 
2.2.3.2.2 Region of Interest (ROI) Analysis 
As the deep GM structures were difficult to segment with the available software, the 
mean ADCs  in the head of the caudate nucleus, putamen and pulvinar were determined 
bilaterally by manually drawing around each region on the axial b0 image at the level of 
the genu of the internal capsule using the DispImage software 152.  The ROIs, ranging in 
size from 40-70mm2, were transferred to the inherently co-registered ADC map (Figure 
2.2) and mean ADC recorded for each.   
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. Fig 2.1:  Examples of histograms: (A) Average mean whole brain histograms 
across all patients (blue) and all controls (red) and (B) average mean grey matter 
histograms in all symptomatic patients (blue) and controls (red) demonstrating 
right-ward shift of the histogram. 
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To assess intraobserver variability, the ROI analysis in all 6 regions was repeated for 4 
patient data-sets in 2 sessions separated by 10 days. Bland-Altman analysis 
demonstrated a mean difference of -5.1 mm2/s, (95% CI = -13.75 to 3.55), p=0.235.  To 
assess interobserver variability, a second observer placed ROIs on the same four 
patients and Bland-Altman analysis demonstrated a mean difference of 3.81 mm2/s, 
(95% CI = -5.47 to 13.08), p=0.40.  See Appendix H. 
 
2.2.4 Statistical analysis 
2.2.4.1 Age effects on ADC measures and NBV 
I performed a preliminary Spearman rank bivariate correlation analysis across all the 
subjects (patients and controls) considering age and disease duration versus NBV and 
all the ADC measures, these comprising for the ROIs: mean right head of caudate (RC) 
ADC, mean left head of caudate (LC) ADC, mean right putamen (RP) ADC, mean left 
putamen (LP) ADC, mean right pulvinar (RPu) ADC, mean left pulvinar (LPu) ADC, 
and for the WB and GM histograms the peak height (PH), peak location (PL), mean 
ADC and ADC value of the 25th, 50th and 75th percentiles. 
 
2.2.4.2 Comparison of ADC measures between control and patient groups 
Differences in the central tendencies of the ADC measures between healthy control 
subjects, asymptomatic gene positive and symptomatic patients with inhPrD were 
evaluated with the Kruskal-Wallis test with post-hoc tests.   
 
Patients were considered symptomatic if they or a close informant complained of 
clinical and neuropsychiatric symptoms.  Individuals were considered asymptomatic at 
risk if tested positive for PRNP mutation but they or a close informant did not report 
any clinical or neuropsychiatric symptoms and a clinician thought that they were not 
affected on the basis of the clinical examination. 
 
2.2.4.3 Relationships between MRI measures and disease severity 
The relationship between MRI measures and clinical scores were assessed across the 
whole patient group (symptomatic and asymptomatic patients) in 3 stages.  Initially, 
Spearman rank correlation was used to explore the relationship between each clinical 
score and each MRI variable.  To adjust for multiple comparisons, the significance 
value was set at p<0.01 for each test.  I then assessed correlations between each clinical 
score and each MRI variable by fitting standard normal linear regression models, with 
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outcome the baseline clinical score, considering WB, GM, RC, LC, RP, LP, RPu and 
LPu mean ADC and NBV one at a time in a univariate analysis.  Finally, any factors 
which reached the significance level of p<0.05 were jointly considered in a multivariate 
model with outcome measure clinical score.  The aim of this model was to identify 
which of the MRI variables were independent predictors of clinical score as opposed to 
potential confounders.  All of the predictor variables in the univariate and multivariate 
model were rank transformed to avoid violations of the assumption of a linear 
relationship. 
 
The statistical methods were performed with advice from Dr Sarah Walker, Reader in 
Statistics and Head of Statistics at the MRC Clinical Trials Unit.  With such small 
numbers, non-parametric test were used for initial exploration of the data, followed by 
rank transformation to enable the linear regression analyses.  Strict corrections were not 
used for the multiple comparisons as it was felt that clinical scores and many of the 
ADC histogram parameters were highly related. As a result, a Bonferroni correction 
would have been too conservative, rather, it was better to present the data showing the 
effect size in the linear regression analyses.  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2:  ADC map demonstrating positions of the  
caudate, putamen and pulvinar ROIs bilaterally. 
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2.3 Results 
2.3.1 Clinical Findings 
PRNP genotyping revealed the following mutations in the patient group: 6OPRI, n=9; 
P102L, n=7; D178N, n=2; 5OPRI, n=2; A117V, n=2; Q212P, n=1; E200K, n=1; 
Y163X; n=1.  Nineteen of the patients were symptomatic at baseline with mean disease 
duration at the time of MRI scan of 43.94 months (range 3-138 months).  Six patients 
with mutations in the PRNP gene were asymptomatic at the time of the MRI 
examination.   
 
2.3.2 MRI findings 
Good quality images were obtained in all patients.  Motion artefacts or changes in head 
position between the b0 and b1000 images hindered the segmentation of grey matter in 
2 symptomatic patients.  However, in these patients, it remained possible to segment the 
CSF and therefore calculate the WB ADC histograms. 
 
2.3.3 Conventional MRI appearances 
On initial assessment, there were discrepancies in 2 patients where one observer noted 
signal change in the frontal cortex in one patient and another observer noted signal 
change in the peri-habenular region in another patient (kappa score 0.835).   On 
consensus review of these cases, no evidence of pathological signal change in any of the 
areas: caudate, putamen, thalamus, frontal parietal, temporal and occipital cortex was 
demonstrated.   
 
2.3.4 Age effects on ADC parameters and NBV 
There was no significant correlation between age or disease duration (for symptomatic 
patients only) and any of the MRI variables. 
 
2.3.5 Comparison of ADC measures between control and patient groups 
Table 1 lists the mean age, MMSE, ADC measures for healthy control subjects and 
symptomatic patients with inhPrD.  Bilateral ROI ADCs were considered as separate 
parameters, since a Wilcoxon test revealed a significant right ROI versus left ROI 
difference for the putamen (p=0.002) and pulvinar (p=0.009) ROIs in the patient  
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Table 2.1: Mean baseline ADC parameters in symptomatic patients, asymptomatic 
gene positive subjects and healthy control subjects. 
Index A: Healthy control 
subjects (n=7) 
B: Asymptomatic 
gene-positive (n=6) 
C: Symptomatic 
patients (n=19) 
P 
value# 
Age (years) 54.14 (6.69) 39.67 (4.84) 43.26 (8.06) <0.01* 
MMSE 29.7 (0.49) 29.5 (0.74) 20.7 (6.60) <0.01 
WB mean ADC x10-3 (mm2/s) 0.89 (0.03) 0.87 (0.02) 0.96 (0.08) <0.01* 
WB PH 0.84 (0.09) 0.88 (0.07) 0.73 (0.13) 0.02 
WB PL (x10-3mm2/s) 0.71 (0.02) 0.71 (0.02) 0.73 (0.04) 0.07 
WB p25 (x10-3mm2/s) 0.66 (0.02) 0.65 (0.02) 0.69 (0.04) 0.02 
WB p50 (x10-3mm2/s) 0.75 (0.02) 0.74 (0.02) 0.81 (0.06) <0.01* 
WB p75 (x10-3mm2/s) 0.89 (0.04) 0.88 (0.03) 0.10 (0.12) 0.01 
GM mean ADC (x10-3mm2/s) 0.91 (0.09) 0.87 (0.06) 1.09 (0.26) <0.01* 
GM PH (x10-3mm2/s) 0.78 (0.14) 0.95 (0.15) 0.68 (0.20) 0.29 
GM PL (x10-3mm2/s) 0.78 (0.06) 0.78 (0.04) 0.94 (0.26) 0.02 
GM p25(x10-3mm2/s) 0.72 (0.06) 0.72 (0.04) 0.86 (0.21) 0.02 
GM p50(x10-3mm2/s) 0.83 (0.08) 0.80 (0.06) 0.99 (0.25) 0.03 
GM p75(x10-3mm2/s) 0.96 (0.11) 0.90 (0.07) 1.16 (0.31) 0.04 
RC mean ADC (x10-3mm2/s) 0.71 (0.05) 0.72 (0.05) 0.74 (0.05) 0.37 
LC mean ADC (x10-3mm2/s) 0.74 (0.03) 0.69 (0.04) 0.75 (0.07) 0.06 
RP mean ADC (x10-3mm2/s) 0.74 (0.02) 0.73 (0.02) 0.75 (0.04) 0.31 
LP mean ADC (x10-3mm2/s)  0.73 (0.05) 0.71 (0.02) 0.73 (0.03) 0.45 
RPu mean ADC (x10-3mm2/s) 0.79 (0.05) 0.76 (0.03) 0.83 (0.06) 0.02 
LPu mean ADC (x10-3mm2/s) 0.78 (0.04) 0.73 (0.02) 0.80 (0.05) 0.02 
Note. All values are mean (standard deviation). 
WB = whole brain histogram, GM = grey matter histogram, RC = right caudate ROI, LC = left caudate ROI, RP = right 
putamen ROI, LP = left putamen ROI, RPu = Right pulvinar ROI, LPu = Left pulvinar ROI, PH = Peak Height, PL = Peak 
Location, p25 = 25th percentile, p50 = 50th percentile, p75 = 75th percentile. 
 
#Kruskal-Wallis test 
 
*post-hoc tests: 
Age:  A versus B (p=0.002), A versus C (p=0.004), B versus C (p=0.366) 
WB mean:  A versus B (p=0.445), A versus C (p=0.006), B versus C (p=0.004) 
WB p50:  A versus B (p=0.731), A versus C (p=0.008), B versus C (p=0.005) 
GM mean:  A versus B (p=0.731), A versus C (p=0.024), B versus C (p=0.002)
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group.   Mean age and MMSE were higher in the healthy control subjects than the 
symptomatic patients.  For the WB and GM tissue fractions, the ADC histograms were 
shifted towards higher values in the symptomatic patient group compared to the healthy 
control subjects (Figure 2.1A and B).  The most significant differences between groups 
were for the WB mean ADC (p=0.006) and WB median ADC (p=0.008).  There were 
also significant differences between patient groups for GM mean ADC (p=0.024) and 
GM p25 ADC (p=0.019).  For the ROIs, although there was a trend for higher mean 
ADCs in the symptomatic patient group compared to the healthy control subjects, 
differences in the individual ROI mean ADCs did not reach significance. 
There were no significant differences in any of the MRI measures comparing the 
healthy control subjects and the asymptomatic gene positive subjects with inhPrD.  
 
2.3.6 Relationships between MRI measures and disease severity 
I found a number of significant associations suggesting increases in ADC, and a 
decrease in NBV, with increasing disease severity.  Table 2.2 provides a synopsis of the 
correlations observed.  All the GM histogram parameters correlated with MMSE, ADL, 
ADAS-COG, CDR and CGIS.  The strongest associations were between GM mean 
ADC and MMSE (p<0.0001) (Fig 2.3A), ADAS-COG (p<0.0001), CDR (p<0.0001) 
(Fig 2.3B) and CGIS (p<0.0001).  All the WB histogram parameters correlated with 
MMSE and less strongly with ADAS-COG and CDR.  The strongest association was 
between mean WB ADC and MMSE (p=0.006).  NBV was strongly associated with 
MMSE (p=0.001) (Fig 2.3C) and CDR (p=0.001)  
For the ROI analysis, mean ADCs also increased with disease severity.  The strongest 
associations were between RPu mean ADC and ADAS-COG (p<0.0001), MMSE 
(p=0.001) and CGIS (p=0.001) but the LPu mean ADC correlated most strongly with 
CGIS (p=0.003) and less strongly with MMSE (p=0.032).  Figure 2.4 demonstrates the 
association between global severity score and pulvinar mean ADC.  The other ROI 
mean ADCs correlated with some of the clinical scores but only weakly and 
inconsistently except the left head of caudate mean ROI which correlated with MMSE 
(p=0.008).   
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Table 2.2:  Synopsis of Spearman Rank Correlations between Clinical Scores and 
MRI measures. 
MRI measures MMSE Barthel ADAS-
COG 
CDR CGIS Rankin BPRS 
WB mean ADC (x10-3mm2/s) -0.541 -0.198 0.433 0.565 0.399 0.432 0.151 
WB PH  0.511 0.267 -0.415 -0.582 -0.408 -0.466 -0.209 
WB PL (x10-3mm2/s) -0.328 -0.059 -0.013 0.322 0.215 0.314 0.042 
WB p25 (x10-3mm2/s) -0.462 -0.156 0.276 0.517 0.457 0.424 0.144 
WB p50 (x10-3mm2/s) -0.539 -0.274 0.336 0.587 0.474 0.516 0.177 
WB p75 (x10-3mm2/s) -0.506 -0.180 0.434 0.529 0.353 0.390 0.132 
GM mean ADC (x10-3mm2/s) -0.767 -0.610 0.757 0.832 0.682 0.608 0.149 
GM PH 0.583 0.545 -0.586 -0.751 -0.567 -0.576 -0.015 
GM PL (x10-3mm2/s) -0.544 -0.332 0.513 0.526 0.389 0.351 0.063 
GM p25(x10-3mm2/s) -0.654 -0.483 0.671 0.652 0.564 0.458 0.130 
GM p50(x10-3mm2/s) -0.677 -0.570 0.679 0.765 0.642 0.576 0.081 
GM p75(x10-3mm2/s) -0.709 -0.584 0.717 0.804 0.660 0.615 0.112 
RC mean ADC (x10-3mm2/s) -0.405 -0.054 0.250 0.157 0.085 0.146 -0.245 
LC mean ADC (x10-3mm2/s) -0.531 -0.283 0.420 0.443 0.469 0.260 0.274 
RP mean ADC (x10-3mm2/s) -0.376 -0.155 0.404 0.253 0.244 0.049 -0.037 
LP mean ADC (x10-3mm2/s) -0.026 0.136 -0.006 -0.107 -0.017 0.041 0.021 
RPu mean ADC (x10-3mm2/s) -0.625 -0.368 0.713 0.504 0.615 0.338 0.316 
LPu mean ADC (x10-3mm2/s) -0.439 -0.544 0.421 0.501 0.575 0.526 0.527 
NBV (mL) 0.646 0.284 -0.480 -0.622 -0.488 -0.511 0.316 
 
Note. p<0.01 are in bold.  WB = whole brain histogram, GM = grey matter histogram, RC = right caudate ROI, LC = left 
caudate ROI, RP = right putamen ROI, LP = left putamen ROI, RPu = Right pulvinar ROI, LPu = Left pulvinar ROI, PH = 
Peak Height, PL = Peak Location, p25 = 25th percentile, p50 = 50th percentile, p75 = 75th percentile, NBV = normalized 
brain volume, MMSE = Mini Mental State Examination, ADL = Barthel Activities of Daily Living scale, ADAS-COG = 
Alzheimer’s Disease Assessment Scale, CDR = Clinician’s Dementia Rating Scale, CGIS = A Clinician’s Global 
Impression of Disease Severity, Rankin = Rankin scale, BPRS = Brief Psychiatric Rating Scale.
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B 
          
C 
 
  
Fig 2.3:  Scatter plots of (A) Grey Matter mean ADC and MMSE, (B) Grey Matter 
mean ADC and CDR, (C) Whole Brain mean ADC and MMSE.  
r=-0.767 
r=-0.832 
r=-0.646 
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A 
 
B 
 
Fig 2.4: Scatter plots of (A) Right and (B) Left pulvinar ROI mean ADC and CGIS. 
 
Using a stepwise multivariate regression procedure with each clinical score as the 
dependent variable and each of the MRI variables that correlated significantly in the 
univariate analysis as the independent predictors, GM mean ADC was an independent 
predictor of CDR (p=0.001), Rankin (p=0.02), ADL (p=0.009).  Right pulvinar mean 
ADC was an independent predictor of ADAS-COG (p=0.001) and CGIS (p=0.001). 
r=-0.575 
r=-0.615 
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2.4 Discussion 
This study quantifies cerebral ADC in a cohort of patients with inhPrD.  I have 
demonstrated significantly higher WB and GM mean ADCs in a symptomatic patient 
population compared to a healthy control group. ADC measures from both the WB and 
GM tissue fractions, and pulvinar ROIs correlated positively with disease severity and 
NBV decreased with disease severity. The ADCs obtained in the basal ganglia and WB 
for our control group are consistent with those reported previously 153-155.  Although no 
significant differences between asymptomatic patients with inhPrD and the control 
group were demonstrated for any MRI measure, such changes cannot be excluded given 
the small number of asymptomatic subjects included in the study and the slightly higher 
mean age of our control group.  Our results suggest that quantitative DWI can detect 
tissue damage associated with inhPrD as increased mean ADC in the whole brain, grey 
matter and pulvinar region. 
 
The negative correlation between NBV and disease severity supports the observation 
that progressive cerebral atrophy is a feature of inhPrD 156;157.  It is known that partial-
volume edge-effects can influence segmented brain tissue-fraction diffusion histogram 
measures 158 and it is a concern that cerebral atrophy may modulate this effect, and thus 
indirectly contribute to observed changes in the histogram metrics.  I attempted to 
minimize partial-volume effects in this study by applying a single morphological 
erosion operation to both the whole brain and grey matter ADC masks. However, since 
in the univariate analysis, the GM ADC measures provided stronger correlations with 
clinical scores than NBV, and that the stepwise multivariate analysis suggested that 
NBV did not contribute additional predictive power to the linear model, I believe that 
cerebral ADC, and in particular GM ADC histogram metrics, provide a highly sensitive 
index of pathology in inhPrD, essentially independent of, although possibly 
complementary to, quantifiable changes in brain volume.  
 
Several recent reports have established DWI as the most sensitive sequence for the 
diagnosis of prion diseases, particularly sCJD 26;30;72;135.  However, thus far few studies 
have addressed quantitative cerebral ADC measurement in prion diseases.  Only three 
studies have attempted to quantify cerebral ADCs in inhPrD, two of which have been in 
patients with the E200K mutation which is pathologically similar to classical MM1 
sCJD.  In one study, values in the basal ganglia in 4 symptomatic patients with the 
E200K mutation were lower in the putamen and caudate compared to controls 83.  
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However, voxel-wise SPM analysis demonstrated increased ADC in multiple cortical 
and cerebellar regions where no SI changes could be detected on DWI.  In a larger study 
including asymptomatic gene positive subjects and symptomatic patients with the 
E200K mutation, decreased ADC was seen in thalamo-striatal regions before symptom 
onset 159.  However, in another study increased ADC values were noted in the thalamus, 
in a patient with the D178N mutation, corresponding to increased thalamic gliosis on 
pathological examination 137. These findings suggest that cerebral water diffusivity 
changes may vary according to anatomical location, perhaps reflecting anatomical 
patterns in the severity of histopathological changes.   
 
In other neurodegenerative disorders, whole brain or regional ADC values are usually 
increased in association with clinical or subclinical disease, consistent with our findings.  
Whole brain and caudate ADCs in patients with Huntingdon disease are increased and 
rise with disease progression 160.  In patients with amnestic mild cognitive impairment 
or AD whole brain and hippocampal ADCs have been shown to be higher than in 
controls 118 and higher hippocampal baseline diffusivity is associated with a greater risk 
of progression from mild cognitive impairment to AD 102.   
 
It has been reported that DWI derived ADC measurements inversely correlate with 
histopathological assessment of cellular density in tumours 161;162.  Increase in ADC 
measurements can be seen in in tumours after treatment 163, thought to reflect a decrease 
in tumour cellularity after necrosis, cell death and microcyst formation.  Similarly, the 
increase in diffusivity in neurodegenerative diseases is thought to be associated with 
loss of neuron cell bodies, synapses and dendrites which cause an expansion of the 
extracellular space 102.  
 
The hallmark of all forms of inhPrD is spongiform degeneration of neurones and their 
processes, neuronal loss and intense reactive astrocytosis 164.  Histopathological changes 
are found in the cerebral neocortex, the subiculum of the hippocampus, putamen, 
caudate nucleus, thalamus and the molecular layer of the cerebral cortex 164.  The 
stronger association of the global ADC measures, particularly the grey matter mean 
ADC with disease severity reflect the diffuse nature and anatomical distribution of 
histopathological change seen in prion disease.   
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There is considerable variability of pathological appearance within a patient, between 
patients with the same genotype and between different genotypes in inhPrD.  The 
histopathology also changes with the stage of the disease.  In an animal model of 
scrapie, complete loss of neurons in the terminal stages of disease also resulted in a 
reduction in spongiosis due to loss of the cells exhibiting vacuoles 165.  Our findings of 
increased ADC measurements with disease severity may reflect these histopathological 
changes at the terminal stages of the disease: a combination of decreased spongiosis, 
increased neuronal loss and increased gliosis. 
 
Quantitative MRI studies are susceptible to a number of potential sources of error and 
measurement limitations.  Although masks for the white matter were obtained, these 
were not used to calculate white matter histograms.  Using the essentially T2W b0 
image to segment the CSF and grey matter, some of the basal ganglia structures were 
consistently mis-classified into the white matter mask.  The recent development of more 
sophisticated segmentation approaches may allow the future unambiguous interrogation 
of the cerebral WM tissue fraction in this disease.  In addition, delineation of small 
ROIs manually may increase measurement error and could account for our failure to 
correlate ADC signal change in the caudate and putamen with disease severity.  
 
It is also possible that the changes in ADC observed were influenced to an unknown 
extent by the effects of the drug Quinacrine.  Although I demonstrated clear associations 
between disease severity and ADC measures, it is possible that an as yet unspecified 
interaction of the drug Quinacrine with water diffusivity may have influenced our 
results. It will be necessary to confirm in a larger cohort of affected patients who are not 
undergoing treatment that cerebral ADC changes detected do indeed reflect the disease 
process. Full reports regarding the safety and therapeutic efficacy of Quinacrine in 
inhPrD will be the subject of future communications.  
 
Conventional MRI findings in inhPrD report cortical atrophy, cerebellar atrophy or 
increased T2 signal in the basal ganglia 156;166;167. Some inhPrD cases show 
hyperintensity in the basal ganglia and fronto-parietal cortices, similar to sCJD 168.  In 
the EUROCJD experience with data on 23 specified PRNP mutations, MRI scans were 
only positive in 50% of E200K mutations, 30% of GSS and 18% of FFI cases 43.  In our 
study, conventional MRI, including visual assessment of DWI, was relatively 
insensitive to cerebral pathology in this patient group.  Despite this, I have shown that 
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quantification of cerebral ADC provides both regional and global measures that 
correlate with clinical neurological status.  
 
The advent of potential treatments for a number of neurodegenerative diseases has 
increased the need to develop non-invasive and objective biomarkers of disease 
progression. These should be quantitative with a high test re-test reliability 134.  The 
demonstration that cerebral ADC values correlate with clinical measures of disease 
severity suggests that these techniques will be useful surrogate markers in future 
therapeutic trials in patients with inhPrD. 
 
2.5 Conclusion 
Whole brain and cortical grey matter mean ADCs are significantly higher in 
symptomatic patients with inhPrD compared to controls.  Both global and regional ADC 
metrics correlated with disease severity and were more sensitive predictors of disease 
status than brain volume measurements.  Global and regional ADC measures, 
particularly GM mean ADC correlate with clinical neurological status and show 
promise as quantitative pathological biomarkers in inhPrD.
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3 High b-value diffusion MR imaging and basal nuclei ADC measurements in 
Variant and Sporadic Creutzfeldt-Jakob disease  
 
3.1 Introduction 
The diffusion-weighting factors (“b values”) that are used in routine clinical DWI 
studies are usually in the order of b=1000s/mm2.  Recently higher b value DWI has 
shown increased sensitivity for detection of signal abnormality in ischaemic stroke 
107;108, the grading of cerebral gliomas 169 and has been shown to improve sensitivity to 
white matter degeneration in AD 109.  Higher b values lead to a decrease in SNR but the 
disease detection may be facilitated by an increase in CNR 110;111.  This is partially due 
to the increased diffusion weighting per se, and additionally, high b value DWI offers 
increased sensitivity to any slower diffusion component water compartment present 
within the tissue. 
 
The purpose of this chapter was to investigate whether DWI at high b value 
(b=3000s/mm2) and ADC measurements in the basal nuclei improve the diagnosis of 
vCJD and sCJD compared to visual assessment of than DWI at standard b value 
(b=1000s/mm2). 
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3.2 Methods 
3.2.1 Patients 
Eight patients with vCJD (5 male, mean age 36.1 years, range 19-76) and 9 patients 
with sCJD (6 male, mean age59.2, range 54-72) referred to the National Prion Clinic, 
National Hospital for Neurology and Neurosurgery, London, U.K. were included in this 
study.  All patients were recruited into the MRC Prion-1 trial 133 and ethical approval 
for the study was given by the Eastern MREC and informed consent for participation in 
the study was given by either the patient or patient’s next of kin.  Five healthy 
volunteers (2 male, mean age 41.2 years, range 33 – 52) with no personal or family 
history of neurological disorders were also recruited and gave informed consent.   
 
3.2.2 MRI acquisition 
All subjects were examined using a clinical 1.5T MRI system (GE Healthcare, 
Milwaukee, WI).  After scout images were obtained, axial images with slice thickness 
5mm parallel to the bicommisural line from the craniovertebral junction to the vertex 
were acquired for T2W (TE 106ms, TR 6000ms, 2 averages, FOV 24x18cm, matrix 
256x224), FLAIR (TE 161ms, TI 2473ms, TR 9897ms, one average, FOV 24 x 24cm, 
matrix 256 x 224) and DWI.  DWI was performed using a single-shot echo-planar 
technique (TR 10000ms, one average, matrix 96 x 128, FOV 26x26) with diffusion-
weighting factors (‘b values’) of 0 and 1000 s/mm2 (TE 101ms, 1 average) and of 0 and 
3000 s/mm2 (TE 136ms, 3 averages)  applied sequentially along three orthogonal axes.   
 
Ten patients (5 with vCJD, 4 with sCJD, and 1 growth hormone-related CJD) had 
additional DWI with b values of 0 and 3000 s/mm2 (TE 136ms, 3 averages).  The DWI 
images obtained for each orthogonal direction were averaged to yield diffusion trace-
weighted images for each slice.   
 
3.2.3 MRI analysis 
3.2.3.1 Qualitative analysis by visual inspection  
Two independent consultant neuroradiologists (JS and RJ) with experience in DWI 
imaging performed qualitative analysis of the diffusion trace images in a non-blinded 
fashion.   
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3.2.3.1.1 Assessment of signal intensity changes on b=1000 and FLAIR images 
Basal ganglia and cortical signal intensities were compared with normal grey matter and 
classified and hyper, iso or hypointense to grey matter. 
 
3.2.3.1.2 Comparison of b=1000 and b=3000 DWI images  
Each of the b = 1000 and b = 3000 trace-weighted images were assessed for 
pathological signal changes.  The observers then compared the b = 1000 with the b = 
3000 images side by side, and using a scoring system concluded whether the b = 3000 
images were better (+1), the same as (0), or worse (-1) than the b = 1000 images for 
signal conspicuity.  Where a discrepancy was identified, the images were re-reviewed in 
a consensus reading.  A kappa statistic was calculated to assess the level agreement 
between the two independent observers for pathological signal change. 
 
3.2.3.2 Quantitative MRI 
Post-processing was performed at a dedicated work station (Sun Microsystems, 
Mountain View, Calif) by a single neuroradiologist.  Using commercially available 
software (Jim Version 4.0; Xinapse Systems Ltd, Thorpe Waterville, UK.), pixel-by-
pixel ADC maps were generated, from the b=0 and b=1000 trace-weighted images 
using the Stejskal Tanner equation 95 for ADC calculation:  ADC=-{In(S1/S2)/(b1-b2)}, 
where S1 and S2 are the signal intensities of DWI with b-factors of 0 (b1) and 1000 
(b2), respectively.  This process was repeated for the b=0 and b=3000 trace-weighted 
images. 
 
3.2.3.2.1 Measurement of signal intensity ratios on diffusion-weighted trace images 
The ROIs as described above were also used to measure the MR SI of the caudate, 
putamen, dorsomedial thalamus and white matter from the trace-weighted images 
obtained with both b values of 1000 and b 3000 s/mm2.  Right versus left asymmetry 
was assessed for ADC and SI measurements in the caudate, putamen, pulvinar and 
dorsomedial thalamus using the paired t-test.  As no significant asymmetry was 
detected, mean SI of the caudate (C), putamen (P), dorsomedial thalamus (DM) and 
pulvinar (Pu) ROIs were calculated.  From these SI measurements, the SI ratios of each 
ROI to WM ROI were calculated. 
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3.2.3.2.2 Regional ADC measurements 
Mean ADC in the head of the caudate nuclei, putamen and dorsomedial thalamus were 
determined bilaterally by manually defining regions of interest (ROIs) enclosing each 
anatomical region on the axial b0 image from the b=1000 dataset at the level of the 
genu of the internal capsule.  For the vCJD cases, the ADC values in the pulvinar 
nucleus of the thalamus were also determined.  Two control ROIs were selected in the 
right frontal white matter (FWM) and the superior pons (SP).  The ROIs, ranging in size 
from 40-70mm2, were transferred to the corresponding b=1000 ADC map (see Fig 3.1) 
and then to the b=3000 ADC map, and the mean ADC for each ROI was recorded.  To 
assess intraobserver variability, the ROI analysis in all six regions was repeated for 4 
patient data-sets in 2 sessions separated by 10 days. Bland-Altman analysis 
demonstrated a mean difference of -5.1 mm2/s, (95% CI = -13.75 to 3.55), p=0.235.  To 
assess interobserver variability, a second observer placed ROIs on the same four 
patients and Bland-Altman analysis demonstrated a mean difference of 3.81 mm2/s, 
(95% CI = -5.47 to 13.08), p=0.40.   
 
3.2.4 Statistical analysis 
The paired sample t-test was used to compare ADC and SI ratios between the b=1000 
and b=3000 images. Comparison of mean ADC in each ROI between the vCJD patients, 
sCJD patients and healthy volunteers were determined using a one-way ANOVA and 
ad-hoc multiple comparison tests with Bonferroni correction for each b value.   
 
Figure 3.1:  Demonstrates position of the key ROIs on (A) b0, (B) b1000 ADC map 
and (C) b3000 ADC map. 
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3.3 Results 
3.3.1 Clinical findings 
The 8 patients with vCJD (3 female, 5 male, mean age 36.1 years, range 19-76) were all 
confirmed by either tonsil biopsy or post-mortem examination.  The mean disease 
duration at the time of MRI was 6.2 weeks (range 2 – 16 weeks). The 9 patients with 
sCJD (3 female, 6 male, mean age 59.2, range 54-72) were included in the study.  The 
diagnosis was confirmed in all patients by post-mortem examination in eight patients 
and brain biopsy in one patient.  The mean disease duration at the time of onset was 
16.7 weeks (range 3 – 24 weeks). 
 
3.3.2 MRI findings 
3.3.2.1    Qualitative assessment  
3.3.2.1.1   Visual inspection of trace –weighted and FLAIR images 
All 8 vCJD patients demonstrated bilateral dorsomedial thalamic signal hyperintensity, 
but only 6/8 demonstrated caudate hyperintensity and 4/8 demonstrated putamen 
hyperintensity on FLAIR and DWI (b=1000s/mm2 ).  No cortical hyperintensity was 
visualized.  See Table 3.1 for a summary of SI at b=1000s/mm2 in vCJD and sCJD.  All 
9 patients with sCJD demonstrated cortical signal hyperintensity, predominantly in the 
cingulate cortex and occipital cortex.  All 9 patients demonstrated hyperintensity in the 
head of caudate bilaterally but only 8/9 demonstrated hyperintensity in the putamen and 
6/9 demonstrated hyperintensity in the thalami (see Table 3.1). 
 
3.3.2.1.2  Comparison of b=1000 and b=3000 images 
In the 10 patients that had both b=1000 and b=3000 sequences, I found complete 
agreement between the two observers that in all cases (kappa score 1.0).  In 9 out of the 
10 cases, signal change was more conspicuous on the higher b value images and in one 
case the higher b value image did not aid in assessment, possibly because there was 
some movement artefact.  In all cases, no new areas of signal change were identified on 
the higher b value images, but increased confidence was obtained, particularly for areas 
which were equivocal on the b=1000 images (Fig 3.2).  In particular, cortical and 
thalamic signal changes were more conspicuous at the higher b value.   
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Table 3.1:  Visual assessment of signal intensity findings in vCJD and sCJD on 
FLAIR and DWI (b=1000s/mm2). 
vCJD C P DM Pu Cx SP FWM 
1 + + + + - - - 
2 + + + + - - - 
3 - - + + - - - 
4 + - + + - - - 
5 - - + + - - - 
6 + + + + - - - 
7 + - + + - - - 
8 + + + + - - - 
        
sCJD C P DM Pu Cx SP FWM 
1 + + + + + - - 
2 + + - - + - - 
3 + + + + + - - 
4 + + + + + - - 
5 + + + + + - - 
6 + + - - + - - 
7 + - - - + - - 
8 + + + + + - - 
9 + + + + + - - 
 
 
 
Note. SP = superior-pons, C = caudate, P = putamen, DM = dorso-medial thalamus, Pu = pulvinar, FWM = right frontal 
white matter, Cx = cortex, + hyperintense to grey matter, - isointense to grey matter 
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Figure 3.2:  Differences in signal intensities in the basal ganglia in sCJD at (A) 
b1000 and (B) b3000 and in vCJD at (C) b1000 and (D) b3000 
 
 
3.3.2.2  Quantitative assessment 
3.3.2.2.1  Measurement of SI ratios on trace-weighted images 
The SI ratios were higher in the b=3000 images when compared to b=1000, particularly 
in the DM ROI (1.93 ± 0.72 on b=3000 versus 1.39 ± 0.19 on b=1000, p=0.028). See 
Table 3.2. 
 
Table 3.2:  Summary of SI, values between the b=1000 and b=3000 images in the 
patients (n=10). 
 SI ratio  
b1000 b3000 p value 
C 1.51(0.33) 1.99(1.12) 0.124 
P 1.41(0.47) 2.10(1.73) 0.133 
DM 1.39(0.19) 1.92(0.71) 0.028 
Note. All data is expressed in mean values with standard deviations in brackets. 
SP = superior-pons ROI, C = mean caudate ROI, P = mean putamen ROI, DM = mean dorso-medial thalamus ROI, Pu 
= mean pulvinar ROI, FWM = right frontal white matter ROI 
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3.3.2.2.2   ADC measurements  
3.3.2.2.2.1   ADC measurement in vCJD 
At b=1000, I found significantly higher mean ADC values in the pulvinar ROIs 
bilaterally in the vCJD patients when compared to healthy volunteers (mean Pu ADC = 
837.6±33.0 mm2/s in vCJD patients compared with 748.0±17.3 mm2/s in controls, 
p=<0.001; Table 3.3a).   The mean ADC in the dorsomedial thalamic ROIs were higher 
in vCJD patients when compared to controls but did not reach significance.   There were 
no significant differences in mean ADC in the caudate, putamen and dorsomedial 
thalamic ROIs and there were no significant differences in the mean ADC values for the 
control ROIs.  At b=3000, no significant differences were found for mean ADC values 
in any of the ROIs between vCJD patients and controls. 
 
3.3.2.2.2.2  ADC measurements in sCJD 
At b=1000, I found significantly lower mean ADC values in the caudate and putamen 
ROIs in sCJD patients when compared to controls (mean C ADC = 587.3 ± 84.7 mm2/s 
in sCJD versus 722.7 ± 16.6 mm2/s in controls, p=0.007; mean P ADC = 603.3 ± 98.7 
mm2/s in sCJD versus 727.8 ± 24.4 mm2/s, p = 0.018; Table 3.3A and Fig 3.3A).  There 
were no significant differences in ADC in the DM ROIs between sCJD compared to 
controls.  At b=3000s/mm2, I found significantly lower mean ADC values in the caudate 
and putamen but also in the DM ROIs (mean DM ADC = 485.7 ± 87.4 mm2/s in sCJD 
versus 627.3 ± 13.1 mm2/s in controls, p=0.001) (Fig 3.3B).   
 
Figure 3.3:  Bar charts demonstrating difference in ADC values between sCJD and 
controls at (A) b=1000s/mm2 and (B) b=3000s/mm2    
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Table 3.3: Summary of mean diffusivity values (in mm2/s) measured in vCJD 
patients, sCJD patients and controls for each ROI at (a) b=1000 s/mm2 and (b) 
b=3000 s/mm2 with P-values from post hoc comparisons. 
 
(a) b = 1000 s/mm2 (group averages for 8 vCJD and 9 sCJD patients) 
 
 
 
 
 
 
(b) b = 3000 s/mm2(group averages for  4 vCJD and 5 sCJD patients) 
 
 
Note. All data is expressed in mean values with standard deviations in brackets. 
SP = superior-pons ROI, C = mean caudate ROI, P = mean putamen ROI, DM = mean dorso-medial thalamus ROI, Pu 
= mean pulvinar ROI, FWM = right frontal white matter ROI 
 
Group SP C P DM Pu FWM 
(A)vCJD 741.6(104.0) 687.9(70.6) 670.9(56.2) 834.1(51.3) 837.6(33.0) 820.7(44.6) 
(B)sCJD 753.8(44.3) 587.3(84.6) 603.3(98.7) 691.8(85.7) - 830.9(89.1) 
(C)control 754.8(64.9) 722.7(16.6) 727.8(24.4) 763.7(17.1) 748.0(17.4) 773.7(43.7) 
A versus C P=0.949 P=0.655 P=0.382 P=0.159 P<0.001 P=0.450 
A versus B P=0.941 P=0.021 P=0.167 P=0.001 - P=0.947 
B versus C P=1.000 P=0.007 P=0.018 P=0.137 - P=0.299 
Group SP C P DM Pu FWM 
(A)vCJD 524.5(87.7) 554.8(69.4) 530.3(49.7) 584.7(48.1) 603.2(59.0) 556.6(23.7) 
(B)sCJD 493.9(87.9) 478.4(27.5) 477.1(77.8) 485.8(87.4) - 539.5(39.9) 
(C)control 484.1(19.9) 628.3(15.4) 594.8(8.8) 627.3(13.1) 625.4(10.6) 528.3(41.4) 
A versus C P=0.652 P=0.063 P=0.156 P=0.460 P=0.432 P=0.444 
A versus B P=0.800 P=0.068 P=0.302 P=0.050 - P=0.759 
B versus C P=0.977 P=0.001 P=0.014 P=0.007 - P=0.885 
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3.4 Discussion 
This is, to our knowledge, the first study to investigate high b value DWI in prion 
diseases.  In addition, I have compared regional ADC measurements in patients with 
sCJD and vCJD to those in 5 healthy volunteers and was able to show distinct patterns 
of the ADC changes in the two forms of prion disease.   
 
Several recent reports have established DWI as the most sensitive sequence for the 
diagnosis of sCJD 26;60;72;135.  Visual inspection of the DW trace image demonstrates 
typically increased SI in the cerebral cortex with up to 95 per cent of cases showing  
hyperintensity affecting the insula, cingulate and superior frontal cortex independently 
of deep grey matter involvement 60.  DWI is superior to FLAIR in detecting MRI 
cortical signal change and this has been shown to correlate with lateralised clinical and 
EEG abnormalities 170.  It is suggested that the anatomical distribution of abnormal 
hyperintensity affecting the basal ganglia is influenced by PRNP genotype and PrPSc 
strain type 171;172.  However, using conventional b values, DWI signal change is not seen 
in all patients with sCJD 173.  I have shown that at high b value DWI, both cortical and 
basal ganglia signal changes are better detected in sCJD, thereby improving confidence 
in the radiological diagnosis.  
 
Due to the reported high sensitivity of the pulvinar sign on conventional MRI for the 
diagnosis of vCJD 36, very few studies have investigated DWI in vCJD.  DWI is less 
motion sensitive due to their rapid acquisition time, and pulvinar signal change may be 
more easily detected on DWI images in a restless patient 174.  In vCJD, I also found 
pathological signal change to be more conspicuous on high b value images.  Using 
frontal white matter as reference, I found higher SI ratios at the higher b values, 
particularly in the thalamus.  This is likely to have contributed to the improved detection 
of signal change by our observers.  
  
High b value diffusion-weighted imaging could be very useful for the radiological 
diagnosis of sCJD and vCJD where SI changes are equivocal on the low b value DWI 
images.  As therapies are being developed, the early identification of vCJD and sCJD 
cases is important and DWI at high b value may be helpful.  As the pulvinar sign has 
also been shown to be a late feature in a blood-transfusion acquired case of vCJD 3, it 
remains to be seen whether high b value DWI would allows earlier detection of this sign 
in patients at risk from this disease. 
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There have been a small number of reports on ADC measurements in sCJD 78;89;136 and 
there have been only two case reports describing ADC measurements in vCJD 174;175.  
Although abnormal areas appear bright on trace-weighted images in both sCJD and 
vCJD, I found distinct differences in the ADC values of the affected areas: the ADC 
was reduced in sCJD but elevated in the thalamus in vCJD, when compared to normal 
volunteers.  Reduced ADC measurements in the caudate, putamen and thalamus in 
sCJD are in concordance with previous reports 78;135.  Tschampa et al found decreased 
ADC measurements before signal change was detected in the thalamus in sCJD, 
suggesting that ADC measurements could be more sensitive than visual DWI inspection 
to pathology in this disease 78.  Two studies addressed longitudinal measurements of 
ADC in sCJD 78;135: whereas Murata et al found persistence of reduced ADC values in 
the corpus striatum for over two weeks, Tschampa et al detected an increase in ADC 
values with time and suggested that ADC may vary according to the stage of disease 78.   
 
The precise histopathological correlates for the decreased ADC are not yet known. The 
histological hallmarks of CJD are spongiosis, neuronal loss and gliosis.  It is likely that 
the proportion of these histological changes that are present in the target tissue 
determines the ADC.  Severe spongiform change with areas of confluent vacuolation, 
restricting the extracellular space, has been advocated as potential cause of decreased 
ADC 85;88;135;176.  In  a single case report, Russman et al found a reduction of ADC in all 
regions with spongiform alterations but no correlation between the histological degree 
of spongiform alterations and the decrease in the ADC 89.  Another study claimed that 
DWI signal change correlated with accumulation of the abnormal prion protein PrPSc 177 
and in a further study of 10 patients, decreases in ADC correlated with increased 
spongiosis, gliosis and abnormal prion protein deposition in the cortex but not deep grey 
nuclei of patients with sCJD 88. 
 
In our eight patients with vCJD I found increased ADC in the pulvinar which is in 
concordance with the two previous case reports using ADC measurements 174;175. As in 
these case reports I also found a slightly decreased ADC in the caudate and putamen, 
compared to volunteers, but this did not reach statistical significance.  
 
In some cases the clinical presentation and radiological findings are very similar in 
vCJD and sCJD.  In our study, the thalamus was the only anatomical region where I 
found a significant difference in ADC between sCJD and vCJD.  It is possible that 
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thalamic ADC measurements may be used to differentiate vCJD from sCJD in cases 
where the radiological findings are similar. 
 
From our ADC measurements I conclude that the pulvinar high SI seen on DWI trace 
images in vCJD is due to T2 prolongation rather than restricted diffusion.  The T2 
prolongation of the tissue appears to be made more conspicuous by the longer echo time 
at the higher b value.  It is believed that the histopathological substrate of the pulvinar 
sign is astrocytosis 37.  It is therefore likely that the increased T2 and increased 
diffusivity noted in the pulvinar is due to reactive astrocytosis.  Spongiform change is 
also seen in the pulvinar but the changes are much less pronounced as in the caudate and 
putamen 37.   
 
At higher b values the changes in ADC measurements were more pronounced for sCJD 
and less pronounced for vCJD.  Compared to normal brains I found more significant 
ADC differences, in sCJD at b =3000, but not in vCJD.  As the b value increases, a 
progressive change in visual contrast between brain regions is noticed with reversal of 
the grey-white matter and an overall decrease in ADC 109;111;178.  At high b values, the 
decrease in ADC cannot be adequately explained by monoexponential diffusion in 
tissues and it has been suggested that there are fast and slow components of diffusion in 
the random motion of water molecules in brain tissues 105;179.  Niendorf et al suggest 
that at low b value, DWI signal is dominated by the fast component and at high b value 
the DWI signal is dominated by the slow component.  Our results demonstrate that 
heavier weighting on the slow component at higher b value is more sensitive to 
pathology in sCJD.  Measurements of ADC based on high b value imaging appear to be 
more specific to the histopathological changes that occur in vCJD and sCJD.  
 
3.5 Conclusion 
I have shown that at high b values, signal change is better detected, improving 
confidence in the radiological diagnosis of human prion disease.  I have demonstrated 
anatomically specific ADC changes in human prion disease compared to the normal 
brain and have demonstrated different patterns in the ADC measurements between 
sCJD and vCJD, reflecting the regional variation in the underlying pathology.   
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4. Short TE 1H-MRS as a biomarker in prion disease 
 
4.1 Introduction 
Single and multi-voxel 1 H-MRS at short and long TEs has previously been performed 
in patients with all forms of human prion disease at single time points.  The findings are 
that of a decrease in the NAA/Cr peak area ratio, a marker of neuronal loss, in diseased 
patients when compared to healthy volunteers at various anatomical locations, including 
the basal ganglia, thalami, and cerebellar vermis 83;180-186.   1 H-MRS at short TE permits 
detection of cerebral MI, postulated to be a glial marker 112, in addition to other 
metabolites  In all three studies, an elevation of MI was observed:  in the pulvinar in a 
case of vCJD 180and in the caudate, thalamus and frontal white matter in both 
asymptomatic and symptomatic cases of inhPrD with the P102L mutation 186 and in the 
thalamus in sCJD 187.   
 
The purpose of the work described in this chapter was to i) determine short TE 1H-MRS 
cerebral metabolite concentrations and metabolite ratios in inhPrD and to correlate these 
with clinical scores to investigate cross-sectional relationships with disease severity and 
ii) to investigate longitudinal changes in these metabolites which may provide potential 
biomarkers of disease progression.  
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4.2  Methods 
4.2.1 Subjects 
Seven patients (3 male, 4 female, range 32- 58 years, mean 43.1 years) were included in 
the study.  All patients were being followed in the MRC Prion-1 trial 133 and ethical 
approval for the study was given by the Eastern MREC and informed consent for 
inclusion in the study and 1H-MRS under general anaesthesia (GA) was given by either 
the patient or the patient’s next of kin.  Five healthy volunteers (3 female, 2 male; mean 
age 42.6 years; range 33 – 52 years), with no personal or family history of neurological 
disorders underwent scanning without GA after giving informed consent.   
 
Patients were subjected to a structured neurological examination at 3 month intervals by 
a qualified neurologist.  At each time point, cognitive impairment was assessed using 
MMSE 138, ADAS-COG) 141 and CDR 139;  functional ability was assessed using the 
Rankin scale 140 and ADL 142; psychiatric impairment was assessed with the BPRS 144 ; 
and overall disease severity using CGIS 143.  See Appendices for A – G for examples of 
the score sheets used. 
 
All patients had inhPrD as identified by PRNP genotyping.  Five patients had a 6-
octapeptide repeat insertion (6-OPRI), one a P102L mutation, and one a Y163X 
mutation.  Mean disease duration at the time of first measurement was 65.2 months 
(range 24 – 146 months).  Six of the patients were assessed at 3 month intervals with a 
mean follow up of 8.0 months (range 3-18 months).  Patients 1, 2 and 4 were not taking 
quinacrine.  Patients 3, 5, 6 and 7 were being treated with quinacrine at 300mg daily as 
part of the MRC PRION-1 Trial. 
 
4.2.2 MRI and 1H-MRS acquisition 
Short TE, single-voxel 1H-MRS was performed using an automated PRESS  localisation 
technique with TE 35ms, TR 3000ms, number of excitations (NEX) 8, at 1.5T (GE 
Medical Systems, Milwaukee, WI) under GA (see Appendix I for MRI patient 
information sheet and Appendix J for Standard Operating Procedures under GA).  A 
standard transmit-receive birdcage head coil was used.  In all sessions, axial T2W (TE 
105ms, TR 4000ms, 3 NEX) fast spin-echo (FSE) MRI images through the basal 
ganglia with 1.7mm slice thickness were acquired in order to plan voxel position with a 
neuroradiologist supervising.  In all subjects a 13x15x18mm voxel (volume 3.51ml) 
was centred on the right head of caudate (RHC) to include the right anterior putamen 
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(Figure 4.1a) and a second 13x13x20mm voxel (volume 3.38ml) was centred on the 
right thalamus (RTH) (Fig. 4.1b).   
 
Figure 4.1:  Axial T2W fast spin-echo images demonstrating the positions of: (a) 
RHC voxel, (b) RTH voxel and representative spectra from (c) the RHC voxel (d) 
and RTH voxel in a patient with inherited prion disease (patient 6). 
 
 
 
Water suppression was achieved before localization by a chemical shift selective 
excitation.  T2W FSE (TE 110ms, TR 6000ms, 2 NEX) and FLAIR (TI 2500ms, TE 
160ms, TR 10000ms, 1 NEX) images were also acquired and directionally-averaged 
DWI images were acquired using a single-shot echo-planar technique (diffusion-
weighting (b) = 1000 s/mm2; TE = 100ms, TR 10000ms, 3 NEX).  All patients were 
studied under general anaesthetic to enable tolerance of the MRI protocol and were 
anaesthetized by administration of 50-100mg intravenous propofol.  In 6/7 patients 
where serial examinations were performed, spectra were obtained using the same 
a 
c d 
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protocol at each visit, care being taken to ensure consistency in voxel placement on 
follow-up scanning. For healthy volunteers spectra were acquired using the same 
protocol at one time point only without GA. 
 
4.2.3 MRI analysis 
4.2.3.1  Qualitative 
The T2W, FLAIR and DWI images were reviewed by 2 independent consultant 
neuroradiologists.   Pathological signal changes were assessed in the following regions:  
caudate, putamen, thalamus, frontal, parietal, temporal and occipital cortex.  Where a 
discrepancy was identified, the images were re-reviewed in a consensus reading.   
 
4.2.3.2 Quantitative 
LCModel software 188 was used to estimate relative metabolite peak-areas for NAA, Cr, 
Cho,  and MI using an LCModel basis set obtained for the TE 35ms GE PRESS 
sequence.  As metabolite relaxation times were not measured, absolute quantification 
was not possible and therefore T2W metabolite levels relative to tissue-water were 
estimated and expressed in institutional units (IU) rather than as millimolar 
concentrations.  The metabolite peak-area ratios NAA/Cr, Cho/Cr, MI/Cr and NAA/MI 
were also calculated for each voxel at each time point.  All spectra were visually 
assessed by an independent observer and metabolite data excluded if the standard 
deviation for the model fit in each case were less than 15%, or the spectrum 
demonstrated inadequate signal-to-noise ratio or water line width.  Please see Figure 4.2 
for example of LCModel output. 
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      Figure 4.2:  Example of LCModel output 
 
 
 
4.2.4 Statistical Analysis 
Differences in the central tendencies of metabolite concentrations and metabolite ratios 
between the patient and healthy volunteer groups were assessed for each voxel location 
after logarithmic transformation using the independent t test.  The relationship between 
MRS measures and disease severity at baseline were assessed using linear regression, 
incorporating subject age as a potential confound.  Pair-wise comparisons of the 
metabolite concentrations and metabolite ratios at baseline, 3 months, 6 months and 9 
months were performed using the paired t test.  To account for multiple comparisons, a 
p value of 0.01 was considered significant.  Finally a kappa statistic was calculated to 
assess the level of agreement between the two independent observers for pathological 
signal change on the structural MRI sequences. 
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4.3 Results 
4.3.1 Clinical findings 
The mean patient MMSE of 17.83 ± 4.02 was lower compared to a mean of 30 in the 
healthy volunteers (p=0.004). There was no significant difference in age between the 
patients (41.71 ± 10.09 years) and healthy volunteers (mean age 42.6 ± 7.861 years). All 
patients were symptomatic at the time of baseline MRS, although estimated disease 
durations at this time point ranged from 24 months (patient 5) to 146 months (patient 6).  
They exhibited differing severities of illness at baseline and differing clinical courses.  
Table 4.1 provides a summary of the patient characteristics and clinical scores at 
baseline.   
 
Table 4.1:  Patient characteristics and neurological scores obtained at baseline 
Patient Mutation Disease 
duration 
(months) 
ADAS-
COG 
(75) 
MMSE 
(30) 
BPRS 
(168) 
BARTEL 
(20) 
CDR 
(18) 
RANKIN 
(5) 
CGIS 
(7) 
          
1 P102L 63 13 23 35 13 5 4 4 
          
2 6OPRI 43 - - - 9  3 5 
          
3 6OPRI 93 33 13 - 14 8 3 4 
          
4 6OPRI 33 24 19 35 20 7 3 4 
          
5 Y163X 24 20 19 42 17 3.5 2 4 
          
6 6OPRI 146 23 13 31 15 8 3 4 
          
7 6OPRI 52 13 20 - 18 7 4 3 
 
Note. Scores expected from healthy individuals are indicated in brackets.  – indicates that 
patient was not able to compete the assessment.  ADAS-COG = Alzheimer’s Disease 
Assessment Scale, MMSE = Mini-Mental State Examination, BART = Barthel Activities of 
daily living scale: these measures decrease with disease severity.  BPRS = Brief 
Psychiatric Rating Scale, CDR = Clinician’s dementia rating, RANKIN = Rankin scale and 
CGIS = clinician’s impression of global severity: these measures increase with disease 
severity.
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All patients demonstrated clinical deterioration over time.  Patient 1 was moderately ill 
with a baseline MMSE score of 23 at baseline but had a rapid progression in disease 
severity following the last assessment resulting in death within 2 months.  Patient 2 was 
markedly ill with global dysphasia and disorientation in time and place preventing 
assessment by MMSE, ADAS-COG, BPRS and CDR clinical scores.  Patient 3 was 
moderately ill with marked dyspraxia and disorientation in time and place.  Patients 4 
and 5 were moderately ill at baseline with MMSE scores of 19 each and progressed 
slowly.  Patient 6 was followed up over the longest period (18 months) and progressed 
slowly from moderately ill at baseline to markedly ill.  Patient 7 was mildly ill with 
symptoms of depression and apathy. 
 
4.3.2 Qualitative image assessment 
On initial assessment, there were discrepancies in 2 patients where one observer noted 
signal change in the frontal cortex in one patient and another observer noted signal 
change in the peri-habenular region in another patient (kappa score 0.835).   On 
consensus review of these cases, no evidence of pathological signal change in any of the 
areas: caudate, putamen, thalamus, frontal parietal, temporal and occipital cortex was 
demonstrated.   
 
4.3.3 Quantitative results 
4.3.3.1 Baseline findings 
Representative spectra from the RHC voxel in patient 6 can be seen in Figure 4.1c and 
from the RTH voxel in Figure 4.1d.   A spectrum at 3 months from the RHC voxel in 
patient 2 was excluded from the analysis as the standard deviations for model fitting 
were greater than 15% for all metabolites.  For the same patient, the MI at 6 and 9 
months was excluded from the analysis as the model-fitting standard deviation for this 
metabolite was greater than 15%, possibly due to poor shim and inaccurate water 
suppression. 
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In the RHC voxel, I found a significantly lower [NAA] in patients than in the healthy 
volunteers (6.59IU ± 1.27 in patients versus 9.20IU ± 1.55, p=0.01; Figure 4.3a).  [Cr] 
was borderline lower in the patients than in controls (Figure 4.2b).  No significant 
difference in mean metabolite concentration was noted for [MI].  The mean MI/Cr was 
higher and the mean NAA/MI was lower in the patients than in the healthy volunteers 
but did not reach significance. The standard deviations for each metabolite 
concentration and metabolite ratio were higher in the patient group than in the controls, 
particularly for MI, reflecting the clinical heterogeneity of the former (see Table 4.2).  
In the RTH voxel, [Cr] was borderline lower and [MI] was borderline higher in patients 
than controls (Figure 4.3 d-e).  There were no further significant differences in the other 
metabolites and metabolite ratios between patients and controls in this voxel. 
 
Table 4.2:  Baseline metabolite concentration estimates and metabolite peak-area 
ratios for patients and controls in the RHC voxel. 
 
Parameter Patients Controls Significance* 
Cr 5.86(1.46) 7.72(0.81) 0.03 
Cho 4.28(1.34) 4.43(0.80) 0.69 
MI 3.96(1.38) 4.01(1.75) 0.90 
NAA 6.59(1.27) 9.20(1.55) 0.01 
Cho/Cr 0.74(0.19) 0.61(0.05) 0.26 
MI/Cr 0.69(0.25) 0.53(0.24) 0.24 
NAA/Cr 1.17(0.34) 1.19(0.09) 0.73 
NAA/MI 1.79(0.52) 3.09(2.55) 0.21 
 
 Note. Values are mean (sd) institutional units or ratios 
 *independent t  test on log values, patients vs. controls 
Cr = total creatine, MI = myoinositol, Cho = choline containing compounds, NAA = N-acetylaspartate 
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Fig 4.3:  Metabolite concentration estimates (institutional units) in patients and 
healthy volunteers at baseline: in right head of caudate and putamen voxel (A) 
[NAA], p=0.01; (B) [Cr], p=0.03, (C) [MI], p=0.90; in thalamus voxel (D) [NAA], 
p=0.18; (E) [Cr], p=0.04, [MI], p=0.04.  p-values refer to unpaired t test 
performed on log transformed values, patients versus controls 
 
 
Linear regression revealed no dependence of either metabolite concentrations or peak-
area ratios upon the age of the patient.  In the RHC voxel, I found a significant 
association between higher [MI] and increased CDR (p=0.005; Figure 4.4A).  MI/Cr 
demonstrated weaker association with disease duration at initial scan (p=0.021) and also 
with CDR (p=0.029), increasing with disease severity (Figure 4.4B and C).  There were 
no significant correlations between baseline clinical scores and MRS-measures in the 
RTH voxel. 
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Figure 4.4:  Associations between baseline metabolite right head of caudate 
concentration estimates and peak-area ratios, with clinical scores: (A) [MI] versus 
CDR, r=0.943, p=<0.01; (B) MI/Cr versus CDR r=0.857; p=0.03, (C) MI/Cr versus 
disease duration at baseline, r=0.830 p=0.02 
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A  
  B  
C  
Fig 4.5:  Changes in estimated right head of caudate metabolite 
concentrations with time: (A) Cr, (B) MI, (C) NAA 
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4.3.3.2 Longitudinal findings 
Longitudinal data was obtained in 6 of the patients with a mean follow-up interval of 
8.0 months (range 3-18).   Longitudinal MI estimates in the RHC voxel were available 
in only 5 patients due to the necessary exclusion of poor quality data as detailed above.  
For all patients, [Cr] and [MI] increased with time (Figure 4.5A and B).  Patient 6 was 
followed up for the longest and [MI] initially increased from baseline to 6 months 
before subsequently slightly declining.  [NAA] remained stable except for patient 6 
where [NAA] decreased with time (Figure 4.5C).   
 
Using pair-wise comparisons, I found significant increases in mean [MI] between 
baseline and 3 months (3.96IU ± 1.38 versus 6.44IU ± 0.46, p=0.004), baseline and six 
months (3.96IU ± 1.38 versus 7.32IU ± 0.27, p=0.001) and baseline and 9 months 
(3.96IU ± 1.38 in patients versus 7.27IU ± 0.15, p=0.001).  There were no significant 
differences in the other mean metabolite and metabolite ratios in the RHC voxel or any 
time points in the RTH voxel.  
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4.4  Discussion 
I have quantified cerebral metabolites and metabolite-ratios in a small group of patients 
with inhPrD.  I have shown significantly lower NAA concentrations in symptomatic 
patients compared to healthy volunteers in the caudate and putamen but not in the 
thalamus.  Although no significant differences in MI concentrations were observed 
between patients and controls in the RHC voxel I found borderline higher MI in the 
RTH voxel.  I also found, in the RHC voxel, a significant association of MI with disease 
severity at baseline, and significant increases in MI concentrations with time.  These 
results are preliminary in a small number of patients and need to be confirmed in a 
larger cohort.   
 
Our results are supported by the literature where a number of 1H-MRS studies 
performed with long TEs have reported a decrease in NAA/Cr in inhPrD in multiple 
anatomical regions, including the caudate, putamen, cingulate gyrus and corpus 
callosum at single time points 84;181;184;186.  NAA is exclusively synthesized in the 
mitochondria of neurons and is widely considered to be a marker of neuronal density 
and integrity 114.  In our study, using a short TE, there was no significant change in 
[NAA] with time.  It is possible that our follow-up interval of on average 8 months, was 
too short to allow the evolution of sufficiently large changes in NAA to allow detection.  
Certainly, in an animal model of this disease,  reduced NAA/Cr in the posterior fossa 
was noted at an advanced symptomatic stage (180 days post infection) 189. 
 
In contrast, very few studies in this disease have investigated cerebral metabolite 
abnormalities at short TE, which enables quantification of MI.  An increase in MI was 
observed in the thalamus and frontal white matter in 2 symptomatic patients with the 
P102L mutation 186 and MI was the only metabolite that was elevated in 2 
asymptomatic carriers of the mutation:  in the thalamus, caudate and frontal white 
matter in one patient and in the frontal white matter in the other.  In an animal model, an 
increase in MI was observed in the cerebral cortex of hamsters infected with CJD prions 
190 and an increase in MI/Cr has been observed in the posterior fossa of BSE prion-
infected mice 189.   In the latter study, the increase in MI/Cr preceded clinical signs by 
20 days.  The detected changes coincided with subtle alterations in behaviour 
suggesting that not only is MI/Cr a more sensitive marker of disease progression but 
that MI may be an indicator of functional impairments that precede the development of 
overt motor symptoms. 
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In our study mean [MI] and MI/Cr, although elevated in the RHC voxel, were not 
significantly different between patients and controls in the caudate and only borderline 
elevation was noted in the thalamus.  One possible explanation is the rather wide spread 
of  [MI] in our control group compared to that reported in previous studies 186;187.  I 
found accurate quantification of [MI] challenging in our control subjects compared with 
the inhPrD group; this may be partially a result of greater motion artefact in the awake 
controls, compared with the patients under GA, compromising data quality in the 
spectral region closer to the water resonance. Nevertheless in the RHC voxel in the 
inhPrD group I found a strong association of [MI] with disease severity and significant 
changes in mean [MI] with time, suggesting that [MI] could indeed prove a sensitive 
index of disease progression.   
 
The function of MI is not well understood but as glia are known to express higher levels 
of MI than neurons, it has been proposed as a glial marker 112.  The triad of spongiform 
change, neuronal loss and gliosis involving astrocytes and microglia are the 
neuropathological hallmarks of prion disease, together with abnormal PrP 
immunoreactivity, and although neuronal loss and gliosis are not specific to prion 
diseases, it is generally accepted that the degree of reactive astrocytosis is more intense 
than would be predicted by the degree of nerve cell loss 164. 
 
The severity of the histopathological changes can vary between different forms of prion 
disease with spongiform degeneration found in the cerebral neocortex, the subiculum of 
the hippocampus, putamen, caudate nucleus, thalamus and the molecular layer of the 
cerebral cortex 164.  I observed changes in cerebral metabolite ratios in the right head of 
caudate and putamen voxel but not in the right thalamus voxel.  Although elevated [MI] 
was noted in the thalamus voxel an increase in [MI] with time or correlations between 
[MI] and clinical scores were perhaps not observed due to a saturation effect of the 
greater histological changes. 
 
In our study, the Cr level apparently increased with time in all patients in the RHC 
voxel.  The Cr peak is often presumed stable and is commonly used as a concentration 
reference but decreased levels are observed with tumours and stroke and increased 
levels with myotonic dystrophy 112.  The concentration of Cr is highest in 
oligodendrocytes and astrocytes compared to other cell types 191 and therefore the 
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elevation in Cr could reflect the reactive astrocytosis that is a histological feature of this 
disease.  However, since our measurements were limited to a single TE it cannot be 
discounted that disease-related changes in the concentration or T2 of tissue water in the 
interrogated voxel may also have contributed to the observed changes.  
 
Stability and homogeneity of the main magnetic field are important factors that directly 
impact the accuracy of MRS experiments.  Major sources of frequency drifts include 
air-conditioning cycles and normal drift in the main magnetic field that fall within the 
magnet’s specifications.  Whilst it is possible that magnetic drift may have influenced 
our findings, a standard GE NAA phantom was used to check reproducibility and 
stability of our MRS measurements at each month throughout the time course of the 
MRS study.  
 
The degree of change in the cerebral metabolite ratios differs between the various 
patients studied, with the largest change observed in Patient 1 who died shortly after the 
last assessment.   Patient 6 was followed up for the longest time and showed a plateau in 
the cerebral metabolite ratios.  This large inter-patient variability is possibly due to the 
clinical heterogeneity of our patient group where I observed a wide range of clinical 
scores at baseline.  Our patients also had different mutations in the PRNP gene:  5 
patients with 6OPRI, one patient with Y163X, one patient with P102L mutations.  
There is heterogeneity of clinical phenotype between the different mutations.  Within 
the 6OPRI mutation, the disease course can vary between an aggressive course similar 
to sCJD to a more indolent course over several decades 192.   
 
A potential confound in our study is the use of general anaesthetic in patients but not in 
controls during MRS examinations, which could contribute some of the observed 
between-group differences in metabolite ratios.  However, one study in the literature 
which measured metabolite concentrations in both anaesthetized and awake monkeys 
found that the only difference in the spectra acquired under GA were a decreased line 
width and therefore improved spectral separation and higher sensitivities for the 
detection of metabolite concentrations 193.  It is also possible that changes in cerebral 
metabolites observed were modulated to an unknown extent by the effects of the drug 
Quinacrine.  Pharmacokinetic studies of Quinacrine in mice demonstrate a 
concentration of up to1500ng/g in brain tissue 194 which is several orders of magnitude 
below the concentration of cerebral metabolites that can be detected by MRS.  Although 
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I demonstrated clear associations between clinical presentation and 1H-MRS measures, 
it is possible that an as yet unspecified interaction of the drug Quinacrine with the 
metabolism of NAA and MI may have influenced our results and therefore it is 
necessary to establish in a larger cohort of affected patients who are not undergoing 
treatment, that the MRS changes detected do indeed reflect the disease process. Full 
reports regarding the safety and therapeutic efficacy of Quinacrine in inhPrD will be the 
subject of future communications.  
 
For the assessment of therapeutic efficacy of neuroprotective drugs, there is an 
increasing need to complement clinical outcome markers with objective and 
quantifiable outcome measures that are non-invasive, relatively inexpensive and have a 
high test re-test reliability 134.  Although MRI fulfils many of the above criteria, 1H-
MRS may be particularly useful as changes in cerebral metabolite ratios can be detected 
before the onset of clinical symptoms in prion 186 and other neurodegenerative diseases 
117;118;195  Proton-MRS thus offers promise as a biomarker in detecting neuronal 
dysfunction prior to the onset of neurodegeneration. 
 
4.5 Conclusion 
In this pilot study, anatomically specific changes in MI and NAA were observed with a 
strong association of MI with disease severity at baseline and increases in time that 
were concomitant with clinical deterioration.  In contrast to conventional MRI, 
longitudinal short-TE 1H-MRS metabolite-measures show significant promise as 
surrogate markers of disease progression in inhPrD.  
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B EX VIVO 
 
The previous chapters (2-4) have demonstrated the potential of in vivo quantitative MRI 
in the assessment of prion disease activity in the brain.  As the histopathology of this 
disease is distinctive, MRI examination of post-mortem specimens may inform our 
understanding of the microstructural changes underlying these quantitative MRI 
changes.  The following chapter describes a number of experiments that were performed 
on formalin-fixed brain tissue samples from patients who had died from vCJD.  I focus 
on vCJD because of its importance as a public health issue and the aim of the 
experiments was to determine whether post-mortem MRI at high field (9.4T) can detect 
and quantify the microstructural changes that affect the MRI signal in vCJD.   
 
 
5 Imaging microstructural changes in post mortem brain in vCJD using MRI 
at 9.4T 
 
5.1 Introduction 
The precise histopathological correlates for the MRI signal changes in prion diseases are 
not yet known with conflicting reports in the literature.  Severe spongiform change with 
confluent vacuolation, restricting the extracellular space, has been advocated as a 
potential cause of decreased cerebral ADC seen in vivo 85;87;88;135.  However, another 
study claims that DWI signal change correlates with accumulation of the abnormal 
prion protein PrPSc 88;177.  Due to the inevitable time delays between investigations, 
correlation of post-mortem histopathological findings with antemortem MRI should be 
interpreted with caution in such a rapidly progressive disease.  Magnetic resonance 
microscopy (MRM) of post-mortem tissue, therefore, provides an opportunity to 
directly investigate the relationship between MRI and histopathology by providing high 
resolution structural and quantitative MRI data concurrently with histopathology. 
 
In the work described in this chapter by performing MRI at 9.4T on fixed human tissue 
samples, I aimed to (i) detect structural differences between excised formalin-fixed 
specimens from patients who died from vCJD and a non-CJD control group, comparing 
the results with histological findings and (ii) systematically explore the association of 
quantitative histopathological measures with two important diffusion measures derived 
from DTI: MD and FA, in addition to T1 and T2 relaxometry. 
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5.2 Methods 
5.2.1  Subjects 
This study was approved by the Joint Ethics Committees of The National Hospital for 
Neurology and Neurosurgery and the Institute of Neurology, University College 
London, London WC1N 3BG, UK.  Pulvinar and frontal lobe samples were excised 
from post-mortem formalin-fixed cerebral hemispheres from 6 patients who had died 
from vCJD (4 male, 2 female, mean age 41.6 years, range 19-76 years.  Six non-prion 
disease controls (1 male, 5 female, mean age 68.6 years, range 47-86 years) were also 
obtained.   Prior consent had been given by patients or their families to the National 
Prion Clinic, The National Hospital for Neurology and Neurosurgery, and the Division 
of Neuropathology, Institute of Neurology, University College London, London WC1N 
3BG, UK.  The course of the disease was assessed retrospectively from the case notes 
and the mean length of disease duration at presentation was 16.6 weeks (range 4 – 20 
weeks) and the mean MMSE at presentation was 20.5 (range 18-23).  The control 
specimens were obtained from patients that had died of a number of conditions which 
included AD, Lewy body dementia and vascular dementia.  The mean age was 68.5 
years ± 17.8 and the mean length of fixation was 46.5 weeks ± 14.7. 
 
All the vCJD patients had in vivo MRI imaging performed before death.  4/6 patients 
had antemortem imaging performed at our institution where all subjects were examined 
using a GE Signa LX 1.5T MRI system (GE Healthcare, Milwaukee, WI).  After scout 
images were obtained, axial images with slice thickness 5mm parallel to the 
bicommisural line from the craniovertebral junction to the vertex were acquired for 
T2W (TE 106ms, TR 6000ms, 2 averages, FOV 24x18cm, matrix 256x224, slice 
thickness 5mm), and FLAIR (TE 161ms, TI 2473ms, TR 9897ms, one average, FOV 24 
x 24cm, matrix 256 x 224, slice thickness 5mm).  DWI was performed using a single-
shot echo-planar technique (TE 101ms, TR 10000ms, 1 average, matrix 96 x 128, FOV 
26 x 26cm, slice thickness 5mm) with diffusion-weighting factors (‘b values’) of 0 and 
1000 s/mm2 applied sequentially along three orthogonal axes. 
 
5.2.2  Specimens 
Post-mortem specimens were obtained 24 hours - 7 days after death.  The specimens 
(right cerebral hemisphere) were stored in plastic containers bathed in formalin at room 
temperature, approximately (22°C), until immediately prior to scanning.  The mean 
duration of formalin-fixation for both control and patient specimens was 46.25 weeks 
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(range 4-88 weeks). Two tissue blocks were excised per specimen:  from the pulvinar 
nucleus of the thalamus (the region of specific interest in this study) and the frontal 
cortex (control region). 
 
5.2.3  Specimen preparation 
Excised frontal cortex and pulvinar samples of approximately 20 x 20 x 7mm were held 
in a standard histopathology cassette (Figure 5.1) which was positioned tightly in a 
50ml Vycon tube filled Fomblin Perfluorosolv PFS-1 (Solvay Solexis, Milan, Italy) to 
minimize sample motion (see Appendix K).  Fomblin® is a perfluoropolyether which 
has no MRI visible protons and acts as an embedding and wetting agent, minimizing 
magnetic susceptibility-induced edge artefacts and I have shown that it has no 
significant effect on either quantitative MRI measures or subsequent histopathology 
(see Appendix L).  All samples were transported to the Biological Imaging Centre at 
Imperial College London following appropriate risk assessment, optimisation of 
transport procedures and using a specimen trail document (see Appendix K and M) 
 
 
Figure 5.1:  Protocol for ex-vivo sectioning of the brain and tissue block selection. 
(A)  Coronal FLAIR MRI study demonstrating the pulvinar sign in a patient with v 
CJD, (B) 10mm thickness coronal section of the brain ex-vivo of the same patient 
matched to the MRI slice, (C) 20x20x7mm tissue block of the pulvinar nucleus cut 
from the coronal brain slice in image (B)in standard histopathology cassette, (D) 
T2W image of the same tissue block at 9.4T (TE = 24ms, TR = 2400ms, 
FOV=40x40mm, matrix=512x512, number of averages = 24, slice thickness 
=1mm). 
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5.2.4 MRI sequence optimisation 
MRI was performed with a horizontal bore 9.4T/21cm Varian Inova MRI system 
(Varian Inc, Palo Alto, CA) located within the Biological Imaging Centre at Imperial 
College London using a 43 mm internal diameter quadrature transmit-receive volume 
RF coil (Magnetic Resonance Laboratories, Oxford) at room temperature (bore 
temperature was approximately 22 ºC).  To determine the optimal imaging parameters 
for measurement of MD, FA T1, T2 and for high resolution T2W imaging, a number of 
pilot experiments were performed on a single control specimen.  This was necessary to 
establish preliminary estimates of the MRI properties of these specimens at 9.4T: the 
fact that formalin-fixation may affect quantitative MRI parameters is well known with 
several studies reporting a decrease in T1 and T2 at 1.5T in both grey and white matter 
compared to in vivo values 196-198.  A further complication is that T1 relaxation times are 
prolonged at high magnetic field strengths 199.   
 
5.2.4.1 T2 pilot experiment 
For T2 measurement, a single SE sequence with 4 repeat SE acquisitions with TEs 24, 
36, 48 and 60ms and TR of 2000ms (Figure 5.2).  A single exponential model was fitted 
using the equation S(TE) = ρ(exp(-TE/T2)) where S(TE) is the SI obtained at each TE.  
All image processing was performed off-line, on a dedicated workstation (Sun 
Microsystems, Mountain View, CA, USA), using commercially available software (JIM 
Version 4.0, Xinapse Systems Ltd., Thorpe Waterville, UK.).  A typical T2 of 20ms was 
calculated for the grey matter and 17ms in the white matter.  Poor signal at the TE of 
60ms and a resultant T2 map with reduced SNR and standard deviations for the mean 
T2 grey matter ROI (20ms) were 11.7 – 15.0%.  With adjusted TEs of 10, 22, 34 and 
46ms, the T2 maps were improved with ROI standard deviations of 10.5-11.2%. 
 
 
 
 
Figure 5.2:  Initial T2 experiment:  TE of 24, 36, 48 and 60ms demonstrating 
change in tissue contrast and poor signal at TE of 60ms. 
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5.2.4.2 T1 pilot experiment 
A progressive saturation technique was used for the determination of T1 with a series of 
successive SE sequences with progressively longer TRs.  Compared to low-field in vivo 
work, a shorter TE and longer TRs were used:  TE 15ms and TR 450, 600, 800, 1000, 
2000, 4000ms (Figure 5.3).  Model fitting using the equation S(TR) = ρ(1 – exp(-
TR/T1)) where S(TR) is the SI acquired at each successive TR, again using JIM 
software, revealed a T1 of 959ms for grey matter and 767ms for white matter with 
standard deviations for ROI measurements ranging between 8.2-9.0%. 
 
 
 
 
Figure 5.3:  T1 experiment with TR of 450, 600, 800, 1000, 2000 and 4000ms, 
demonstrating change in tissue contrast at successive TRs. 
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5.2.4.3 High resolution T2W images 
Finally, for the high resolution imaging, the TEs were adjusted for optimal visualization 
of the grey matter by choosing a TE as close to the measured grey matter T2 (20ms) as 
possible and a TR of approximately 3 x the measured T1 for grey matter (959ms).  The 
initial parameters used were TE24ms, TR2000ms and TE60ms, TR 3000ms (Figure 
5.4).   
 
Figure 5.4:  Optimisation of MRI parameters for visualization of the cortex. 
 
 
 
As can be seen above, the images produced with the longer TE and TR are heavily T2W 
and are ideal for viewing the white matter.  However, a more intermediate weighted 
sequence with a shorter TE and TR, revealed more detail within the grey matter (frontal 
cortex).  The matrix size was increased to 512 x 512 and 20 averages were performed to 
increase signal with an acquisition time of approximately 7 hours.   
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5.2.4.4 Image artefacts 
On the initial image acquisition, a low SI line parallel to the edge of the cortical surface 
was noted (Figure 5.5).  In order to investigate whether this was a magnetic 
susceptibility or imaging sampling artefact from the MRI acquisition, the phase and 
frequency encoding directions were reversed for a further acquisition but the artefact 
was still present.  In order to determine whether the artefact was due to RF 
inhomogeneity from the surface coil, the specimen was pushed further into the coil and 
turned around but the artefact remained in the same location.  Finally the sample was 
cut into a smaller piece so that the specimen was not in such close proximity to the 
plastic histopathology cassette to avoid possible chemical shift artefact from the 
plastic/air interface, but again the artefact was in the same location. 
 
 
Figure 5.5:  Fixation artefact in the cortex.  (A) Baseline image demonstrating a low 
signal intensity line parallel to the outer surface of the specimen (arrows).  In order 
to ascertain whether this was an acquisition artefact or intrinsic to the specimen, 
the phase and frequency encoding directions reversed (B), the sample was pushed 
further into the coil (C), the specimen was turned in the coil (D) and finally the 
sample was cut into a smaller piece.  The artefact was present on all images and 
concluded to be intrinsic to the specimen. 
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On histological processing, no abnormality was observed in that location to correlate 
with the MRI abnormality.  It was therefore proposed that the artefact could represent 
the leading edge of formalin fixation which could occur when the formol-saline, in 
which the sample is immersed, is changed.  The artefact could represent a concentration 
of unknown ions which are then dissolved by histological processing.  There are no 
reports of similar artefacts in the literature and the exact cause of this is being currently 
investigated.  I  therefore remained alert to this artefact during the course of our 
experiments.  Fortunately, when the T1, T2 and FA and MD maps were calculated, the 
artefact was no longer visualised and therefore not thought to affect the quantitative 
measurements obtained (Figure 5.6). 
 
 
 
 
Figure 5.6:  T1 and T2 maps of the same specimen as that shown in Figure 5.5 
demonstrating absence of the fixation artefact. 
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5.2.5 Final MRI protocol 
For T1 measurement, successive SE images were acquired with TRs of 450, 600, 800, 
1000, 2000, 4000 ms; TE 15 ms; 2 averages; acquisition matrix size 256x128; slice 
thickness 2 mm. T2 measurements were obtained using a SE sequence to acquire 
successive images with TEs of 10, 22, 34 and 46 ms; TR 2000 ms; 2 averages; matrix 
size 256x128; slice thickness 1 mm.  To investigate tissue-water diffusion, successive 
images were acquired with diffusion weighting applied along 6 non-colinear directions 
(Gx, Gy, Gz = [(1,1,0), (0,1,1), (1,0,1), (-1,1,0), (0,-1,1), (1,0,-1)]) with a diffusion 
weighting (b factor) of 1000 s/mm2, and with no diffusion gradients (i.e. with a b factor 
of 0 s/mm2) and TR 2000 ms; TE 22 ms; matrix size 256x256, 2 averages and slice 
thickness 1 mm. Finally, a high-resolution T2W coronal image (TE 24 ms; TR 2400 ms; 
matrix size 512x512; 20 averages, slice thickness 1 mm; in-plane resolution 78 µm) was 
acquired providing good anatomical contrast for qualitative assessment.  For all 
acquisitions the FOV was 40x40mm and 7 contiguous coronal slices were obtained.  
The total measurement time per specimen was approximately 10 hours. 
 
 
5.2.6 Image analysis  
All image processing was performed off-line, on a dedicated workstation (Sun 
Microsystems, Mountain View, CA, USA), using commercially available software (JIM 
Version 4.0; Xinapse Systems Ltd, Thorpe Waterville, UK.). 
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5.2.6.1 Qualitative 
The high-resolution intermediate-weighted images for each pulvinar and cortical 
specimen were assessed by a single neuroradiologist in a non-blinded manner for visible 
artefacts and any differences in signal intensities between the control and diseased 
specimens.  For the cortical specimens, T2W SI profiles were generated perpendicular 
to the cortical surface, from deep (subcortical U fibres) to superficial (pial surface), to 
objectively depict the differences between vCJD and control specimens. 
 
5.2.6.2 Quantitative 
All quantitative image processing was performed off-line on a dedicated workstation 
(Sun Microsystems, Mountain View, CA, USA). The process was fully automated 
taking ~20 mins. Using commercially available software (JIM Version 4.0; Xinapse 
Systems Ltd, Thorpe Waterville, UK.), T1 and T2 maps were computed by performing 
pixel-by-pixel non-linear fitting to the equations S(TR) = ρ(1 – exp(-TR/T1)) and S(TE) 
= ρ(exp(-TE/T2)), respectively.  S(TR) and S(TE) are the signal intensities of the T1- 
and T2W images acquired at the respective TR or TE, and ρ is the proton density in 
arbitrary units.  DTI data were calculated using Camino 
(http://www.cs.ucl.ac.uk/research/medic/camino/) (Cook et al., 2006) to provide FA and 
MD maps.  
 
5.2.7 Region of Interest (ROI) 
To assess differences between the control and vCJD specimens ROIs were defined in 
the FC and FWM for each frontal lobe specimen and in the Pu for the pulvinar 
specimen (Figure 5.7).  The ROIs (size 40 - 170 mm2) were defined on the SE images 
providing optimal grey-white matter contrast (TE 10 ms; TR 2000 ms), saved and then 
re-loaded for each of the T1, T2, MD and FA maps.  One ROI in each area was 
determined per specimen. 
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Figure 5.7:  High resolution T2W images (TE=24, TR=2400) of the (A) frontal 
cortex and (B) pulvinar specimens, demonstrating manually drawn ROIs in the FC 
(1), WM (2) and Pu (3) 
 
 
5.2.8 Histological analysis 
Following the MRI measurements, samples were re-immersed in 10% buffered formal 
saline for one week (Pioneer Research Chemicals, Ltd., Colchester, UK.) followed by 
incubation in 98% formic acid for 1 h. Following further washing for 24 h in 10 % 
buffered formal saline, tissue samples were processed and paraffin wax embedded. 
Sections were cut at a nominal thickness of 4 µm and mounted on Superfrost UltraPlus 
charged glass slides.  Following dewaxing in xylene and an alcohol gradient, the 
sections were stained with haematoxylin (Harris’ haematoxylin) and eosin (0.5%, 
Merck) (H&E).  For immunohistochemical staining, dewaxed sections were treated with 
98% formic acid for 5 min and then boiled in a low ionic strength buffer (2.1 mM Tris, 
1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) for 20 min for antigen retrieval.  Prion 
Protein (PrP) deposition was visualized using KG9 as the primary antibody (1:2000) 
and gliosis was detected with anti GFAP rabbit polyclonal antiserum (DAKO, 1:1000), 
using an automated immunostaining system (www.ventanamed.com).  
 
Finally, for the cortical samples, Nissl staining was performed for identification of the 
cortical laminations.   
. 
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Figure 5.8:  Scoring scheme devised in conjunction with the neuropathologist using 
specimens from the study for spongiosis, gliosis and prion protein deposition: 
0=none, 1=mild, 2=moderate, 3=severe; spongiosis was detected using H&E 
staining, gliosis was detected with GFAP staining and prion protein deposition with 
KG9 staining   
 
 
All slides were assessed by a single experienced consultant neuropathologist, who was 
aware of the diagnoses.  Areas corresponding to the ROIs on MRI were scored for the 
degree of spongiosis, gliosis and prion protein deposition in a semi-quantitative manner 
from 0 to 3 (0=none, 1=mild, 2=moderate, 3=severe; Figure 6.8).  The scoring scheme 
was devised in conjunction with the neuropathologist using human cortex samples from 
the study.  Photographs were taken on an ImageView digital camera (www.soft-
imaging.de) and composed with Adobe Photoshop. 
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5.2.9 Statistical analysis 
The independent t-test was used to assess differences for each of the 4 MRI measures: 
T1, T2, MD and FA in the FC, FW and Pu ROIs between the prion-diseased and control 
specimens.  The differences in each histology measure: spongiosis, gliosis and prion 
protein deposition between the diseased and control specimens was assessed using the 
Mann-Whitney-U test. A one-way ANOVA with post-hoc tests was used to assess 
differences in measures between the FC, FW and Pu ROIs in each specimen group.  The 
Spearman rank correlation was used to assess the relationship between each MRI 
measure and each histopathology score for the cortex and pulvinar regions in the 
diseased specimens only.  The relationship between each MRI measure and length of 
fixation was also assessed to avoid any confounders.   A value of p < 0.05 was 
considered statistically significant and all statistical tests were performed using SPSS 
for Windows (version 11.5, SPSS, Chicago, IL, USA). 
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5.3 Results 
5.3.1 Specimens 
All vCJD patients exhibited the pulvinar sign on conventional antemortem MRI and 
where obtained (n=4), pulvinar hyperintensity on b1000 DWI in vivo.  No cortical 
signal change was detected on any sequence in vivo.  The control specimens were 
obtained from patients that had died from a number of conditions which included: AD, 
Lewy body dementia and vascular dementia.  Using the independent t-test, the mean age 
was borderline higher in the control specimens (68.5years±17.8 in control versus 
47.8years±25.2 in diseased specimens, p=0.07) but there were no significant differences 
in mean length of fixation (46.5 weeks ± 14.7 in control versus 46.2 weeks ± 25.2 in 
diseased specimens, p=0.98) between the vCJD and control specimen groups. 
 
5.3.2 Post mortem MRI findings 
5.3.2.1 Differences between diseased and control groups 
5.3.2.1.1 Qualitative 
Visual inspection of high resolution T2W images of the frontal cortex revealed, in all 6 
control specimens, an intracortical laminar structure with a low SI layer (arrow, Fig 
5.9A).  When directly compared to the corresponding Nissl stain, the low SI band 
correlated to layer IV of the cortex (Fig 5.9B).  However, in 5/6 vCJD specimens, there 
was apparent loss of the intracortical laminations with homogenous SI across the cortex 
(see Fig 5.9D).  In the remaining vCJD specimen the intracortical structure was 
attenuated but not completely absent.  The cortical SI profiles revealed a focal dip in 
intensity corresponding to layer IV in all 6 control specimens (Fig 5.9C) while for 5/6 
vCJD cases the cortical signal intensities exhibited a smoother profile (Fig 5.9F).  The 
Nissl staining revealed loss of the intracortical structure in vCJD due to neuronal loss 
where there was spongiosis and prion protein deposition (Fig 5.9E). 
Visual inspection of the high resolution T2W images of the pulvinar specimens revealed 
no differences between the diseased and control specimens. 
 
5.3.2.1.2 Quantitative 
I found no significant differences in T1, T2, MD or FA in the frontal cortex, white 
matter and pulvinar ROIs between the diseased and control specimens (Table 5.1).  
However, I found differences in MRI measures between the different regions in both the 
control and vCJD specimens.   
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Figure 5.9:  High resolution MRI and signal intensity profiles in vCJD and controls. 
High resolution T2W image of control specimen (A) demonstrating low signal  
intensity line, (B) corresponding to layer IV in H&E slide and corresponding to the 
dip in SI on the SI profile (C).  (D)  High resolution T2W image of vCJD specimen 
demonstrating more homogenous SI, (E) corresponding to attenuation of layer IV 
due to spongiosis and neuronal loss and supported by loss of demonstration of 
layer IV on the SI profile (F). 
 
 
In the control specimens, significant differences in mean T2, MD and FA were found 
between the cortex compared to white matter but there were no significant differences 
between the pulvinar and any region for any of the MRI parameters (mean FW T2 
=21.3±3.2ms versus mean FC T2 = 28.9±6.5 ms, p=0.01; mean FW MD = 223.5±56.7 
versus mean FC MD=409.8±105.7, p=0.01; mean FW FA = 0.75±0.08 versus mean FC 
FA=0.41 ± 0.08, p=0.001).  In the vCJD specimens, mean T2 was higher in the frontal 
cortex than in the pulvinar and in the white matter:  mean FC T2 =31.7±7.4 ms versus 
mean Pu T2 = 21.1 ± 4.3 ms (p=0.03); and versus mean FW T2 = 21.78±2.92 ms 
(p=0.01).  As in the control specimens, the mean MD was also higher in the frontal 
cortex than in the white matter (mean FC MD = 517.0 ± 186.5 s/mm2 versus mean FW 
MD = 315.1 ± 85.3 s/mm2, p=0.02) and FA was higher in the white matter than in the 
frontal cortex (mean FW FA = 0.75±0.20 versus mean FC FA=0.42±0.19 for cortex, 
p=0.001; Fig 5.10).   
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Table 5.1:  Summary of quantitative MRI parameters in each ROI in the control and 
diseased specimen groups. 
MRI 
measure 
Region Controls specimens 
(n=6) 
vCJD specimens 
(n=6) 
P value  
  mean SD mean SD  
T1 (ms) Frontal cortex 1159.9 289.1 939.5 194.2 0.15 
White matter 939.7 215.6 807.8 127.6 0.23 
Pulvinar 1075.8 320.8 873.2 220.6 0.23 
T2 (ms) Frontal cortex 28.9 6.5 31.7 7.4 0.50 
White matter 21.3 3.2 21.8 2.9 0.77 
Pulvinar 23.6 6.1 21.1 4.3 0.43 
MD (mm2/s) Frontal cortex  409.8 105.7 517.0 186.5 0.24 
White matter 223.5 56.7 267.7 98.7 0.36 
Pulvinar 380.3 85.4 315.1 85.4 0.21 
FA Frontal cortex 0.41 0.08 0.42 0.18 0.89 
White matter 0.75 0.13 0.76 0.20 0.94 
Pulvinar 0.63 0.21 0.58 0.16 0.67 
 
 
5.3.2.2 Semi-quantitative histology findings 
Spongiosis and prion protein deposition were detected in the vCJD specimens in the 
cortex and pulvinar but not in the white matter (median spongiosis in the frontal cortex 
= 1, (range 0-2) and pulvinar = 2 (range 1-3); median prion protein deposition in the 
frontal cortex = 2 (range 2-3) and pulvinar = 3 (range 2-3).  Gliosis was detected in all 
three regions in the vCJD specimens.  Spongiosis and prion protein deposition were not 
detected in the non CJD control specimens except for one specimen where the 
spongiosis was thought to be due to degradation of tissue before fixation rather than 
intracellular vacuoles.  Gliosis was detected in the frontal cortex, pulvinar and white 
matter (Table 5.2).   There was no significant difference in gliosis scores in each region 
between vCJD and controls.  
 
Table 5.2:  Summary of histopathological scores in each region on the vCJD group 
(A) and control group (B) 
(A) 
Histology White matter Frontal cortex pulvinar 
gliosis 2 (2-3)* 1 (0-2) 2.5 (2-3)* 
spongiosis 0 1 (0-2) 2 (1-3) 
PrP 0 2 (2-3) 3 (2-3) 
    
(B)    
Histology White matter Frontal cortex pulvinar 
gliosis 1 (1-3) 1 (0-2) 2 (2-3) 
spongiosis 0 1 (0-2) 0 
PrP 0 0 0 
 
Note. Median values with range in brackets 
* p=0.038, white matter versus frontal cortex; p=0.024, pulvinar versus frontal cortex in vCJD 
patient group 
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Figure 5.10:  Comparison of MRI measures in the frontal cortex, white matter and 
pulvinar ROIs in vCJD specimens: (A) no significant differences in T1 
measurements between regions are demonstrated; (B) increased T2 measurements 
in cortex compared to the white matter (p=0.017) and cortex compared to the 
pulvinar (p=0.011) are noted; (C) increased MD is seen in frontal cortex compared 
to the white matter (p=0.017); (D) FA is lower in the cortex compared to the white 
matter (p=0.021). 
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5.3.2.3 Relationship between MRI measures and histology measures 
In the vCJD group, correlations between ex vivo MRI measures and histopathological 
scores were significant for FA and spongiosis (r=-0.926, p=0.008) and FA and gliosis 
(r=0.878, p=0.021) in the pulvinar ROI only (Figure 5.11).  No significant associations 
between MD, T1 and T2 and any of the histological measures were observed ex vivo in 
the pulvinar.  In the cortex ROI, I found no significant association between any of the 
MRI measures and any of the histopathological measures.  I found no association 
between any MRI measure and length of fixation of the specimens. 
 
 
  
            A                                                              B  
 
Figure 5.11:  Scatterplots demonstrating the relationship between FA and 
spongiosis (A) and FA and gliosis (B) in the pulvinar ROIs
 112 
5.4 Discussion 
I have shown that ex vivo MRM at 9.4T can depict pathology characteristic of vCJD. I 
have demonstrated apparent loss of the normal intracortical laminations in vCJD caused 
by neuronal loss due to a combination of spongiform degeneration and astrocytic 
gliosis.  In this study, I found a significant association of FA, decreasing with the 
severity of spongiosis but increasing with the severity of gliosis in the pulvinar in vCJD.  
I found no association of any other MRI measure with histology parameters in this 
region and no association of MRI and histopathology measures in the cortex.  This 
study is limited by a small sample size but nevertheless, provides novel information on 
the relationship between quantitative MRI measures and histopathology in human prion 
diseases.   
 
The triad of spongiform change, neuronal loss and gliosis involving astrocytes and 
microglia is the neuropathological hallmark of prion diseases 53.  Spongiform change is 
relatively specific to prion disease and characterised by diffuse or focally clustered, 
small, round or oval vacuoles in the neuropil of the cerebral cortex (whole thickness or 
deep layers), the subcortical grey matter and the cerebellar molecular layer, especially 
head of caudate nucleus and rarely present in the brainstem and spinal cord 54.  In vCJD, 
this is accompanied by deposition of the abnormal prion protein PrPSc in the form of 
multiple rounded amyloid plaques often with a dense eosinophilic core and a pale 
radiating fibrillary periphery surrounded by a rim or halo of spongiform change and are 
present in large numbers in the cerebral and cerebellar cortex, particularly in the 
occipital cortex 53.  Spongiform change is most severe in the basal ganglia, particularly 
in the caudate nucleus and putamen which contain relatively few amyloid plaques.  The 
thalamus, hypothalamus, brainstem and spinal cord exhibit little spongiform change or 
amyloid plaque formation 53.   
 
Despite this, cortical signal change or abnormalities have not been described in vivo in 
vCJD.   Our findings of loss of intracortical laminations in cortical specimens at 9.4T 
may prove highly beneficial in the early diagnosis and monitoring of therapy in vCJD.  
With prelimary reports of in vivo 9.4T human MRI studies 199, future in vivo assessment 
of the cerebral cortex, particularly with the generation of SI profiles may help to 
identify and characterize intracortical disease.   
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Our findings of intracortical laminations in non-CJD specimens are in keeping with a 
previous report demonstrating the cytoarchitecture of the human cerebral cortex 200.  
Fatterpekar et al showed that by the use of Nissl and myelin stains, the low SI 
horizontal layer in the isocortex corresponded to heavily myelinated laminae such as the 
intracortical layer IVB (external band of Baillarger), which was thickest in the calcarine 
cortex 200.  The cortical layers represent horizontal aggregations of neurons with 
common connections.  Variations in the cellular composition and packing of each layer 
give cortical regions a specific cytoarchitecture that subserves the function of that 
region 201;202.  I have shown that spongiform degeneration which is characteristic of 
prion diseases accompanied by neuronal loss causes destruction of the normal 
cytoarchitecture of the cortex which can be detected by high field MRI.  It is possible a 
sampling error may have affected our results, although I was careful to excise 
specimens from the same part of the frontal cortex between specimens.  
 
Unfortunately, in our study, I could not obtain quantitative MRI correlates of the visual 
differences in the cortex.  In the cortex, I found no significant differences in any of our 
MRI measures between our patient and control samples.  In fact, I also found no 
significant differences in any of our MRI measures between our patient and control 
samples in the pulvinar or the white matter.  In particular, the T2 measurements in the 
pulvinar were not higher than those measured in the control samples.  It is well 
established in the literature that both T1 and T2 decrease with time after death and 
formalin fixation with one study demonstrating a decrease in T1 of 39% after 760 hours 
fixation and a decrease in T2 of 38% in 1110 hours after fixation in human grey matter 
198 while the ADC of grey and white matter remained constant.  ADC is also 
significantly reduced in post-mortem tissue compared to in vivo.  Therefore the use of 
formalin fixation may have masked any differences in MRI measurements between 
patients and controls, highlighting the limitations of formalin fixation in the 
interpretation of MRI measurements ex vivo.  The use of fresh tissue samples may have 
solved this problem but unfortunately was not an option in this particular high risk 
disease.  In addition, our control samples, although non-CJD controls, demonstrated a 
variety of other pathologies including Lewy body dementia and AD.  The presence of 
gliosis in all regions within these non-CJD diseases controls possibly masked any 
differences in MRI measures. 
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Symmetrical hyperintensity in the pulvinar thalami (relative to the cortex and especially 
the anterior putamen) is characteristic of vCJD and is known as the pulvinar sign.  The 
pulvinar sign has a sensitivity of 78-90% and a specificity of 100% for vCJD and was 
originally described on T2W, PD and FLAIR images 36;37.  Through studies which 
correlate antemortem MRI findings with post-mortem histopathology findings in vCJD, 
it has been suggested that the histopathological basis of the pulvinar sign (T2 
prolongation in the pulvinar nucleus) is astrocytic proliferation.  
As yet, there is no evidence that the pulvinar sign should be used for pre-symptomatic 
testing of vCJD as all reports have been is symptomatic patients at the end-stage of 
disease.  In one report of a blood transfusion acquired case of vCJD, imaging at the time 
of initial clinical presentation was negative for the pulvinar sign and was only positive 
only when the patient was severely affected, suggesting that the pulvinar sign is a late 
feature of vCJD 3. 
 
Few studies have investigated measures of water diffusion in vivo in vCJD.  Two case 
reports in vCJD have demonstrated decreased ADC in the caudate and putamen but 
elevated ADC in the thalami 174;175 which in one of the cases was correlated at post-
mortem with the detection of predominantly spongiform cellular changes in the caudate 
and putamen and predominantly astrocytic changes with neuronal loss in the pulvinar 
nuclei.  In our study of formalin fixed specimens, I found no association of MD with 
any histology measure.  
 
There is a considerable reduction of MD and FA ex vivo compared to in vivo, with even 
further reductions in MD post-fixation 196.  It has been postulated that post-fixation, the 
combination of dehydration of tissue, lower temperature than in vivo and failure of 
energy dependent ion transport mechanisms 203 may all contribute to decreased MD, 
possibly reducing the sensitivity to the histopathological changes with the loss of any in 
vivo relationship to histology measures.  FA however, is preserved during the fixation 
process and provides a robust index of the underlying histology.    
 
In our study, I found that FA decreases with the severity of spongiosis and increases 
with the severity of gliosis in the pulvinar.  Very few studies have investigated DTI in 
the grey matter in neurological diseases.  One study of DTI in Huntingdon’s Disease 
(HD) where FA was specifically investigated in the basal ganglia, demonstrated 
significant increases in FA in the putamen and globus pallidus in patients compared to 
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controls 204  The authors speculated that the increases in FA could result from 
pathological processes that modify tissue integrity, such as neuronal remodelling and 
loss and secondary astrocytosis, particularly in the light of post-mortem studies 
demonstrating fibrillary astrocytosis in the caudate, putamen and globus pallidus in HD 
205.  Our finding of increased FA with gliosis is also supported by a DTI study in the 
developing mouse brain where high anisotropy was observed in the cortical plate in the 
embryonic and post-natal stage.  As axonal fibres are not predominant in this region, the 
authors concluded that the high anisotropy was due to the highly organized radial glia 
206.  It is likely that the proportion of the different histological changes that are present 
in the target tissue determines the FA.  Whilst astrocytic proliferation may cause 
organization of the neuropil causing increased anisotropy, it appears that severe 
spongiform change with areas of confluent vacuolation in the extracellular space may 
allow water to diffuse more radially with decreased anisotropy.   
 
I found no association between length of fixation and any of our MRI measures.  Our 
samples had been formalin-fixed for much longer than any of the published reports and 
it is possible that the reduction in T1 and T2 had reached a plateau phase.  Although I 
argue that the relationship of FA with histology measures is not an effect of formalin 
fixation, it could be argued that small sample size and multiple statistical tests may have 
limited our findings. 
 
DTI in vivo is evolving as a potent tool in the examination of the central nervous 
system, improving detection of microstructural changes with clinical applications in a 
wide variety of neurological diseases including neurodegenerative disease 91 207.  In AD, 
several studies have found a specific pattern of regional abnormalities that involve the 
fibre tracts of the corpus callosum, and the white matter of the frontal, temporal and 
parietal lobes which showed strong correlations with neuropsychological measures 
99;100.  Studies of the grey matter in AD, have shown increased diffusivity in the right 
temporal cortex 101.  To our knowledge, there are no reports of the use of DTI in vivo in 
vCJD but our findings suggest that DTI, with specifically measures of FA in the 
pulvinar, could offer potential for the detection of early histopathological changes and 
for monitoring disease severity in human prion diseases.  vCJD remains an important 
public health issue, particularly with recent identification of blood-transfusion acquired 
cases 3;13;14and DTI could offer great potential in the identification of patients in the 
early stages of the disease where therapeutic intervention would be most important. 
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5.5  Conclusion 
I have demonstrated that ex vivo MRM at 9.4T can depict pathology characteristic of 
vCJD through apparent loss of the normal intracortical laminations.  We have also 
shown that FA decreases with the severity of spongiosis and increases with severity of 
astrocytic proliferation in the pulvinar nucleus.  Our findings suggest that in the grey 
matter, astrocytic proliferation in the extracellular space causes directional organization 
of the neuropil.  Measurements of FA in the cerebral cortex and pulvinar, could offer 
potential for the detection of early histopathological changes and for monitoring disease 
severity in human prion diseases. 
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6 Discussion  
 
6.1 Summary of findings in thesis 
In this work I aimed to evaluate the potential of quantitative MRI measurements in 
providing neuroimaging biomarkers of disease activity and in understanding the 
pathophysiology of prion diseases.  We chose to address these aims through a dual 
strategy of both in vivo and ex vivo quantitative MRI experiments.  The results 
presented in this thesis demonstrate that I have achieved these aims.  At the start of this 
thesis our aims were: 
 
1.  To detect regional differences in cerebral ADC in variant, sporadic and inherited 
forms of prion disease when compared to controls.   
I achieved this in chapters 2 and 3 by ROI measurement in the caudate, putamen and 
thalamus demonstrating different patterns of regional ADC changes in vCJD, sCJD and 
inhPrD which reflected the different distribution of histopathology in these diseases. I 
also showed that by probing slower diffusion compartments with high b value DWI, 
there was improved confidence in the detection of pathological signal change in sCJD.  
Our results suggest that high b value DWI could be a useful additional sequence in the 
radiological diagnosis of prion diseases especially as there have been no previous 
reports of high-b-value DWI in prion diseases. 
 
2.  To establish whether regional and global cerebral ADC in inhPrD correlate with 
clinical disease severity.   
The results presented in chapter 2 demonstrate an association of whole brain, regional 
and mean GM ADC with clinical scales of disease severity.  In particular the marked 
association between mean GM ADC and clinical neurological status suggests this 
measure may provide a promising quantitative biomarker.  
 
3.  To demonstrate whether  regional differences in short TE 1H-MRS in inhPrD can be 
detected compared with controls, can be correlated with disease severity and can be 
demonstrated to evolve in serial MRS examinations. 
In Chapter 4, I showed that in a small subgroup of inhPrD patients, there was an 
association of MI with clinical scales of disease activity and an increase in myo-inositol 
with time.  Although there have been previous reports of differences in 1H-MRS 
measurements in patients with prion diseases compared to controls, to our knowledge 
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there have hitherto been no reported attempts to correlate these differences with clinical 
scores in order to assess their potential as biomarkers.  
 
 
4.  To determine whether quantitative MRI measurements of T1- and T2 relaxation 
times, FA and MD in fixed post-mortem brain tissue at 9.4T can be correlated with 
histopathological measures to better understand the pathophysiological changes 
underlying the early disease course. 
In chapter 5, I demonstrated that MRI at high magnetic field strengths can demonstrate 
the microstructural changes that affect quantitative MRI measurements.  In this chapter, 
I showed a positive association of FA with gliosis and a negative association of FA with 
spongiosis in the pulvinar in vCJD.  It is likely that the proportion of the different 
histological changes that are present in the target tissue determines the FA.  These 
results also suggest that DTI, with specifically measures of FA in the pulvinar, could 
offer potential for monitoring disease activity in human prion diseases.  
 
5.  To evaluate whether high resolution MRI images of fixed post-mortem tissue at 9.4T 
can detect the histopathological changes characteristic of human prion diseases. 
Finally, also in Chapter 5, I showed that high resolution MRI images of fixed post-
mortem tissue at 9.4T can detect the histopathological changes characteristic of human 
prion diseases through loss of intracortical laminations.  As high field scanners become 
more routine in clinical diagnosis, these observations may help distinguish prion 
diseases from other dementias. 
 
Altogether, our findings show that DWI and 1H-MRS offer potential as neuroimaging 
biomarkers in future prion disease therapeutic trials.  Important insights into the 
histopathological basis for the MRI changes are observed.   Although our results are 
limited by small numbers and need to be confirmed in larger studies, they confirm the 
potential of quantitative MRI in understanding the pathophysiology of this disease. 
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6.2 Potential future directions 
6.2.1 MRI as an objective measure in future trials 
As the clinical application of emerging neuroimaging techniques expands, the 
combination of neuroimaging studies with other investigations that provide data on 
genetic risk and biomarkers from other tissues (such as serum or CSF) might increase 
the combined diagnostic sensitivity and specificity as well as the predictive value of the 
information.  As a relevant comparison, already in the AD Neuroimaging Initiative, a 
large multi-centre study is performing structural MRI scans and FDG- PET scans, in 
addition to other biomarkers to improve diagnostic accuracy and treatment monitoring 
of this disease 208. 
 
A biomarker is defined as an indicator of disease activity whereas a surrogate marker 
can substitute as a clinically meaningful end-point in a clinical trial 209.  A useful 
neuroimaging biomarker would not only be an indirect measure of neurodegeneration 
but could be used to monitor a relevant aspect of disease pathophysiology, correlate 
with treatment-induced changes and assist in identifying responders to a specific 
treatment 210. 
 
Currently in AD, volumetric MRI is the method of choice to monitor drug effects in 
neurodegenerative disease, especially in Phase II and III registration trials, mainly 
because the relationship between neuron loss and atrophy has been well-established in 
many studies 121 211 and also because of the availability of volumetric sequences on 
most clinical MRI scanners 212.  However, an important application of neuroimaging is 
in the detection of neuronal dysfunction before neuronal loss, particularly in the context 
of the administration of neuroprotective drugs.  It is likely that quantitative imaging 
techniques, although only in the research stages at present, are likely to be more helpful.  
 
6.2.2 MRI as a biomarker in future prion disease trials 
The National Prion Monitoring Cohort (NPMC) study launched in October 2008 aims 
to build on the work of PRION-1 by gathering information on clinical care and 
therapeutic interventions in as many people diagnosed with or at risk of human prion 
disease as possible.  The objectives are to: 
• Characterise the natural history of human prion disease 
• Develop a staging system to mark disease progression  
• Identify surrogate markers of disease progression 
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• Monitor any treatments received 
• Determine clinical onset in at-risk individuals 
As no drug is being trialled, a further opportunity to describe the clinical and MRI 
features in prion diseases will be provided with the aim of identifying and validating 
neuroimaging and other biomarkers such that when a therapeutic agent becomes 
available, measures will already be in place to evaluate treatment efficacy. 
 
6.2.2.1 MRI sequences for the NPMC 
6.2.2.1.1 DTI 
DTI provides measures theoretically independent of the experimental implementation, 
reflecting aspects of tissue microstructure size, orientation and organization. From this 
sequence, it is possible to obtain multiple measures characteristic of water self-diffusion 
which may be more or less sensitive to disease severity.  Based on our post-mortem 
study findings, I would expect increased FA in the grey matter in patients with prion 
disease, perhaps as a more sensitive marker of disease activity than MD. 
 
6.2.2.1.2 Chemical shift Imaging 
Chemical shift imaging allows the acquisition of spectra from multiple voxels during 
the same acquisition.  This technique will significantly shorten the time taken to acquire 
multiple spectra such that the entire brain can be imaged in approximately 12 minutes.  
In addition, imaging at higher magnetic field strengths gives improved signal-to-noise 
ratio, greater spectral separation and likely improved diagnostic accuracy and better 
test-retest reproducibility for 1H-MRS.  Higher magnetic field strengths will also allow 
more accurate detection of glutamate and glutamine which may provide additional 
neuroimaging biomarkers 
 
6.2.3 Other imaging techniques 
6.2.3.1 PET-amyloid imaging 
Recent developments in PET imaging have enabled the detection of β-amyloid in vivo 
in AD.  A number of radiolabelled agents that bind to β-amyloid have recently been 
developed which have detected amyloid plaques in mice and in humans with AD 213;214.  
The most extensive experience has been with amyloid binding radiotracer [11C]-labelled 
Pittsburgh compound B (2-[4L’-methylamino)phenyl]-6-hydrobenzothiazole; PiB 215, a 
thioflavin-T amyloid dye derivative that binds to β-amyloid plaques but not to tangles.  
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Although the amyloid deposits associated with prion diseases and the amyloid deposits 
found in AD are composed of different peptides, they share common physical-chemical 
properties 216, including a high β-sheet secondary structure. As thioflavins bind to β-
amyloid plaques associated with AD, it is likely that 11C-PiB PET will also provide an 
in-vivo marker of prion amyloid deposits. Limitations include the invasive nature of the 
test, the relative inaccessibility compared to MRI and the relatively high costs 217 
 
6.2.3.2 Monitoring treatments in development 
Animal models of prion disease may be useful in the co-development of neuroimaging 
measures and treatment.  In the future, it may be possible to develop PET and MRI 
labels that specifically bind to PrPSc.  As anti-aggregation treatments are developed for 
prion disease initial testing of compounds in animals could be followed by pre-clinical 
trials in small animals with microPET and MRI microscopy to measure a biomarker for 
PrP-amyloid and to guide investigators on further testing in humans. 
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7  Conclusion 
 
The findings in this thesis are a major step forward in the understanding of quantitative 
MRI in prion diseases.  I have shown that quantitative MRI measures of ADC at low 
and high b-value and short TE 1H-MRS are potential neuroimaging biomarkers of 
disease activity.   The use of high field ex vivo MRI has provided important insights into 
the microstructural changes underlying the sensitivity of some of these quantitative MRI 
methods to prion disease-related changes in the brain.  The findings presented here 
exemplify the potential of quantitative MRI in both increasing our understanding of the 
pathophysiology of prion diseases and to provide neuroimaging biomarkers which will 
be of great importance for the future assessment of the efficacy of therapeutic agents.
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APPENDIX A 
Clinical assessment 
All neurological assessments were performed by a qualified neurologist:  either the 
Consultant Neurologist at the National Prion Clinic or by the two neurology Research 
Fellows.  In addition, the following neurological rating scale scores were calculated at 
each time point in order to assess disease severity: 
• Mini Mental State Examination (MMSE) 138: used as an overall severity score for 
cognitive function. A maximum score of 30 indicates no deficit of memory or 
language and a minimum score of 0 indicates severe deficit of memory and 
language.  
• Clinician’s Dementia Rating Scale (CDR) 139: a measure widely used in clinical 
studies of dementia. Using a semi-structured interview with the patient or a 
caregiver, it measures a patient’s function in areas of memory, orientation, 
judgement and problem solving, community affairs, home and hobbies, and personal 
care, providing a score ranging from 0 to18. Each component is scored from 0 to 3 
(0=no impairment, 1=mild impairment, 2=moderate impairment, 3=severe 
impairment). 
• Rankin scale 140: a global assessment of the impact of disease on activities of daily 
living, providing a score ranging from 0 to 5 (0=no symptoms, 1=no significant 
disability despite symptoms, 2=slight disability, 3=moderate disability, 
4=moderately severe disability, 5=severe disability). 
• Alzheimer’s Disease Assessment Scale (ADAS-COG) 141: performed in those with a 
MMSE of 10 or greater. This is a more detailed assessment of cognition, validated 
in Alzheimer’s disease. Score ranges from 0 to 75. It assesses 12 items covering 
word recall, naming objects and fingers, performing simple commands, 
constructional praxis, ideational praxis, orientation, word recognition, remembering 
test instructions, spoken language ability, word-finding difficulty, comprehension 
and concentration. 
• Barthel Activities of Daily Living scale (ADL) 142: measures ability to perform 
activities of daily living on a scale of 0 (unable to perform any ADL) to 20 (can 
perform all ADSL). 
• A clinician’s global impression of disease severity (CGIS) 143: A scoring system 
completed by both doctors and nurses to assess change in severity of disease 
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(0=normal, not ill, 1=borderline mentally ill, 3=mildly ill, 4=moderately ill, 
5=markedly ill, 6=severely ill, 7=amongst the most ill).  
• Brief Psychiatric Rating Scale ( BPRS) 144: Psychiatric status was assessed by using 
a series of standardised structured questions, providing a final score ranging from 24 
to 168. It scored 24 items on a qualitative scale from 1 to 7 (according to whether 
the symptom was absent, very mild, mild, moderate, moderately severe, severe or 
extremely severe). Components included somatic concern, anxiety, depression, 
sociality, guilt, hostility, elated mood, grandiosity, suspiciousness, hallucinations, 
unusual thought content, bizarre behaviour, self-neglect, disorientation, conceptual 
disorganisation, blunted affect, emotional withdrawal, motor retardation, tension, 
uncooperativeness, excitement distractibility, motor hyperactivity, mannerisms and 
posturing, anxiety, depression, hostility, disorientation and blunted affect. 
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APPENDIX H 
 
 
Intra-observer and inter-observer variability: 
To assess intraobserver variability, the ROI analysis in all 6 regions was repeated for 4 
patient data-sets in 2 sessions separated by 10 days. Bland-Altman analysis 
demonstrated a mean difference of -5.1 mm2/s, (95% CI = -13.75 to 3.55), p=0.235. 
  
 
Output: 
 
. Biography time1 time2 
 
Number of measurement pairs: 24 
 
difference derived: time1-time2 
Mean difference (relative bias) = -5.1000036, 95% CI = [-13.755958, 3.5559507] 
SD of difference = 20.498966 SE of difference= 4.184334 
 
Test (t-test) that mean difference is zero: t= -1.2188328 do= 23 P= .2352616 
 
95% of differences are predicted to lie within the 95% limits of agreement: -
46.097936, 35.897929 
 
These limits of agreement are of course estimates, and have the following 
confidence intervals: 
95% CI for LOWER limit of agreement = [-61.090489, -31.105383] 
95% CI for UPPER limit of agreement = [20.905376, 50.890481] 
 
SD of time1: 43.668542 
SD of time2: 49.441602 
 
Pitman test of equality of paired variances: P=.17214367 
 
The mean difference and the 95% limits of agreement are indicated on the 
Bland-Altman graph... 
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Inter-observer variability: 
To assess inter-observer variability, a second observer placed ROIs on the same four 
patients and Bland-Altman analysis demonstrated a mean difference of 3.81 mm2/s, 
(95% CI = -5.47 to 13.08), p=0.40.   
 
Output: 
 
. Biography observer1 observer2 
 
Number of measurement pairs: 24 
 
difference derived: observer1-observer2 
Mean difference (relative bias) = 3.808342, 95% CI = [-5.4670195, 13.083703] 
SD of difference = 21.965842 SE of difference= 4.4837587 
 
Test (t-test) that mean difference is zero: t= .84936373 do= 23 P= .40443343 
 
95% of differences are predicted to lie within the 95% limits of agreement: -
40.123342, 47.740026 
 
These limits of agreement are of course estimates, and have the following 
confidence intervals: 
95% CI for LOWER limit of agreement = [-56.188739, -24.057944] 
95% CI for UPPER limit of agreement = [31.674628, 63.805423] 
 
SD of observer1: 65.470005 
SD of observer2: 60.284534 
 
Pitman test of equality of paired variances: P=.25957636 
 
The mean difference and the 95% limits of agreement are indicated on the 
Bland-Altman graph... 
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APPENDIX I 
 
 
Patient Information Sheets:  
PRION-1: Clinical investigations 
 
 (Form to be on local headed paper) 
Version: 2.0 Date: 12 January 2006 
  
PRION-1: MRI  
 
What is MRI? 
 
MRI stands for Magnetic Resonance Imaging. This is a scanning procedure that uses a combination of a 
strong magnet, radio waves and a computer to produce very detailed pictures of your body. The scan will 
not hurt and has no long-term effect on your body once it is over. 
 
What does an MRI scan show? 
 
An MRI scan provides pictures of the inside of your body. Whereas an ordinary x-ray produces very good 
pictures of the bones, an MRI scan can show details of the brain, muscles, nerves, cartilage and other 
internal organs. 
 
Preparation for an MRI scan 
 
As the MRI scanner uses a very strong magnet, there are some safety guidelines that must be 
followed. Let the staff in the scanning department know as soon as possible if any of the following 
applies to you: 
• you have a pacemaker 
• you have an artificial heart valve 
• you have ever had surgery on your head or spine 
• you have any metallic implants, for example joint replacement 
• you have ever had metal in your eyes, for example from welding or metalwork 
• you may be pregnant 
 
In some of these cases you may need to have an X-ray to make sure that it is safe for you to have an MRI 
scan. The staff in the MRI Department will discuss this with you. You will also be asked to remove 
personal belongings such as your watch, jewellery, keys, credit cards and coins. This is because if you go 
into the scan room with loose metal objects in your pockets they may be pulled out by the strong 
magnetic field and fly into the scanner. If you wear your watch into the scanner it may not work when 
you come out and if you have credit cards in your pocket the information held on the magnetic strip will 
be wiped off. Metal fastenings on your clothes are all right because the magnetic field is not strong 
enough to pull them off. However, if they are close to the part of your body you are having scanned they 
may interfere with the pictures and you may be asked to change into a gown. 
 
Involuntary movements such as muscle jerking, which is common in prion disease, can interfere with the 
MRI scan. If this is likely to be a problem with your scan, the study doctor will discuss with you about 
having sedation before the scan. This sedation may either be taken in tablet form or as a general 
anaesthetic. If the MRI scan were to be performed under a general anaesthetic it carries the usual risks 
associated with receiving general anaesthetic.  
 
What happens during the scan? 
 
You will be asked to lie on the scanner couch where you will be made as comfortable as possible. The 
position will vary depending on the part of the body that is being scanned. For example, for a scan of the 
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head you will be asked to lie with your neck or head in a specially shaped support. You should tell the 
staff if you are not comfortable as you will need to keep very still during the scan which may take up to 
45 minutes to complete. There will be an intercom in the scanning room or some other means of 
communicating with the staff during the scan. Once you are ready to start you will be moved into the 
scanner. The scanner is a long tube, and the part of your body being scanned must be completely inside 
this tube. Although the staff will be able to reassure you during the scan, some people do find this 
unpleasant and slightly frightening.  
 
Each set of pictures takes about five minutes and while the pictures are being taken you will hear a 
knocking sound. This noise means the scanner is collecting information to produce the pictures and 
therefore you must keep very still. If you move while the pictures are being taken they will be blurred and 
the scan may need to be repeated. Several sets of pictures may be taken during each examination and 
there will be a short pause between them. The scanner will go quiet between pictures; during this time the 
staff will be setting up ready to start the next set. 
 
Will I need an injection? 
 
When certain areas of the body are scanned, you may need an injection of a special dye known as a 
contrast agent that helps to see more detail on the pictures. If you need an injection it will be given into a 
vein in your arm by a radiologist or one of the radiographers trained to give injections. Sometimes several 
scans will be taken before the dye is injected and then further scans are taken after the injection. If your 
scan is being performed under general anaesthetic, you would be assessed by an anaesthetist who would 
give you an injection as part of this procedure. 
 
Can anyone be with me during the scan? 
 
As there are no harmful rays, a friend or relative can stay in the room with you during the scan. Anyone 
coming into the scan will also be asked questions about pacemakers and metal objects in their body, and 
will be asked to remove all metallic objects such as watches and jewellery. 
 
What happens after the scan? 
 
There are no after effects from the scan so you can carry on with your normal activities immediately. 
5 47 6 
When will I receive the results of the scan? 
 
For each scan as many as 50 images may be produced which need to be carefully studied by the 
radiologists? The radiologists will produce a detailed report that will be sent to your specialist, usually 
within 7 to 14 days. More complicated analyses comparing information from different scans over long 
periods of time will only be carried out at the end of the trial, so the results will not be available to you for 
example, at your routine clinic visits. 
 
This information sheet has been adapted from an information sheet prepared by the Brain and Spine 
Foundation. Their permission to reproduce this is gratefully acknowledged. 
www.brainandspine.org 
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APPENDIX J 
 
STANDARD OPERATING PROCEDURE FOR MRI SCANS DONE UNDER 
GENERAL ANAESTHESIA (GA) AT THE NATIONAL HOSPITAL FOR 
NEUROLOGY AND NEUROSURGERY (NHNN) FOR THE NATIONAL PRION 
CLINIC (NPC) 
  
  
1. Patients with different forms of prion disease will be scanned under general 
anaesthetic, where patient movement would otherwise prevent scans of adequate 
quality being obtained.  
  
2. The procedure will be discussed with patients, or their next of kin (in cases 
where patients are cognitively impaired and lack capacity to consent), as far as 
possible in advance by one of the trial fellows or the trial nurse. Information 
about the procedure will be provided and intended benefits and risks explained. 
In addition, in cognitively impaired patients, written assent will be obtained 
from next of kin in advance of the scan appointment. This procedure will be 
repeated at follow-up trial visits. The next of kin may be referred to Dr. Sally 
Wilson, consultant anaesthetist, NHNN (email: sally.wilson@uclh.org or 
extension 8711 at NHNN) if they request a detailed discussion directly with the 
anaesthetist.  
  
3. Dr. Sally Wilson (email: sally.wilson@uclh.org or extension 8711 at NHNN or 
air call through NHNN switchboard) and Caroline Andrews, superintendent 
radiographer, MRI Department, NHNN (email: caroline.andrews@uclh.org or 
extension 3638 at NHNN) will be informed (where possible) two weeks in 
advance by one of the trial nurses (Christopher Rhymes, email: 
christopher.rhymes@uclh.org or Suzanne Walker, email: 
suzanne.walker@uclh.org or phone 02074052882).  
  
4. MRI scans will be done under GA on Wednesday afternoons at 2:30 pm. 
Patients will usually be admitted for planned assessments on Tuesday to the 
Nuffield Ward at NHNN and stay for 2 nights. Dr. Sally Wilson will consent 
those patients on the ward who are able to give consent themselves. She will be 
assisted by one of the trial or clinical research fellows (Dr. D. Sodium, email: 
d.siddique@prion.ucl.ac.uk, Dr Tom Webb, email: t.webb@prion.ucl.ac.uk, Dr. 
H. Hyare, email: harpreet.hyare@uclh.org or phone: 02074052882) or by one of 
the trial nurses (see above).  
  
5. Patients will be kept overnight after MRI scan under GA has been performed. 
Out of hours neurology cover will be provided by the on-call neurology SHO 
and Spry, and anaesthetic cover will be provided by the on-call anaesthetic Spry 
(bleep 8131). Dr Sally Wilson will be available out of hours through 
switchboard in case of an emergency.  
  
6. All patients having MRI scan under GA will be resuscitated in the event of a 
cardio respiratory arrest during or after the procedure.  
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APPENDIX K 
 
 
Risk assessment  
In accordance with the Health and Safety Department at Imperial College a risk 
assessment was performed for handling of Category 3 substances and an application 
was made to the Health and Safety Executive (HSE), UK.  Approval from the HSE was 
obtained for the project on 01/03/07. 
 
To control possible exposure during transportation brain samples were double-sealed by 
placing in a screw-top histopathology pot and then inside a plastic grip bag.  The 
double-sealed samples were placed inside a Bio jar and then within an UN-approved 
transport container with a biohazard sticker and the names of 2 people to contact in case 
of emergency (see below).  The histopathology pot and plastic grip bag would not be 
opened in the laboratory and therefore a spillage should not occur.   
 
 
 
If when the transport boxes were opened, there was evidence of a leak, then the samples 
were not removed but taken immediately back to the MRC Prion Unit, Institute of 
Neurology, UCL.  In the unlikely event of a spillage, the area was to be wiped with a 
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paper towel dampened with 2M sodium hydroxide and then re-wiped with a paper towel 
dampened with water.  Paper towels would be contained in a sharps box and returned to 
the MRC Prion Unit for autoclaving at 134 degrees Celsius. 
 
All samples were transported to the Biological Imaging Centre (BIC), Imaging Sciences 
Department, MRC Sciences Centre, Hammersmith Hospital, Imperial College, London.  
In accordance with the Human Tissue Act 2004, the tissue specimens of prion disease 
and controls to use in the project were stored in the Department of Neuropathology at 
the Institute of Neurology under a storage licence held by UCLH.  In section 30, 
subsection (2)(a) of the Act, a licence is not required for possession of an anatomical 
specimen away from licensed premises “where the specimen has come from premises in 
respect of which a storage licence is in force” and (b)(i) is “authorised in writing by the 
designated individual to have possession of the specimen”.  In section 16 subsection 
(7)(a) the Act states that “references to storage do not include storage which is 
incidental to transportation”.  Therefore, in accordance with the Act, samples were 
transported to the BIC with a letter of authorisation and with a documented specimen 
trail (Appendix L) and were returned to the Institute of Neurology the next working day. 
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APPENDIX L 
 
Experiment to determine the effect of perfluoropolyethers (PFPE) on quantitative 
MRI and corroborative histology of brain tissue. 
 
Purpose 
To establish whether the immersion of fixed tissue samples in PFPE either alters their 
qualitative and quantitative MRI properties, or influences subsequent histological 
findings. 
 
Methods 
Specimen preparation 
All studies were performed in accordance with the Animals (Scientific Procedures) Act 
1986 (UK).  To assess effect of prolonged PFPE exposure on quantitative MRI, 8 male 
CD1 mice (12-15 weeks old) were culled by carbon dioxide asphyxiation. Their brains 
were excised from skull and dura and immersed in 10% formol-saline (Pioneer 
Research Chemicals, Ltd., Colchester, UK).  After 10 days of fixation, 4 brains were 
immersed in Fomblin® Perfluorosolv PFS-1 (Solvay Solexis, Milan, Italy) while the 
remaining 4 were kept in the 10% formol-saline. After 48 hours, each brain was 
positioned within a 2.5 ml plastic syringe filled with Fomblin®, wedged between 
cotton-wool plugs to minimize sample motion, and MRI acquisitions performed the 
same day.  All specimens were immersed in Fomblin® during the actual MRM 
acquisitions.   
 
A second experiment was performed to compare histological findings in a group of 
specimens exposed to PFPE for 48 hours with a group with no such exposure: a further 
8 adult CD1 mice were culled by carbon dioxide asphyxiation and the excised brains 
immersed into 10% buffered formol saline. After 2 days of fixation, 4 were immersed in 
Fomblin® for 48 hours before being returned to 10% formol-saline for one week before 
processing.  The remaining 4 brains remained in 10% formol-saline throughout.   
 
MRI  
MRI was performed with a horizontal bore 9.4T/21cm Varian Inova MRI system 
(Varian Inc, Palo Alto, CA) using a 43 mm internal diameter quadrature volume coil 
(Magnetic Resonance Laboratories, Oxford) at room temperature (bore temperature was 
22 ºC). For T1 measurement, successive SE images were acquired with TRs of 450, 
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600, 800, 1000, 2000, 4000 ms; TE 15 ms; 2 averages; acquisition matrix size 256x128; 
slice thickness 2 mm. T2 measurements were obtained using a SE sequence to acquire 
successive images with TEs of 10, 22, 34 and 46 ms; TR 2000 ms; 2 averages; matrix 
size 256x128; slice thickness 2 mm.  To investigate tissue-water diffusion, successive 
images were acquired with diffusion weighting applied along 6 non-colinear directions ( 
Gx, Gy, Gz = [(1,1,0), (0,1,1), (1,0,1), (-1,1,0), (0,-1,1), (1,0,-1)] ) with a diffusion 
weighting (b factor) of 1000 s/mm2, and with no diffusion gradients (i.e. with a b factor 
of 0 s/mm2) and TR 2000 ms; TE 22 ms; matrix size 256x256, 2 averages and slice 
thickness 2 mm. MTR was measured using a gradient-echo sequence with TE 5 ms; TR 
186ms; matrix size 256x256; 16 averages; slice thickness 2 mm acquired with and 
without an effective off-resonance saturation pulse (offset frequencies 6 and 100 kHz 
respectively). Finally, a high-resolution T2W coronal image (TE 20 ms; TR 2400 ms; 
FOV 50x50 mm; matrix size 256x256; 20 averages, slice thickness 1 mm; in-plane 
resolution 158 µm) was acquired providing good anatomical contrast for qualitative 
assessment.  For all acquisitions the FOV was 50x50mm and 7 contiguous coronal 
slices were obtained.  The total measurement time per specimen was approximately 10 
hours. 
 
Image analysis 
Qualitative analysis 
The high-resolution T2W images were assessed by a single neuroradiologist, blinded to 
the grouping of the mouse brains, for visible artefacts or variations in SI.   
 
Quantitative analysis 
All quantitative image processing was performed off-line on a dedicated workstation 
(Sun Microsystems, Mountain View, CA, USA), being fully automated taking ~20 
mins. Using commercially available software (JIM Version 4.0; Xinapse Systems Ltd, 
Thorpe Waterville, UK.), T1 and T2 maps were computed by performing pixel-by-pixel 
non-linear fitting to the equations S(TR) = ρ(1 – exp(-TR/T1)) and S(TE) = ρ(exp(-
TE/T2)), respectively.  S(TR) and S(TE) are the signal intensities of the T1- and T2W 
images acquired at the respective TR or TE, and ρ is the proton density in arbitrary 
units. MTR maps were generated pixel-by-pixel according to the formula: MTR = [(Mo 
– Ms)/Mo] x 100, where Mo and Ms, are the SI without and with the off-resonance 
saturation pulse. DTI data were calculated using Camino 
(http://www.cs.ucl.ac.uk/research/medic/camino/) 218 to provide FA and MD maps.  
 146 
For each specimen, ROIs in the right thalamus (Figure A, ROI 1) and right cerebral 
cortex (Figure A, ROI 2) were defined manually by a single experienced observer 
according to a published mouse brain atlas 219. The cortical ROI was chosen specifically 
to investigate quantitative MRM changes close to the edge of the specimen. The ROIs 
(size 1.8 – 2.4 mm2) were defined on the SE images providing optimal grey-white 
matter contrast (TE 10 ms; TR 2000ms), saved and then re-loaded for each of the T1, 
T2, MT, MD and FA maps.  
 
Statistics 
The effect of Fomblin® on MRI measures was analyzed using a repeated measures 
ANOVA with ROI location as the within-subjects factor and group (control versus pre-
treatment with Fomblin®) as the between-subjects factor.  Where an effect was 
detected, post-hoc comparison tests were performed.  Parametric tests were used despite 
the small number of specimens, to provide increased power to detect a significant 
difference compared to the equivalent non-parametric test.  A value of p < 0.05 was 
considered statistically significant and all statistical tests were performed using SPSS 
for Windows (version 11.5, SPSS, Chicago, IL, USA). 
 
Histological Analysis 
For both experiments, following re-immersion in 10% buffered formal saline for one 
week (Pioneer Research Chemicals, Ltd., Colchester, UK.), tissue samples were 
processed and embedded in paraffin wax.  Wax sections were cut at a nominal thickness 
of 3 µm and mounted on Superfrost UltraPlus charged glass slides. Following dewaxing 
in xylene and an alcohol gradient, the sections were stained with H&E. For 
immunohistochemical staining, dewaxed sections were boiled (microwaved) in a low 
ionic strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) for 
20 minutes. Immunoreactivity of astrocytes and neurones were tested using rabbit anti-
glial fibrillary acidic protein (GFAP) antiserum (DAKO) and mouse monoclonal anti-
neurofilament antibodies (NF200, Sigma-Aldrich Co. Ltd, Poole), respectively. A 
biotinylated-anti IgG secondary antibody (iView SA-HRP, Ventana Medical Systems, 
Tuscon, AZ, USA) was applied before development with 3,3’-diaminobenzidine 
tetrachloride as the chromogen (iView DAB, Ventana Medical Systems, Tuscon, AZ, 
USA). H&E was used as the counterstain and appropriate controls were used 
throughout. 
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All slides were assessed by a single consultant neuropathologist.  Fine nuclear detail, in 
particular the chromatin and nucleoli were assessed within neurons, astrocytes and 
oligodendrocytes.  The synaptic structure of the neuropil and the integrity of myelinated 
fibre tracts were assessed throughout the mouse brain.  Specific structures assessed 
included the hippocampus, thalamus and cerebellum.  
 
 
Figure A:  High resolution T2W images (TR/TE 2400/24 ms, 20 averages, FOV 
50x50mm, 256 x 256 matrix, in plane resolution 158µm, slice thickness 1 mm) of 
(A) control and (B) Fomblin® pre-treated mouse brain; no differences were 
apparent on visual inspection. The location of the right thalamic (1) and right 
cortical (2) ROIs from which quantitative MRI values were obtained is shown in (A) 
 
 
Results 
Qualitative MRI 
Visual inspection of high resolution T2W MRI images of control and PFPE-immersed 
mouse brains revealed no detectable differences between the two groups (see Figure A).  
 
Quantitative MRI 
I detected an effect of ROI location for MTR at the 5% level (mean MTR = 61.6 ± 6.0 
for right thalamus ROI versus 58.6 ± 4.7 for right cortex ROI; p=0.005) and MD at the 
10% level (mean MD = 324.0 ± 74.4 for right thalamus ROI versus 361.4 ± 89.3 for 
right cortex ROI; p=0.058).  When adjusted for Fomblin treatment®, the differences in 
MTR and MD between the cortical and thalamic ROIs no longer reached significance 
(Table).  I did not detect an effect of Fomblin® in any of the MRI measures.   
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Table:  Mean regional quantitative MRI values for control (n = 4) and PFPE pre-
treated specimens (n = 4) 
 Right thalamus ROI Right cerebral 
cortex ROI 
     
     F 
 
P* 
 Control PFPE 
pre-
treated 
 
Control PFPE 
Pre-
treated 
  
T1(ms) 1499.7 
(85.1) 
1505.3 
  (3.0) 
1535.9 
(79.6) 
1503.2 
(71.0) 
0.065 0.808 
T2(ms) 34.8 
(4.4) 
33.6 
(3.1) 
36.3 
(4.6) 
39.3 
(11.2) 
0.046 0.837 
MTR 62.6 
(5.4) 
60.6 
(7.2) 
59.7 
(4.4) 
57.4 
(5.3) 
0.298 0.605 
MD(mm2/s) 339.3 
(59.8) 
308.7 
(93.4) 
383.3 
(84.6) 
339.5 
(100.8) 
0.402 0.550 
FA 0.35 
(0.06) 
0.41 
(0.11) 
0.36 
(0.10) 
0.35 
(0.05) 
0.583 0.583 
 
 
Note.  T1 = spin-lattice and T2 = spin-spin relaxation time constants respectively, MTR = 
magnetisation transfer ratio, MD = mean diffusivity, FA = fractional anisotropy. Values are mean 
(standard deviation). *test of between subjects effects in repeated measures ANOVA 
 
Histopathology 
For both experiments, H & E staining revealed fine nuclear detail with well discernible 
chromatin and nucleoli in neurons, identical structure of astrocytic and oligodendroglial 
nuclei. The neuropil had the same fine granular synaptic structure in both experimental 
and control groups. Myelinated fibre tracts were also identical in both groups. In 
particular, no vacuolisation or other artefacts were observed. Specific structures, such as 
the stratum radiatum in the hippocampus, showed delicate processes that were unaltered 
by extended PFPE immersion. Immunoreactivity in the treated group was no different 
from that in the control group with respect to intensity and immunostaining. GFAP 
which labels astrocytes and neurofilament (NF200) which labels axons throughout the 
brain, were identical in both groups.  For both experiments, there was no discernable 
histological difference between formalin-fixed brains immersed in PFPE for extended 
periods of time compared those remaining in formalin (Figure B). 
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Figure B:  Left column Fomblin®-immersed brain, right column control brain. A, 
B: H&E stained sections from the striatum. Nuclear detail, grey matter and white 
matter structures are well preserved and are identical in control and Fomblin® 
exposed specimens. C, D: high-power magnification from the neuronal ribbon of 
the hippocampus. Well preserved nuclear detail in both groups, including equal 
visualisation of delicate processes in the stratum radiatum. E, F: GFAP 
immunohistochemical staining for detection of astrocytes. In both controls and 
Fomblin®-immersed brains GFAP immunoreactivity is the same with delicate 
processes and contrast. G, H: Neurofilament immunohistochemistry, which labels 
delicate processes in the hippocampus as well as thick fibre bundles in the corpus 
callosum (in the upper edge of both images). No difference in staining contrast, 
intensity and visualisation of delicate processes is seen.  
 Scale bar 50µm (A-F), 100µm(G-H)  
 
Conclusion 
In conclusion, I have confirmed that prolonged immersion of fixed cerebral tissue in a 
PFPE for the purpose of MRM does not significantly modify quantitative magnetic 
resonance findings and does not compromise detection of histopathological features. 
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APPENDIX M 
 
UCL INSTITUTE OF NEUROLOGY 
QUEEN SQUARE 
 
THE NATIONAL HOSPITAL FOR NEUROLOGY AND  
NEUROSURGERY 
QUEEN SQUARE 
LONDON WC1N 3BG 
 
 
DEPARTMENT OF NEURODEGENERATIVE DISEASES 
HEAD OF DEPARTMENT: Professor J. Collinge BSc, MB, ChB, MD, FRCP, FRS 
 
DIVISION OF NEUROPATHOLOGY 
HEAD OF DIVISION:  Professor S. Brander MD, Micah 
 
 
 
 
                                  INSTITUTE OF NEUROLOGY (ION) /  
BIOLOGICAL IMAGING CENTRE, HAMMERSMITH HOSPITAL (BIC) 
SPECIMEN TRAIL DOCUMENTATION SHEET 
 
1 Specimen identification number (NP code)  
2 Person collecting specimen (ION)  
3 Time and Date of collection (ION)  
4 Time and Date of Arrival (BIC, Hammersmith Hospital)  
5 Person assuming responsibility for specimen (BIC, 
Hammersmith Hospital) 
 
6 Expected Time and Date of specimen collection  
7 Person, witnessing the removal of specimen (BIC, 
Hammersmith Hospital) 
 
8 Person collecting specimen (BIC, Hammersmith Hospital)  
9 Time and Date of Collection (BIC, Hammersmith Hospital)  
10 Time and Date of return of specimen (ION)  
11 Person returning specimen (ION)  
12 Contact Details (for use in the event of any unforeseen 
eventualities): 
 
1. Clinical Research Fellow: Harpreet Hyare 
07939061494 
2. ION histopathology’s: Caroline Powell 07970931026 
3. Pathologist: Professor S Brander 
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